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Abstract 
 
Physical forces regulate cellular behaviour and function during all stages of life. 
Mechanotransduction, the process by which cells convert mechanical stimuli into 
biochemical signalling events is central to a number of physiological and 
pathological processes. The first part of this work focuses on the effect of retinoid 
therapy on the mechanobiology of pancreatic cancer. Pancreatic cancer is 
characterised by a persistent activation of stromal fibroblasts, known as 
pancreatic stellate cells (PSCs), which can perturb the biomechanical 
homeostasis of the tumour microenvironment to favour tumour invasion. Using 
biophysical and biological techniques, we report that all-trans retinoic acid 
(ATRA), an active vitamin A metabolite restores mechanical quiescence in PSCs 
via a mechanism involving a retinoic acid receptor beta (RAR-β)-mediated 
downregulation of actomyosin (MLC-2) contracility. We show that ATRA reduces 
the ability of PSCs to generate high traction forces and adapt to extracellular 
mechanical cues (mechanosensing), as well as suppresses force-mediated 
extracellular matrix remodelling to inhibit local cancer cell invasion in 3D 
organotypic models. We thus suggest that ATRA may serve as a stroma 
reprogramming agent for the treatment of pancreatic cancer. 
In the second part of this work, we focus on syndecan-4 (Syn-4) - a ubiquitous 
transmembrane proteoglycan receptor. We identify Syn-4 as a cellular 
mechanotransducer that tunes cell mechanics by eliciting a global 
mechanosignalling response. We outline a mechanotransduction model whereby 
localised tension on Syn-4 triggers a synergistic cell-wide activation of β1 
integrins, in a PI3K-dependent manner, to subsequently activate the RhoA 
pathway and induce adaptive cell stiffening. Furthermore, syndecan-4 mediated 
mechanosensing is required for YAP activation and downstream changes in gene 
expression. We propose that this newly identified mechanotransductive ability of 
Syn-4 should have direct implications for the field of mechanobiology. 
 
 
 
 
 
	   4	  
Acknowledgements 
 
I am indebted and eternally grateful to my supervisor and mentor Dr. Armando 
del Rio Hernandez for his unwavering commitment to improving my research and 
continual support throughout this journey. Working with him has been an 
absolute pleasure. 
 
I also wish to thank all CMBL lab members that I have had the pleasure to work 
with during these years. I am particularly gratetul to Jose Cortes Lopez for his 
immense help in the tissue culture lab throughout my PhD. I am also extremely 
grateful to Dr. Benjamin Robinson for helping me with microscopy and LabVIEW 
coding, Dr. Muge Sarper for her help with transfections and Western Blots, Dr 
Simon Attwood for his help with MATLAB coding, Dariusz Lachowski for his help 
with the ATRA paper and immunofluorescence, Rebecca Garcia for her help with 
organotypic cultures. I would also like to thank William Haining, Alistair Rice and 
Tyler Lieberthal for the thoughtful discussions and all the fun times we had 
together. I am also extremely indebted to Dr. Stephen Thorpe for his continuous 
support and help biological assays for the syndecan project. I would further like to 
thank Dr.Vasyl Mykuliak and Dr. Vesa Hytonen from Finland for helping with the 
molecular simulations as well as Professor John Couchman and Dr. Mark 
Morgan for providing us with MEF cell lines and DNA plasmids for the syndecan 
project 
 
I would also like to acknowledge my friends who have been there during the 
stressful times by taking me out and about. Last but not least, I am also 
extremely grateful to my parents and sister for their support, advice and 
perspectives throughout this rollercoaster of a journey, which is coming to an end 
with this thesis. 
 
 
 
 
 
 
	   5	  
Publication List 
 
1. Chronopoulos A, Robinson B, Sarper M, Cortes E, Auernheimer V, Lachowski 
D, Attwood S, Garcia R, Ghassemi S, del Rio Hernandez A. "ATRA mechanically 
reprograms pancreatic stellate cells to suppress matrix remodelling and inhibit 
cancer cell invasion" (Published in Nature Communications 2016) 
http://www.nature.com/articles/ncomms12630 
 
2. Chronopoulos A, Thrope S, Cortes S, Mykuliak V, Lachowski D, Rog T, Lee 
D.A, Hytonen V, del Rio Hernandez A "Syndecan-4 is a cellular 
mechanotransducer that tunes cell mechanics by activating the integrin-RhoA 
axis and YAP" (Sent to peer-review: Nature Cell Biology 2017) 
 
3. Chronopoulos A, Lieberthal T, del Rio Hernandez A "Exosomes as a platform 
for liquid biopsy in pancreatic cancer" (Published in Convergent Science Physical 
Oncology 2017 - IOP publishing) http://iopscience.iop.org/article/10.1088/2057-
1739/aa5beb 
 
4. Chronopoulos A, Lieberthal T, del Rio Hernandez A "Pancreatic cancer - a 
mechanobiology approach" (Published in Convergent Science Physical Oncology 
2017 - IOP publishing) http://iopscience.iop.org/article/10.1088/2057-
1739/aa5d1b/meta 
 
5. Lachowski D, Cortes E, Pink D, Chronopoulos A, del Rio Hernandez A 
"Substrate rigidity controls activation and durotaxis in pancreatic stellate cells" 
Scientific Reports 2017, http://www.nature.com/articles/s41598-017-02689-x  
 
6. Cortes E, Sarper M, Robinson B, Chronopoulos A, Attwood S, Karim S, Morton 
J, del Rio Hernandez A "Tamoxifen reprograms the mechanics of pancreatic 
stellate cells and the tumour microenvironment" (Submitted to Cell) 
 
 
7. Cortes E, Robinson B, Sarper M, Lieberthal T, Lachowski D, Chronopoulos A, 
Karim S, Morton J, del Rio Hernandez A "The biomechanical signature of 
	   6	  
tamoxifen in the architecture of the tumour microenvironment (Submitted to 
PNAS) 
 
8. Cortes E, Lachowski D, Chronopoulos A, del Rio Hernandez A "Tamoxifen 
reprograms hepatic stellate cells to mechanical quiescence" (in preparation to be 
submitted to the journal of Hepatology) 
 
9. Cortes E, Lachowski D, Chronopoulos A, del Rio Hernandez A "Effect of all-
trans retinoic acid on the activation of hepatic stellate cells (in preparation to be 
submitted to Nature Communications) 
 
10. Meira A R, Uggetti A, Chronopoulos A, Faronato M, Shousha S, Steel J, 
Patel N, Coombes C, del Rio Hernandez A, Pruneri G, Magnani L. "KRT80 links 
epigenetic reprograming and changes to cell mechanics to promote ERa breast 
cancer invasion" (In preparation to be submitted to Nature Cell Biology) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
	   7	  
Presentations and conferences 
 
1. STEM for BRITAIN 2017 (UK-wide competition; invited to the Houses of 
Parliament to present my research in the Engineering Category) 
 
2. European Institute of Technology and Innovation - EIT Health PhD Doctoral 
Transition Fellowship (Gold award winner) 
 
3. Institute of Global Health Innovation (IGHI) - Global Health Innovation 
award (UK-wide student challenge competition - 3rd place) 
 
4. Gordon Research Conferences - Physics of Cancer (Feb. 2017) - Texas (US) 
(Presented mechanotransduction poster and gave elevator pitch) 
 
5. EIT Health Summit - Barcelona (Nov 2016) - Invited speaker as EIT-Health 
gold award recipient. Pitched start up idea. 
 
6. Precision Medicines Conferences/ Institute of physics (Royal Geographical 
Society UK, July 2017) – Invited speaker & 1st prize poster award 
 
.  
 
 
 
 
 
 
 
 
 
 
 
 
 
	   8	  
Table of Contents 
 
Chapter 1 
 
1.1 Cellular mechanotransduction – implications for health and disease            13 
1.2 The mechanotransduction machinery in a cell-ECM unit                              14 
1.3 Experimental tools to study cellular mechanotransduction                           19 
 
Chapter 2 
 
2.1 Design and development of custom-built magnetic tweezers apparatus to 
study cell mechanics and mechanotransduction                                                 40 
2.2 Basic principles of magnetic tweezers                                                           41 
2.3 System design and setup                                                                              41 
2.4 Demagnetisation                                                                                            45 
2.5 Force calibration                                                                                            46 
2.6 Magnetic beads and ligand conjugation                                                        48 
2.7 Experimental application of magnetic tweezers                                            49 
 
Chapter 3 
 
3.1 The tumour microenvironment (TME) as a target for cancer therapy          56  
3.2 Cancer –a disease of altered mechanobiology                                            56 
3.3 Role of cancer-associated fibroblasts (CAFs) in tumour progression          62 
3.4 Emerging TME-targeted cancer therapies                                                   67 
 
Chapter 4 
 
4.1 ATRA mechanically reprograms pancreatic stellate cells to suppress matrix 
remodelling and inhibit cancer cell invasion…                                                   84 
4.2 Introduction                                                                                                  84 
4.3 Results                                                                                                         86 
4.3.1 ATRA increases focal adhesion size and cell-ECM adhesion strength    86 
4.3.2 ATRA treatment reduces endogenous force generation and cell  
	   9	  
stiffness                                                                                                             89 
4.3.3 ATRA treatment suppresses PSC mechanosensing                               96 
4.3.4 ATRA inhibits matrix remodelling and cancer cell invasion                     98 
4.3.5 ATRA downregulates MLC-2 actomyosin contractility                            101 
4.3.6 ATRA induces the formation of dorsal stress fibres                                109 
4.3.7 ATRA impedes PSC migration                                                                111 
4.4 Discussion                                                                                                  113 
4.5 Methods                                                                                                     117 
 
Chapter 5 
 
5.1 Syndecan-4 is a cellular mechanotransducer that tunes cell  
mechanics by activating the integrin-RhoA pathway and YAP                        136                                              
5.2 Introduction                                                                                                136 
5.3 Results                                                                                                       138 
5.3.1 Tension on syndecan-4 induces adaptive cell stiffening and 
mechanosignalling                                                                                           138 
5.3.2 Tension on syndecan-4 drives global β1 integrin activation  
in a PI3K dependent manner…                                                                       142 
5.3.3 New integrin-fibronectin connections are required for adaptive cell  
stiffening and RhoA activation downstream of mechanical tension  
on syndecan-4                                                                                                 144 
5.3.4.Syndecan-4 mediated tension at the cell-ECM interface is required  
for YAP activation                                                                                            146    
5.3.5 The variable (V) region of the cytoplasmic domain of syndecan-4 
is indispensable for the mechanical adaptation to force                                  148 
5.3.6 Steered molecular dynamics simulation reveal that tension  
applied on the extracellular domain of syndecan-4 is able to induce a 
conformational change in the cytosolic domain                                               151                                                                                
5.3.7 Force stabilizes a syndecan-4/a-actinin/F-actin molecular  
scaffold to provide mechanical linkage to the cytoskeleton and 
potentiate the mechanoresponse                                                                    156                       
5.4 Discussion                                                                                                 159 
5.5 Methods                                                                                                     161 
	   10	  
Chapter 6 – Concluding remarks 
 
6.1 Stromal biology and therapeutic approaches in pancreatic 
ductal adenocarcinoma (PDAC) – Implications and future directions            170 
6.2 Implications and future directions for syndecan-4 in  
mechanotransduction                                                                                     173 
                                                                                                                       
 
 
 
 
 
List of Figures/Tables 
 
Figure 1.1 Cellular mechanotransduction                                                        16 
Figure 1.2 Focal adhesion “clutch”                                                                  18 
Table 1.1 Summary of methods and techniques used in cellular  
biomechanics                                                                                                   33 
Figure 2.1 Schematic of magnetic tweezers                                                   40 
Figure 2.2 Magnetic tweezers setup                                                               42 
Figure 2.3 Overview of the integrated magnetic tweezers apparatus             44 
Figure 2.4 Hysteresis and demagnetization                                                    45 
Figure 2.5 Force calibration                                                                            47 
Figure 2.6 Cell mechanical response to force                                                 50 
Figure 2.7 Viscoelastic creep response                                                          51 
Figure 2.8 Power-law creep response of mouse embryonic fibroblasts         53 
Figure 3.1Tensional homeostasis in breast cancer progression                    58 
Figure 3.2 Activated stellate cells (or CAFs) promote disease  
progression                                                                                                     64 
Figure 3.3 The CAF in tumour stroma remodelling                                        66 
Figure 3.4 Targeting mechanotransduction pathways in  
cancer as a therapeutic strategy                                                                    75                                          
Figure 4.1 ATRA increases focal adhesion size and cell-ECM  
adhesion strength of PSCs                                                                             87 
	   11	  
Figure 4.2 Focal adhesion size in PSCs in the quiescent state  
induced by matrigel culture                                                                          88 
Figure 4.3 ATRA reduces traction forces and impairs  
mechanosensing capacity in PSCs                                                             90 
Figure 4.4 Heat maps for PSC traction forces on micropillars                    92 
Figure 4.5 Quantification of FA areas in PSCs seeded on  
12 kPa polyacrylamide gels                                                                         94 
Figure 4.6 Characterisation of cell mechanics in PSCs using  
microrheology                                                                                              95                     
Figure 4.7 ATRA induces a quiescent-like phenotype in PSCs                  97 
Figure 4.8 ATRA impairs PSC capacity to remodel the ECM  
to promote cancer invasion                                                                         99 
Figure 4.9 ATRA treatment upregulates MMP-9 and downregulates 
TIMP-1 expression in PSCs, but has no effect on MMP-2 levels               101 
Figure 4.10 ATRA downregulates MLC-2 actomyosin contractility           102 
Figure 4.11 Flow cytometry analysis of mlc-2 and p-mlc-2 expression 
levels in control and ATRA treated PSCs                                                  103 
Figure 4.12 Quantification of 3D collagen gel contraction expressed 
 as % change of gel area                                                                           104                                
Figure 4.13 ATRA treatment increases focal adhesion size and  
decreases MLC-2 levels and force induced gel contraction  
in PSCs previously exposed to AsPC1 cancer cells  
conditioning media (CM).                                                                          105 
Figure 4.14 Retinoic Acid Receptors (RAR) are expressed in PSCs       106 
Figure 4.15 ATRA biomechanically reprograms PSCs in a RAR-β 
dependent manner                                                                                    107         
Figure 4.16 Dorsal stress fibre formation and RhoA & Rac1 activation 
 levels in control and ATRA treated PSCs                                                110 
Figure 4.17 ATRA treatment impedes PSCs migration                           112 
Figure 4.18 Model for the biomechanical reprogramming of PSCs         114 
Figure 4.19 ATRA treatment does not change cell viability significantly  128 
Figure 4.20 Uncropped images of the Western Blot membranes            129 
Figure 5.1 Adaptive cell stiffening downstream of tension on  
Syn-4 requires filamentous actin and active biochemical signalling 
	   12	  
 via Rho and PI3K                                                                                   139 
Figure 5.2 Tension on Syn-4 increases cellular stiffness                       141 
Figure 5.3 Tension on Syn-4 triggers cell-wide integrin activation         143 
 through the PI3K-dependent production of freely diffusible  
lipid PIP3 phosphoinositides                                                                   145 
Figure 5.4 Tension on Syn-4 activates RhoA-mediated adaptive 
 stiffening in a β1-integrin dependent manner                                        147 
Figure 5.5 Syndecan-4 mechanosignalling is required for  
YAP activation                                                                                        150 
Figure 5.6 The central variable (V) region of syn-4 cytoplasmic  
domain is required for mechanical adaptation to force                           151 
Figure 5.7 Immunofluorescent staining of MEFs transfected with  
Syn-4 plasmids                                                                                       153 
Figure 5.8 Conformational changes of Syn-4 in  
molecular dynamics (MD) and steered molecular dynamics (SMD) 
simulations                                                                                             154 
Figure 5.9 Steered molecular dynamic simulations (i)                          155 
Figure 5.10 Steered molecular dynamic simulations (ii)                       157 
Figure 5.11 Tension on Syn-4 stabilises a Syn-4/α-actinin/F-actin 
molecular scaffold to enable Syn-4 mediated adaptive 
stiffening and mechanosignalling                                                          158 
Figure 5.12 Transfection efficiency of the siRNA alpha-actinin in 
wild type MEFs                                                                                      162 
Figure 6.1 Stromal depletion strategies                                                171 
 
 
 
 
 
 
 
 
 
 
	   13	  
1.1 Cellular mechanotransduction – Implications for health and disease 
 
There is a growing recognition that mechanical factors, such as applied forces or 
the rigidity of the extracellular matrix (ECM), crucially influence the form and 
function of cells and organisms. Traditionally, biological regulation has been 
understood through concepts of solution chemistry, in which enzyme activities, 
reaction rates and affinities govern cellular processes1. However, 
mechanotransduction - the conversion of mechanical forces into relevant 
biochemical information, contributes to numerous developmental, physiological 
and pathological processes and is a rapidly advancing area of research.  
 
The importance of mechanotransduction in regulating tissue structure and 
function becomes easily apparent in many of the mechanically stressed tissues 
of the body, such as muscle, bone, cartilage and blood vessels, although its 
relevance is certainly not limited to any particular subset of specialised cells and 
tissues2. For example, skeletal and cardiac muscle can respond to increased 
load such as intensive resistance exercise, with hypertrophic growth, whereas 
immobilised muscles atrophy over time. Bone is another good example of 
mechanical forces driving tissue remodelling. Gravity and compressive forces 
generated by muscle contractions during locomotion and weight-bearing 
exercise, result in small deformations of the poro-elastic bone, resulting in 
pressure gradients that drive interstitial fluid flow through the lacunae-canalicular 
network 3. The load-induced fluid flow is thought to stimulate localised bone 
remodelling and optimise the physical performance through 
mechanotransduction signalling (Wolff’s law). Likewise, chondrocytes (the main 
cells that comprise cartilage) adapt to widely varying mechanical stresses by 
adjusting the synthesis of a glycosaminoglycan-rich extracellular matrix (ECM) 
that endows cartilage its dynamic mechanical properties. The role of regulatory 
mechanotransduction in the vascular system is particularly fascinating. The 
morphology and physiology of the vasculature is influenced by the pressure and 
shear stress generated from flowing blood. Hypertension causes thickening of 
the arterial walls and is a major risk for cardiovascular diseases. Development of 
atherosclerosis (the inflammation-driven deposition of plaque inside arteries), for 
example, is known to occur preferentially at regions of disturbed (turbulent) flow 
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such as branch points and areas of high curvature, where both the magnitude 
and temporal characteristics of the flow are disturbed4. 
 
Tissue rigidity or ECM stiffness affects many biological processes5. For example, 
stem cells can be steered towards specific fates during differentiation (neurons, 
muscle or bone) on the basis of the stiffness of the substrate on which the cells 
are grown 6; thus developing scaffolds with tunable mechanical properties has 
become a major effort in tissue engineering. Tumours have long been identified 
by palpation, owing to the local increases in tissue stiffness. Emerging data 
highlight these changes in the mechanical environment as key drivers for tumour 
progression7. Fibrotic lung disease and other fibrotic conditions often begin with a 
small chance in tissue stiffness, which is sensed by cells, inducing more severe, 
irreversible remodelling8. 
 
Cellular mechanosensing is based on force-induced conformational changes in 
mechanosensitive proteins that are subject to molecular forces that result in 
opening of membrane channels or altered affinities to binding partners, thereby 
activating downstream signalling. A common denominator of many 
mechanobiology diseases is a disruption in the intricate force transmission 
between the ECM, the cytoskeleton and the nucleus2. Therefore, any changes in 
normal intracellular force transmission through changes in cellular or extracellular 
structure, or the cellular mechanosensing process itself, can lead to altered 
molecular forces acting on these proteins, resulting in attenuated or increased 
mechanosensitive signals.  
 
 
1.2 The mechanotransduction machinery in a cell-ECM unit 
 
The translation of local extrinsic mechanical signals into global changes in 
cellular function relies on cells possessing integrated machinery that is capable of 
sensing and responding to mechanical force. In discussing how mechanical 
forces regulate cellular function, it is essential that we do not consider the cell in 
isolation, but rather in direct physical contact with the ECM. The ECM is the 
principal extracellular component of all tissues and organs. It provides a scaffold 
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that gives physical support to cells and regulates intracellular biochemical and 
biomechanical signalling. The molecular components of the ECM include 
collagens, elastins, fibronectin, proteoglycans and laminin.  
 
In recent years, it has become increasingly apparent that the cellular response to 
environmental signalling extends far beyond the ability of the cell to chemically 
sense specific ECM ligands, and encompasses a wide range of physical cues 
that are generated at, or act on, the adhesive interface between cells and the 
surrounding matrix9. Thus, cells can react to internally generated or externally 
applied forces and can sense the rigidity5,6, topography10 and anisotropy11 of the 
underlying ECM. 
 
Among the most studied mechanosensory complexes are focal adhesions 
(FAs) (Figure 1.1). These dynamic protein complexes consist of transmembrane 
integrins and a multitude of adaptor and signalling proteins, including talin and 
vinculin, which as an integrated unit provide the mechanical link between the 
internal actomyosin cytoskeleton and the ECM. This bridging between the 
internal cytoskeleton and the ECM enables the focal adhesion to serve as the 
conduit through which signal transduction occurs in response to physical force. 
FAs often strengthen or stabilise under force. The application of force can directly 
influence the size, shape and composition of FAs, thereby demonstrating a direct 
correlation between force and downstream biochemical signalling.12 
 
Forces acting across ECM-integrin-cytoskeletal linkages are thought to initiate 
signals by unfolding protein domains and changing binding affinities. Proteins 
within the focal adhesions, including integrins themselves and plaque proteins 
such as talin and p130Cas, undergo conformational changes in response to 
applied force. A well-studied example is talin, which connects integrins to F-actin, 
thereby transmitting forces between actomyosin filaments and the ECM. Talin 
undergoes a force-dependent unfolding in response to molecular (picoNewton) 
forces, which results in the exposure of otherwise inaccessible vinculin-binding 
sites13. The net result of talin-vinculin binding in response to force is a 
reinforcement of the link between integrins and actin - via increased integrin 
clustering and nucleation of the adhesion plaque proteins- and ultimately 
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activation of downstream cascades via signalling molecules at the intracellular 
face of the adhesion, such as focal adhesion kinase (FAK) and paxillin. Another 
example includes the case of p130Cas, a signalling protein found in FAs. Studies 
with purified proteins have revealed that stretching increases the susceptibility of 
p130Cas to undergo phosphorylation through force-induced changes in protein 
conformation, without changing the intrinsic activity of Src family kinases14. ECM 
proteins can also undergo force-induced unravelling. The first reported instance 
was fibronectin, which self-assembles into fibrils in the ECM. The assembly of 
fibronectin into fibrils is mediated by actomyosin-generated force transmitted 
through integrin-mediated focal adhesions, by unfolding domains with cryptic 
binding sites within the fibronectin molecule that promote self-association and 
matrix assembly15,16. Additionally, physical forces can alter the presentation of 
growth factors to cells. A good example is that of transforming growth factor beta 
(TGF-β), a cytokine involved in fibrosis and inflammation, which is normally found 
tethered to the ECM via latent TGF-β-binding proteins (LTBPs), which are in turn 
anchored to fibronectin fibrils and can be released by integrin-mediated traction 
force17. 
 
Figure 1.1: Cellular mechanotransduction. Cells are equipped with numerous 
mechanosensitive proteins that work in concert to regulate the cellular response 
to mechanical stimuli such as shear stress, stretching or ECM rigidity. a) stretch-
sensitive ion channels on the plasma membrane open in response to membrane 
strain and allow the influx of calcium ions. b) glycocallyx is a fuzzy layer of 
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glycoproteins and sugar moieties located on the plasma membrane of endothelial 
cells that senses fluid-induced shear stress. c) cell-cell junctional receptors, such 
as cadherins, transfer intercellular mechanical forces. d) integrin-enriched focal 
adhesion complexes provide a mechanical link between the ECM and the 
cytoskeleton allowing cells to mechanically probe their microenironment (e.g. 
rigidity sensing). e) force-induced unfolding of ECM proteins such as fibronectin 
can also initiate mechanotransduction outside of the cell. f) cytoskeletal 
elements, such as filaments, motor proteins and crosslinkers can sense 
intracellular strain and alter downstream signalling g) the nucleus itself acts as a 
mechanosensor. Extracellular or cytoskeletal-driven forces can either mediate 
signalling at the nuclear lamina or modulate the conformation of chromatin 
thereby changing gene transcription directly. Adapted from Jaalouk et al.2 
 
But how exactly can changes in ECM rigidity induce widely divergent cellular 
responses? Rigidity sensing relies on the prevailing concept that likens the 
mechanosensitive FA complex to a ”molecular clutch”18. In this model, owing to a 
combination of pushing forces from actin polymerisation at the cell leading edge 
and pulling forces from actomyosin contractility, the actin filaments are thought to 
flow backwards, towards the rear of the cell, over the immobile, ECM-bound 
integrins1,19. Linker proteins (e.g. talin, vinculin) are driven backwards at 
intermediate speeds, slowing down the retrograde actin flow and transmitting 
force through a sort of friction. ECM rigidity is thought to affect this system 
primarily by altering the loading rate of the ECM-integrin-cytoskeleton linkage. On 
soft substrates, rearward movement of the actin is buffered by the deformation of 
the ECM, which slows down the loading rate on adhesions; on stiff substrates, 
the loading rate on the mechanosensitive FA complex is increased (Figure 1.2). 
Alternatively, other studies suggest that the cellular response to stiffness resides 
within the regulatory mechanisms of the cytoskeleton that control the overall level 
of cell contractility20,21. 
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Figure 1.2: Focal adhesion “clutch”. Rigidity sensing of the ECM occurs 
through integrin-based focal adhesions, which are thought to act as a molecular 
“clutch”. Integrins bind to ECM and are coupled to F-actin cytoskeleton via 
mechanosensitive focal adhesion proteins (for example talin and vinculin). The 
focal adhesion complex moves backward as F-actin also flows backwards, under 
the action of actin polymerization and myosin II motors pulling on actin filaments. 
In this way, a pulling force is transferred from F-actin to integrins which pull on 
the ECM a) A stiff matrix resists can resist the force so that integrins remain 
relatively immobile and bound on the matrix. b) A soft matrix deforms under force 
so that the bound integrins can also move backwards. This alters the loading rate 
impinging on the mechanosensitive focal adhesion complex altering 
mechanontransduction signalling and the cellular response to force. Adapted 
from Humphrey at al.19 
 
Because integrins are physically coupled to the cytoskeletal filament network 
that, in turn link, to nuclear scaffolds, nucleoli, chromatin and DNA inside the 
nucleus, mechanical forces that are applied at the cell surface do more than 
initiate membrane signaling events – they promote structural rearrangement 
deep in the cytoplasm and nucleus22. This mechanical connectivity (ECM-
integrins-FA-cytoskeleton-nucleus-chromatin) raises the possibility that 
mechanical stress applied at the cell surface might act at a distance to directly 
promote mechanochemical signal transduction in the nucleus. Experimental 
studies in the past have confirmed that when integrins are directly stressed with 
ligand-coated micropipettes or magnetic beads, immediate force-dependent 
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changes are observed deep inside the cytoskeleton and the nucleus, such as 
mitochondria and nucleoli23,24. Intriguingly, recent evidence also demonstrates 
that local stresses applied to integrins propagate from the tensed actin 
cytoskeleton to the nuclear scaffold and then through the lamin-chromatin 
interaction stretch chromatin to directly influence gene transcription25.  
 
This mechanical action at a distance is made possible owing to the unique form 
of cellular architecture, originally put forward by Donald Ingber, known as 
“tensegrity”. In this model, there is a level of isometric tension or “pre-stress” in 
the cytoskeleton that is generated through the establishment of a force balance 
between the contractile actomyosin filaments and the compression-resisting 
microtubules and extracellular adhesions. In this type of cellular hard-wiring, the 
cytoskeleton allows for mechanical signalling to convey information rapidly and 
across long distances compared to diffusion-based chemical signaling22. 
 
 
1.3 Experimental tools to study cellular mechanotransduction 
 
Analysis of how cells sense and respond to mechanical stress has been limited 
by the availability of techniques that can apply controlled mechanical stimulation 
to cells as well as measure cell-generated forces. Engineers and biologists have 
developed different physical and molecular probes that quantitatively apply 
and/or detect pico- and nano-Newton forces across multiple length scales (e.g. 
cellular and molecular scale) (Table 1.1). 
 
Traction Force Microscopy (TFM) 
 
TFM is a commonly used technique that allows for quantification of cellular 
traction forces.  It involves tracking the deformations of synthetic elastic 
substrates that result from the exertion of cell-generated force. Cells are seeded 
on flat, ECM-coated, deformable substrates that are resistant to degradation, so 
that deformations due to force can be decoupled from changes in the mechanical 
properties of the local microenvironment causes by biochemical factors, such as 
proteases. 
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In standard 2D TFM, small (<1 um) fluorescent beads are mixed into 
polyacrylamide (PA) gel substrates to serve as fiduciary markers that can be 
tracked in space and time with optical microscopy26.  During a typical TFM 
experiment, the displacement field of the fluorescent beads are first imaged in a 
stressed state while the cell pulls on its substrate; then cell traction is released 
via cell lysis, detachment or myosin inhibition and the beads are then imaged 
again to determine their position in the unstressed state.  Computational 
algorithms are then used (e.g. Fourier-based algorithms) to analyse the two 
resulting images to determine the displacement of the beads caused by cells and 
the required force needed to cause such displacement27. TFM enables mapping 
of cellular traction forces with subcellular resolution. 2D TFM technique has 
nowadays been adapted to allow calculation of 3D cellular traction fields by 
tracking bead displacements with confocal microscopy and using modified and 
more computationally intensive algorithms. 
 
Nevertheless, the computational analysis required to calculate bead 
displacements and forces remains a significant challenge for laboratories looking 
to implement TFM as the calculations are complex, nuanced, and difficult to 
validate. This is largely due to the long-range elastic interactions between 
embedded beads, in which a force applied to a single point causes long-range 
displacement of many surrounding beads because of the elasticity of the 
substrate, and also because small errors in measuring the precise bead 
displacement can translate to large errors to the force calculations. However, 
algorithms have now been developed with sufficiently reduced computational 
cost which means TFM can be implemented on standard desktop computers26. 
 
• Basic principles of elasticity theory and TFM 
 
The reconstruction of traction forces on soft elastic substrates requires continuum 
elasticity theory to describe substrate deformations as a consequence of forces 
applied to the substrate surface28. The theoretical framework of elasticity theory 
as it pertains to TFM as well as the constitutive equations are reviewed 
extensively here28. In general, the forces applied to the boundary of an elastic 
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solid are called traction forces t and are measured in units of force per area, 
Pa=N/m2. Traction forces lead to substrate deformation, which are described by 
the deformation gradient tensor F, which is the Jacobian of the coordinate 
transformation from the undeformed state x to the deformed state x’: 
 
                                      F=   𝝏𝒙!𝝏𝒙 𝝏𝒙!𝝏𝒚 𝝏𝒙!𝝏𝒛𝝏𝒚!𝝏𝒙 𝝏𝒚!𝝏𝒚 𝝏𝒚!𝝏𝒛𝝏𝒛!𝝏𝒙 𝝏𝒛!𝝏𝒚 𝝏𝒛!𝝏𝒛                                                  Eq.1 
 
One can also work with the displacement vector field u = x’ - x 
                                             F=1+ (∇⨂𝐮)!                                              Eq.2                                                                   
Here 1 is the unit tensor, ⨂ is the dyadic product that maps two vectors into a 
tensor and the ∇ the gradient operator in the undeformed (Lagrangian) frame.  
Both F and u are spatial fields as they are defined at any point in the body. They 
have to be constructed from the image data and then can be used to derive 
measures for local changes in distances and angles during deformation. For this 
it is useful to use the two non-linear strain tensor, specifically the Green-
Lagrange tensor E and the left Cauchy-Green tensor B:                                                                                               𝑬 = !! 𝐹! ∙ 𝐹 − 1 , 𝑩 = 𝐹𝐹!                                  =Eq.3 
The Green-Lagrange tensor can be written as a function of the displacement 
vector field u: 
 
E =  !! ( ∇⨂u + ∇⨂u ! +    ∇⨂u ∇⨂u !)      (non-linear)                        Eq.4 
 
Linearization for small strains gives the linear strain tensor: 
 
                                               ε = !! ( ∇⨂𝑢 + ∇⨂u !)                             Eq.5                                                
In components this equation reads 
 
                                                    εij = !! (!"!!"! + !"!!"!)                                      Eq.6 
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For simplicity, we assume small strains and thus proceed with the linear strain 
tensor (geometric linearity). If in addition to small strains, we also assume that 
the substrate has a linear and isotropic constitutive relation (material linearity), 
then a linear relation exists between the strain tensor ε and the stress tensor σ. 
 
                                                σij = !!!! (𝜀!" +    !!!!! 𝜀!!𝛿!")                        Eq.7                                                                       
 
where summation over repeated indices is implied. This equation can be inverted 
to 
                                                εij = !! [ 1+ 𝜈 𝜎!" − 𝜈𝜎!!𝛿!"]                      Eq.8                                                               
Here E and ν represent the two elastic constants of the linear and isotropic 
substrate. The Poisson’s ratio ν for PAA gels ≅ 0.5, which is close to being 
incompressible. 
 
The balance of internal and body forces, ∇σ = f, can be written as a partial 
differential equation for the displacement vector field, the Lame equation:  
                                                                                                              !!(!!!)𝛥𝒖+    !! !!! !!!! ∇ ∇ ∙ 𝐮 =   f              Eq.9                        
 
In TFM, one typically has f=0 for the body forces and deformations arise from 
traction forces on the boundaries. However, because Lame equation is linear, a 
propagator can be calculated for point traction forces that in the following we also 
denoted as Green’s function. Most importantly for TFM, such Green’s functions 
are known as the elastic half-space (Boussinesq solution) and for the elastic 
layer of finite thickness28. Once such a Green’s function is known, a general 
solution follows as convolution integral: 
 
                                        u(x) = 𝑮 𝒙,𝒙! 𝒕 𝒙! 𝒅𝒙′                                Eq.10 
 
The typical film thickness used in cell experiments is between 50 µm and 80 µm. 
Then the displacement field decays fast into the substrate such that the boundary 
conditions at the bottom do not matter and the Boussinesq solution can be used. 
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For weak cell types, even 20 µm may suffice. For strong cell types and in case of 
a thick substrate, one can use the Green’s function for finite substrate 
thickness28.  
 
From the basic equations of elasticity theory reviewed here, it is easy to see that 
there two ways to construct forces from displacements. First, one can invert the 
convolution integral Eq.10 as one wants to infer the traction forces t from the 
displacement field u (inverse TFM). Alternatively, one can directly construct the 
strain tensor ε from the displacement field u using Eq. (6) and from this the stress 
tensor using Eq.7. The traction forces are calculated as t = σn where n is the 
normal to the substrate surface (direct TFM)28. 
 
Micropillar Force Sensor Array 
 
Apart from using TFM hydrogels, 2D traction forces can also be measured by 
plating cells on ECM-functionalised microfabricated pillar arrays (created via 
photolithography) made up of synthetic elastomeric substates such as 
polydimethylsiloxane (PDMS). In this technique, each pillar can be used as a 
flexible, force transducing cantilever beam. Cells exert traction forces on the 
micropillar and cause the pillar to bend, which is then quantified. By altering the 
pillar geometry (e.g. height, width, diameter) and material characteristics one can 
tune the elastic modulus of the substrate. For pillar-based studies with known 
Young’s modulus (E), height (L), diameter (D) on fixed substrates, the force can 
be computed directly by the lateral displacement of the pillar (in the linear regime 
of pillar deflection δ) by using Hooke’s law29.The bending stiffness (kbend) of the 
pillar can be derived by the classical Euler-Bernoulli beam theory approximation.  
     𝐹 = 𝑘!"#$ ⋅ 𝛿 =   3𝜋𝐸𝐷!64𝐿! ∙ 𝛿 
 
A key assumption in the derivation of the spring constant equation (kbend) is that 
vertical deflection of the micropillar is small compared to horizontal deflection. For 
large tip deflections, a non-linear relationship between force and deflection must 
be considered. More sophisticated analyses consider contributions from pillar 
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shear30,31, non-linearities30, deviation from an ideal cylindrical geometry32, 
viscoelastic material properties33, and different referencing methods that 
incorporate for instance the lateral displacement of the pillar base29. 
 
By measuring pillar deflection (using custom-tracking software) from its rest 
position, the force generated by the cell to bend the pillar can be quantified. The 
micropillar technique involves discrete displacements of individual focal adhesion 
contacts (area of pillar), while avoiding the problems involved in the finite element 
analysis of continuous surface, as is the case with TFM. While some initial 
concerns had been raised regarding the gaps between pillars would caused 
altered cell geometry and traction force patterns, the pillar arrays generated 
similar traction force maps to those generated by previous techniques.  
  
Magnetic Twisting/Pulling Cytometry (MTC/MPC) 
 
MTC is a well-established technique to apply controlled mechanical stress to 
living cells to study their mechanical properties by measuring local cell 
deformation or investigate force-induced activation of downstream biochemical 
signalling cascades. A traditional MTC setup consists of a horizontal and vertical 
Helmholtz coil around a mechanical stage. The current flowing through the coil is 
controlled using an electronic controller, which modulates the magnetic field. 
ECM-coated ferromagnetic microbeads are attached on the apical surface of 
cells providing a direct mechanical linkage to the cytoskeleton. The beads are 
first magnetized by applying a strong and short magnetic pulse (~ 1000G for less 
than 0.5 ms), followed by a weak twisting field produced by the vertical Helmholtz 
coil in the orthogonal direction with respect to the magnetic moment of the 
bead34,35. As a result, the bead will experience a torque making the bead to align 
its magnetic moment in the direction of the applied field, and due to the partial 
embedding of the bead on the cell surface, the rotation of the bead will be 
resisted. On soft cells, the resulting bead rotation will be larger than on stiffer 
cells. MTC allows the measurement of cellular mechanical properties in live cells 
and in real time, simply by tracking bead displacements while applying external 
stress to the cells. By regulating the amplitude and frequency of the current 
passing through the coils, one can control the amount of torque on the cell 
	   25	  
surface. The magnetic field-induced bead rotation is tracked using custom-
tracking software, from which the complex modulus (G*) is computed. Measuring 
the phase lag between the input current in the coil and the resultant bead rotation 
allows the determination of G’ (elastic modulus) and G’’ (viscous modulus of the 
cell). 
 
A slight variation of this technique, MPC, works on a similar principle34,35. In MPC 
an electromagnetic needle is used to generate a strong magnetic field gradient to 
exert a pulling force force on ECM functionalised superparamagnetic beads 
bound on the apical surface of cells. The pulling force is proportional to the 
current that runs through the electromagnet as well as the distance between the 
electromagnetic tip and the magnetic bead. The force can be reset to zero in 
between pulses of force application by cancelling out the remnant magnetic field 
of the electromagnet either by degaussing or applying a small coercive current. 
The pulling force applied through the electromagnetic needle is often calibrated 
by applying force on a bead suspended in a viscous solution and by using the 
Stokes equation for low Reynold number flow (𝐹 = 6𝜋𝜂𝜐) , where η is the 
viscosity, r is bead diameter and v is bead velocity). The bead displacement is 
tracked optically. Similarly, the MPC can be used to quantify cellular mechanics 
by monitoring the local displacement of the bead and has also been used 
extensively to glean information on mechanotransduction cascades of various 
cellular receptors downstream of applied mechanical tension. The functionality of 
MPC and MTC can be further improved by often combining it with detection 
techniques such as confocal fluorescence microscopy, Forster resonance energy 
transfer (FRET) and/or super-resolution microscopy. 
 
 
Optical Tweezers 
 
Originally developed for trapping biomolecules, optical tweezers have emerged 
as an important tool in biophysics research36,37. Seminal work carried out with 
optical tweezers includes single molecule manipulation including the 
characterisation of DNA mechanics, and motor proteins such as myosins and 
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kinesins. Optical tweezers have also been used for calibration of single molecule 
force sensors for cellular force spectroscopy. 
 
The working principle of optical tweezers relies on the force generated by a laser 
beam focused onto small dielectric beads36,37. It is intuitively helpful to consider 
the two component forces in an optical trap, the gradient force and the scattering 
force, independently. The scattering force arises from the scattering of light and 
is a consequence of photons having momentum. This force pushes the bead 
along the direction of propagation of the light beam and is dependent on the light 
intensity. The second force, the bead experiences emerges from the gradient 
force arising from the gradient light field intensity and on the dielectric contrast of 
the particle to be trapped relative to the surrounding media. The strength of the 
restoring gradient force in an optical trap of radius r can be characterised as a 
Hookean spring with stiffness, k, where force is proportional to small 
displacements (𝐹 = −𝑘 ∙ 𝑟). 
 
Forces generated by optical tweezers are within the range of 0.1 pN – 200 pN, 
which makes this technique ideal for cellular and molecular micromanipulation. 
High-resolution optical tweezers are sensitive enough to measure nanometre 
scale displacements with micrometre sized dielectric beads. As a result, optical 
tweezers are ideal for precisely manipulating a bead tethered onto DNA, proteins, 
enzymes, viruses or cells. However long exposure of cells to a high-powered 
laser could induce unwanted harmful effects and this is the main drawback of the 
technique. 
 
Atomic Force Microscopy (AFM) 
 
The use of AFM for probing living biological systems across multiple length 
scales (tissues, cells and molecules) dates back to the early 1990s. In AFM, a 
cantilever with a tip at one end is used to probe the cell. The displacement in z 
direction of the cantilever is monitored using a laser that reflects off the back 
surface of the cantilever beam. If the spring constant of the cantilever is softer 
than the surface being probed, then the cantilever bends and the deflection is 
measured using a position-sensitive photodetector. The tip of the cantilever is 
	   27	  
sometimes functionalised to carry a ligand of choice (e.g. RGD peptide) to apply 
forces to specific cellular receptors (e.g. integrins). Wet mode AFM is often used 
to probe biological samples and monitor the binding kinetics, folding/unfolding 
events while a specific receptor is being sheared. 
 
The force-indentation curve (applied force vs. distance of the tip from the sample 
surface) is often fitted to a Hertz model of contact mechanics. Depending on the 
application and functionalisation of the cantilever, force curves can reflect either 
cellular elasticity or receptor properties such as adhesion, elasticity, and bond 
rupture strength. The elasticity of the local tip-sample interaction is calculated 
from the slope of the beam deflection to tip displacement. The stiffness of the 
material is measured as the ratio of applied stress (force over contact area) over 
strain along the direction of force. For a perfectly elastic material, the linear 
relationship of stress-strain is given by Hooke’s law, 𝜎 = 𝛦 ∙ 𝜀; where σ is the 
applied stress, E is the Young’s modulus of elasticity, ε is the produced strain. In 
AFM microindentation experiments, using a spherical tip, when the applied force 
varies linearly with surface displacement, the applied force F is given by  𝐹 = 4𝛦3(1− 𝜈!) 𝑅𝛿!/! 
 
where E  is the elastic modulus, R is the radius of the indenter, δ is the 
indentation depth and ν is the Poisson ratio for the material38. 
 
The limitation of the Hertz model should also be marked. The Hertz model that 
has been applied to fit cell mechanical indentation data is a simplistic model. It 
predicts the force-indentation relationship for infinitesmall indentations of purely 
elastic materials by axisymmetric39. Some of these assumptions are often 
violated when applied to cell indentation.  
 
The Hertz model assumes homogeneous and linearly elastic material, while a 
cell is heterogeneous and non-linearly elastic. For instance, in the lamellipodium 
region, it is rather inhomogeneous due to the heterogeneous structure of the 
actin cytoskeleton. The mechanical cell stiffness is often calculated as an 
average of measurements in the perinuclear region that is relatively more 
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homogeneous. Reconstituted networks of actin exhibit strain-stiffening properties 
- that is they become stiffer with increasing deformations. Similar non-linear 
elasticity has been observed for living cells but not accounted for in the Hertz 
model. To avoid this issue, typically only the first 300 nm indentation data is fit to 
the Hertz model39. 
 
An additional issue, as mentioned previously, is that the Hertz model treats cells 
as purely elastic material. However, cells are viscoelastic with stiffness 
dependent on the timescale of measurements. At short time scales, the 
cantilever deflection comes from the elastic response. At longer timescales, the 
sample creeps and gives a viscous response. Thus, the timescale of 
measurements is controlled largely by the tip velocity during AFM indentation and 
has an important impact on the reported cell stiffness value. Hence, different 
AFM cell stiffness measurements are only comparable when acquired under the 
same indentation velocity39. 
 
The assumption of infinite sample thickness is also often erroneous. Cells are a 
few micrometers thick in the perinuclear region and a few nanometers thick in the 
lamella region. Corrections have been made to account for finite sample 
thickness.  
 
Another limitation of AFM elastopgraphy is low throughput. Typically experiments 
are time-consuming and user-intensive, so that a limited number of cells can be 
analysed in one day. AFM has also been used to stretch biomolecules that 
involve intra-domain unfolding mechanisms with multiple conformations as 
monitor receptor interactions such as bond strength, association and dissociation 
rates35. 
 
Micropipette aspiration 
 
This is one of the oldest techniques used to measure cellular and subcellular 
mechanical properties dating back to the middle of the 20th century. This 
technique employs a fine glass micropipette that can be moved about by a 
micromanipulator40. A small known pressure (suction) can be applied through a 
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fluid-filled reservoir attached to the pipette. By controlling the reservoir height, 
this pressure can be altered during the course of an experiment. If the applied 
suction pressure is low enough to avoid cell rupture, an equilibrium is established 
in which the applied suction pressure is balanced by mechanical stresses within 
the cortical cytoskeleton of the cell. One measure of cellular elasticity is the 
distance that this aspirated cellular segment extends into the pipette. The force 
exerted on the cell in a micropipette of internal radius Rp by an imposed suction 
pressure Δp is given by  𝐹 = 𝛥𝑝𝜋𝑅!!(1− 𝑈!𝑈!) 
 
where Ut is the observed velocity of the cell moving within the pipette and U∞  is 
the velocity that the cell would have if there was no tethering force applied to the 
cell, for the same suction pressure41. 
 
 
Microfluidic shear devices 
 
Fluid-induced shear stress is an important mechanical stimulus in regulating both 
physiological and pathological processes in the cardiovascular system (e.g. 
endothelial cells lining the arterial wall), bone  (e.g. osteocytes) and other 
mechanically stresses of the body.  
 
Conventionally, there are two major apparatus designs for generating 
hydrodynamic shear: i) cone-and-plate rotating chambers and ii) parallel-plate 
flow chambers. With advances in microfabrication technologies, microfluidic flow 
chambers with tunable channel geometries, surface chemistries and 
topographies can be fabricated. Due to the microscale length scale of the 
channels, the flow is always laminar (low Reynolds flow number), for a large 
range of shear stresses that are required in cell studies.  
Microfluidic devices have thus been adopted to improve the resolution, 
throughput and reliability of mechanobiology experiments42. An important 
advantage of microchannels over conventional flow chambers is the ability to 
generate a wide range of linear shear stress gradients for the investigation of the 
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cellular responses, such as adhesion and cell alignment. The parallel processing 
nature of microfluidic systems also facilitates the interrogation of multiple 
physicochemical parameters concurrently. Both steady and time-varying flows, 
especially flow patterns that mimic in vivo situations have been studied 
extensively using microfluidic flow channels. 
 
Molecular FRET Tension Sensors 
 
The advent of molecular FRET (fluorescent/Forster resonance energy transfer) 
tension sensors has enabled bioengineers to achieve mechanical force 
measurements at a molecular scale with molecular specificity in situ. FRET is a 
process in which energy is transferred non-radiatively from an electronically 
excited donor fluorophore (D) to a nearby acceptor fluorophore (A). The FRET 
efficiency E is exquisitely sensitive on the D-A separation distance r with an 
inverse 6th-power due to the dipole-dipole coupling mechanism: 
 𝐸 = 11+ (  𝑟 𝑅!)! 
with R0 being the Forster distance of this pair of D-A, i.e. the distance at which 
the energy efficiency is 50%. Analytical description of the classical Forster theory 
and derivation of equation is outlined43. 
 
Molecular FRET tension sensors are genetically encoded molecular springs that 
act as piconewton force sensors to measure tension across a force-bearing 
protein of interest expressed in living cells. In short a tension sensor module, 
such as single-stranded DNA or the elastic spider silk flagelliform peptide, serves 
as a stretchable elastic linker and inserted between two fluorophores undergoing 
efficient FRET. The linker generally has to be short because currently available 
FRET pairs are characterised by a Forster distance R0 ~ 5-6 nm, at which the 
FRET efficiency is most sensitive to changes in fluorophore separation distance. 
Second, the increase in linker length has to be sufficiently large so that applied 
tension translates into measurable FRET efficiency differences. Finally, the linker 
must ideally follow a simple folding/unfolding pattern and quickly return to its 
original conformation when force subsides. 
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Since the FRET efficiency inversely correlates with the D-A fluorophore distance, 
forces that extend the elastic linker molecule also increase the D-A separation 
distance reducing FRET efficiency. The FRET tension sensor is calibrated 
usually with single molecule force spectroscopy, which combines confocal 
scanning fluorescence microscopy and optical tweezers to provide a force to 
FRET efficiency calibration curve. A recent example of such molecular FRET 
tension sensor was put forward by Grashoff et al. to measure piconewton forces 
across vinculin in living cells during spreading and migration44.  
 
 
Nanoscale optomechanical actuators 
 
In this innovative approach light is harnessed to deliver precise mechanical force 
to specific cell surface receptors with high spatio-temporal resolution45. 
Optomechanical actuator (OMA) nanoparticles are comprised of a gold nanorod 
coated with a thermoresponsive polymer. Upon near-infrared (NIR) illumination 
the nanorod functions as a photothermal transducer, converting NIR light to 
localised heat that drives polymer collapse. OMA nanoparticles can be 
immobilised onto virtually any type of surface and can be functionalised with a 
variety of small molecule, peptide and protein ligands specific to a receptor of 
interest, thereby making the mechanical actuation molecularly selective. The NIR 
optical pulse train controls the amplitude, duration, repetition and loading rate of 
mechanical input. Estimation of the force produced by OMAs by DNA-based 
fluorescence tension probes, found that particle collapse exerts a force per ligand 
in the range of 13-50 pN. As a proof of concept demonstration, optomechanical 
actuation has been so far used to control integrin-based focal adhesion 
formation, cell protrusion and migration as well as T cell receptor activation. 
However, OMA nanoparticles require the application of cyclic mechanical 
stimulation rather than sustained force, and illuminating particles at average 
powers > 14 µW µm-2 leads to thermal heating and cell damage. 
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Oil microdroplets as force transducers 
 
Measuring cellular forces in vivo has proven very challenging until recently. This 
technique allows direct quantification of endogenous cellular forces in situ within 
3D living tissues and developing organs46. The technique relies on the use of 
fluorescent microdroplets similar in size to individual cells, with defined 
mechanical properties and displaying ligands for cell surface adhesion receptors, 
as force transducers in living embryonic tissues. 
 
 When a fluorescently labelled microdroplet is injected into the intercellular space 
of a living embryonic tissue, adjacent cells adhere to the surface-receptor ligands 
on the microdroplet and exert forces on it, causing its deformation from the 
equilibrium spherical shape. Subsequent shape reconstruction of the deformed 
droplet in 3D using confocal microscopy and computer image analysis, and 
knowing its precise mechanical properties, one is able to quantify with 
reasonable approximation, the stresses (force per unit area) that cells apply at 
every point on the droplet surface. The stress (in the outward normal direction) 
exerted by cells surrounding a droplet varies across the droplet surface. 
Laplace’s law, here expressed in spherical coordinates can then give an 
approximation of the local force balance on the droplet surface 
 𝑝′! =   𝑝′! + 2𝛾𝐻 𝜃,𝜑 − 𝜎!!(𝜃,𝜑) 
 
where   𝑝  ′!  and 𝑝′!  is the internal and external pressure of the oil droplet 
respectively, H is the local mean curvature of the droplet surface, γ the interfacial 
tension of the droplet and the  surrounding medium and σnn the local normal 
stresses exerted by cells on the droplet surface. A more detailed treatment of the 
technique and related equation is described in the original work of Campas et 
al46. 
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Table 1: Summary of methods and techniques used in cellular biomechanics 
 
Technique Application Force range/ Schematic 
Traction Force 
Microscopy 
(TFM) 
Force sensing 
(2D/3D) 
N/A 
 
Micropillars Force sensing 
(2D) 
>50 nN 
 
Magnetic Tweezers/ 
Magnetic Twisting  
Cytometry 
(MTC) 
Force  
application 
0.1-10 nN 
 
Optical Tweezers Force  
application 
<200 pN 
 
Atomic Force 
Microscopy  
(AFM) 
Force  
application 
0.01-100 nN 
 
Micropipette 
Aspiration 
Force  
application 
0.01-1000 nN 
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Microfluidic Shear  
Devices 
Force  
application 
N/A 
 
FRET Tension 
Sensors 
Force sensing 
(in vivo) 
<10 pN 
 
Optomechanical 
actuator  
nanoparticles 
Force  
application 
10 – 50 pN 
 
Oil microdroplet  
force transducers 
Force sensing 
(in vivo) 
N/A 
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Summary 
 
The techniques described here are used to either apply or sense forces at the 
cellular and/or molecular scale. Every technique has its advantages and 
limitations depending on the application, including ease of fabrication, cost, and 
experimental throughput.  Certain mechanobiological questions can be answered 
with more than one of the biophysical techniques outlined in this section. For 
instance, TFM is accurate in measuring cellular traction forces in a 2D surface 
with reasonable accuracy but the algorithms involved can be complex and the 
measurements computationally intensive. Micropillars can accomplish the same 
general task with TFM but requires microfabrication and availability of clean 
rooms however, the analysis can be quicker and provide additional insight due to 
the ability to tailor the stiffness and topographical characteristics of the surface.  
Similarly FRET tension sensors are ideal for measuring picoNewton levels of 
tension across biomolecular by measuring FRET efficiencies between donor and 
acceptor fluorohpores (usually via fluorescence-lifetime imaging microscopy) but 
suffers from complex fabrication, calibration issues and reproducibility. 
  
As the topic of this thesis involved the application of cellular-level forces with 
biomolecular/ligand specificity and evaluation of the mechanotransductive ability 
of transmembrane receptors, I describe in the next section the fabrication of a 
versatile magnetic tweezers system that employs an electromagnetic needle (a 
fabrication which is a bit more involved compared to permanent magnetic 
needles) and enables precise force application via modulating the input current. 
The force regimen with this magnetic tweezers can be applied remotely in 
multiple directions, with tunable frequency, magnitude and duration, is 
inexpensive to build and can also be used as a tool to measure local cellular 
rheology. Changes in cellular rheology in response to mechanical force applied to 
specific cellular receptors can be used as readout to evaluate mechanosensing 
and lead to novel insights in how cells translate mechanical inputs to biochemical 
outputs. 
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Chapter 2 
 
2.1 Design and development of a custom-built magnetic tweezers 
apparatus to study cell mechanics and mechanotransduction 
 
I herein outline the system design, fabrication along with examples of 
experimental applications of a custom-built electromagnetic tweezers apparatus 
developed for the Cellular and Molecular Biomechanical Laboratory of Dr. 
Armando del Rio Hernandez (Figure 2.1).  
 
     
Figure 2.1: Schematic of magnetic tweezers. The technique relies on 
generating magnetic field gradients to pull onto ligand-coated magnetic beads 
bound on specific cellular receptors The technique can be easily combined with 
live cell microscopy (brightfield or fluorescent) to investigate the cellular response 
to controlled mechanical forces.   
 
The magnetic tweezers system described here is a magnetic micromanipulation 
technology that can apply controlled forces to specific cellular surface receptors 
through bound ligand-coated micrometre-sized magnetic beads. The technique is 
used to investigate force-induced changes of the mechanical properties and 
biochemical signalling functions in single living cells1,2. 
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2.2 Basic principle of magnetic tweezers 
 
If a magnetic bead with volume V and magnetic susceptibility χ is exposed to an 
external magnetic field H = B/µ, the field induces in the bead a magnetic 
moment:                    
                                              𝒎 = 𝜒×𝑉×𝑯  
 
If the magnetic field is inhomogeneous (𝛁𝑩 ≠ 0), the probe experiences a force: 
                                                𝑭𝒙 = 𝑚 !"!" , 
 
along the direction x of the magnetic flux. While the amplitude of the field is 
important, it is the gradient of the magnetic field  𝛁𝑩   that directly factors into the 
magntitude of the force.      
Thus, the limiting factors for F are the magnetic moment of the bead and the 
magnetic field gradient. The magnetic moment of the bead is determined by its 
size and susceptibility, as well as the amplitude of the magnetic field generated 
by the electromagnet, which in turn is proportional to the solenoid current and 
number of coil turns. The magnetic field gradient is mainly dependent on the 
distance between the magnetic core and the bead as well as the core geometry. 
The gradient is the strongest close to the magnet, as the field drops in magnitude 
roughly exponentially with increasing distance. If the core is tapered off to a 
needle shape, the magnetic flux is bundled and the gradient will reach a 
maximum near the needle tip. 
 
 
2.3 System design and setup 
 
An overview of the magnetic tweezers setup is shown in Figure 2.2. The main 
components are: i) electromagnetic coil or solenoid, ii) ferromagnetic core, iii) 
micromanipulator, iv) functionalised magnetic microbeads, v) current amplifier vi) 
PC equipped with Data Acquisition Card (DAQ) and LabVIEW interface, vii) 
inverted microscope with high speed camera, viii) MATLAB for (off-line) data 
analysis. 
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Figure 2.2: Schematic of magnetic tweezers setup. A voltage signal 
generated via the digital-to-analogue converter of a data acquisition card is fed to 
a current amplifier and supplied to the the terminals of an electromagnetic coil 
enclosing a magnetic needle to create a local magnetic field gradient. Magnetic 
beads exposed to the field gradient experience a pulling force towards the tip of 
the needle that is proportional to the current and needle-bead distance. The 
positioning of the tweezers is remotely controlled through a micromanipulator that 
allows translational movements across all axes with sub-micron precision. The 
current going through the electromagnetic coil is controlled and tracked remotely 
in a LabVIEW interface. Demagnetisation of the electromagnetic needle between 
experiments is achieved by applying a small coercive current to cancel out any 
remnant field in the ferromagnetic core. The force-induced displacement of cell-
bound magnetic is recorded through video microscopy using a high-speed 
sCMOS camera and analysed off-line with particle-tracking software to 
extrapolate cellular mechanics and/or how cells respond to a specific mechanical 
stimulus. 
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The working principle of the technique relies on the force generated by an 
electromagnet. The magnetic field is generated when current passes through an 
electromagnetic coil (solenoid); a ferromagnetic core guides the magnetic flux 
along the axis of the coil and generates a high field gradient around its needle 
shaped tip.  
 
The solenoid is made of ~ 200 closely packed turns of AWG25 copper wire, 
wrapped around a 3-cm long aluminum frame that encases a 4-mm (diameter) 
ferromagnetic core holding it in place via 3 small screw pins on its base. 
Increasing the solenoid current or the number of coil turns can increase the field 
magnitude until the core is saturated. 
 
The magnetic permeability of the core is also a material parameter that affects 
the total magnetic flux through the core at a certain external field. Typically soft 
magnetic alloys, like iron-nickel alloys (e.g. permalloy or mu-metal) are used due 
to their high magnetic permeability and/or saturation magnetisation. For our 
system, we regularly use mild steel, which has a relatively low magnetic 
permeability (µ~1000 compared to µ~20,000 for mu-metal) but a high saturation 
induction (~1.9T vs 0.8T for mu metal). 
The end of the cylindrical shapped magnetic core is tapered and has a sharp tip 
with a radius of <30µm. Tapering was achieved with micromachining using a 
cylindrical grinder at ~16,000 RPM and the tip was further polished using #4000 
grade sandpaper.  
 
The magnetic tweezers is mounted onto a micromanipulator (Eppendorf 
Injectman NI-2), which has 3 stepper motors that control the positioning of the 
needle with nanometre precision (~40 nm steps) on all axes. The inclination 
angle of the needle is set to 45° relative to the microscope stage but is generally 
adjustable through an arc of 0-90°. 
 
Our current source – a modulated power supply consisting of a high current 
operational amplifier (Accel Instruments, TS200-0x) – drives the current to the 
solenoid. A 16-bit data acquisition card (NI PCIe-6341) capable digital and 
analogue I/O generates the initial voltage signal that is fed to the amplifier. The 
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current is controlled and tracked in real-time in LabVIEW. The current going 
through the solenoid is picked-off by a 1Ω current sense resistor connected in 
series with the solenoid and the amplifier and projected to the LabVIEW 
interface. Custom-made virtual instrument interface are made in LabVIEW to 
control the amplitude, frequency, duration and the overall current waveform, all 
factors that determine the protocol of the applied force (static, pulsatile etc).  
 
Heating in DC electromagnets arises largely due to the resistive coiling of the 
solenoid, and this could potentially damage biological samples during 
experiments. We have minimised heating issues by restricting the current to I ≤ 
3A and having a resistor connected in series with the solenoid absorbing some of 
the power from the circuit and dissipating it as heat away from the biological 
sample. With the present setup and for DC currents up to 3A we didn’t notice any 
dangerous temperature rise above 37 degrees Celsius for durations of up to 30 
min of static force. The magnetic tweezers setup is shown in Figure 2.3. 
 
 
Figure 2.3: Overview of the integrated magnetic tweezers apparatus. 
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2.4 Demagnetization 
 
In order to reset the force to zero after every experiment, we demagnetize the 
ferromagnetic core by applying a small (negative) coercive current to cancel out 
the remnant magnetic field in the core. This is due to the nature of ferromagnetic 
materials, in general, retaining a degree of magnetisation even after removal of 
the external magnetic field (hysteresis), which can in turn bias measurements. 
The coercive current needed to cancel out the remnant field is dependent on the 
precedent magnetising current, and can be determined experimentally by 
checking the value at which attractive movement of the beads towards the tip of 
the needle stops (Figure 2.4) 
 
 
Figure 2.4: Hysteresis and demagnetization. Coercive current needed to 
demagnetize the magnetic needle for different magnetizing currents. As we reach 
the values of saturation magnetising current, the coercive current plateaus 
accordingly. 
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Optionally a ratiometric hall effect sensor can be attached to the rear end of the 
core to monitor the magnetic flux density B after the current is reset to zero to 
ensure that B=0. 
 
2.5 Force calibration  
 
Calibation of the magnetic tweezers is needed in order to obtain the relationship 
between force and distance across different magnetising currents. Force is 
calibrated by measuring the velocity of micrometre-sized magnetic beads moving 
through a viscous fluid – a commonly used method for measuring microscopic 
forces. It is simplified by the negligible inertia of the small particles and by their 
spherical shape. Stokes law describes the viscous drag F experienced by a 
spherical particle with radius r moving with a laminar velocity u through a medium 
with viscosity η is:    
                                              
                                            𝐹 = 6𝜋𝜂𝑟𝑢  
 
 A small number of beads are diluted in silicone oil with a calibrated viscosity of 1 
Pa.s. The needle is immersed into the solution and bead movements are tracked 
during repeated current on-off cycles. Settling of the viscous fluid causes a 
constant bead drift, which is accounted for during the current-off phase. The drift-
corrected velocity is then used to calculate the force acting on the bead. Video 
acquisition using a sCMOS camera (at 20 frames/sec) is used for bead tracking. 
A custom-made particle-tracking algorithm developed in MATLAB (Dr. Simon 
Attwood) tracks the intensity-weighted centroid of the bead, frame-by-frame, as it 
is attracted towards the tip of the magnetic needle. Force-distance curves are 
produced and the data points are fitted to a power-law (Figure 2.5) 
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Figure 2.5: Force calibration. Representative force calibration curve for 4.5 µm 
magnetic beads at I=1A 
 
Errors in force calculation during calibration or tracking arise mainly from errors in 
measuring the distance between the bead and the tip of the electromagnetic 
needle. For the calculation of the applied force, at a given current, and assuming 
a force-distance relationship that follow the power law 𝐹 𝑑 = 𝐹! !!! !, with the 
exponent β representing the slope of force-distance in a log-log plot, and an 
uncertainty Δd in measuring the distance leads to a relative error in force 
estimation 𝛥𝐹𝐹 = 𝜕𝐹𝜕𝑑 ∙ 𝛥𝑑𝑑 ! = 𝛽 ∙ 𝛥?𝑑  
For a distance d=40 µm and an error Δd=2 µm, the relative error is between 5-
10% and becomes smaller for larger distances. Bead size variation can add up to 
this relative error. 
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2.6 Magnetic beads and ligand conjugation 
 
For our experimental assays we utilise superparamagnetic beads (particle that 
magnetise upon placement in a magnetic field but lose magnetisation upon 
removal from the field) are either 2.8µm diameter carboxylated magnetic beads 
from Thermo Fisher Scientific (Dynabeads M-270 carboxylic acid) or 4.5 µm 
diameter epoxylated Dynabeads if larger forces and surface contacts are desired. 
 
Ligands for targeting cell surface adhesion receptor for mechanotransduction 
analysis can be covalently linked to the superparamagnetic beads of 2.8 µm or 
4.5 µm diameter. Bead diameter is normally restricted to 2-5 µm since smaller 
beads tend to go phagocytosis during the 30-60 min incubation period and larger 
beads have stronger adhesion to the cell that restrict bead displacement under 
the force range generated by our magnetic tweezers device (100 pN-10 nN). 
Limiting bead size and incubation time with the cells avoid these problems. 
 
 
 
Here I outline the conjugation of fibronectin to 2.8 µm carboxylated Dynabeads:  
 
1. Prepare buffers as per Thermo Fisher Dynabeads M-270 caroxylic-acid-activated 
protocol: 
a. 50 mM MES buffer, pH 5 
b. 50 mM Tris buffer, pH 7.4 
c. 0.01 M NaOH 
d. PBS, pH 7.4 
2. Transfer 100 µL of Dynabeads (~2 x 108) into an eppendorf tube. 
3. Wash beads (2x) by adding 100 µL 0.01 M NaOH and incubate for 10 min with 
good mixing. Apply magnet and remove supernatant. 
4. Wash (2x) with 100 µL with dH2O. 
5. Dissolved EDC (carbodiimide crosslinker) in cold dH2O to 0.1-0.4M. Add 100-200 
µL of EDC-solution to the Dynabeads and vortex. Incubate for 30 min at room 
temperature. 
6. Apply magnet and remove supernatant 
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7. Wash (1x) with cold dH2O and wash again (1x) with 50 mM MES buffer, as 
quickly as possible to avoid hydrolysis of the activated –COOH groups. The 
dynabeads are now activated and ready for coating with a ligand containing 
primary amino groups. 
8. Apply magnet and remove supernatant. 
9. Add 60 µg ligand (e.g. fibronectin) in 60 µL 50 mM MES buffer to the activated 
Dynabeads. 
10. Add 40 µL of 50 mM MES buffer to final volume of 100 µL and vortex. 
11. Incubate overnight at 4°C with slow tilt and rotation. 
12. In order to quench the non-reacted activated –COOH groups, incubate the 
Dynabeads coated with ligand with 50 mM Tris buffer, pH 7.4 for 15 min at room 
temperature with slow tilt and rotation. 
13. Wash coated Dynabeads (4x) with 50 mM Tris with by adding BSA (blocking 
agent) to a final concentration 0.1% w/v. 
14. Resuspend the coated Dynabeads to the desired concentration (100 µL) 
in PBS. Long-term storage (weeks/months at 4°C). 
15. Incubate 5-10 µL of coated dynabeads in 2 mL of cell culture media and 
incubate for 20-30 min. Wash unbound beads with warm PBS and resuspend in 
media. Proceed to experiments. 
 
 
 
2.7 Experimental applications of magnetic tweezers 
 
Several studies have utilised magnetic tweezers or some variation of the 
technique to probe any of the following: 
i) cell mechanics   
ii) mechanotransduction - how cells respond to mechanical forces, either 
mechanically or biochemically,  
iii) cell adhesion strength to ECM ligands and/or 
iv) manipulate single biomolecules. 
 
In early work, Wang et al. used RGD-coated magnetic beads to apply (twisting) 
forces to integrins on the surface of endothelial cells and observed a stiffening 
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response that was dependent on the actin cytoskeleton3. McCulloch’s group 
utilised permanent magnets placed above cell cultures to pull vertically on 
collagen-coated beads and measure changes in intracellular calcium influx in 
response to force4, as well as bulk biochemical measurements on large 
populations of cells, such as analysing protein tyrosine phosphorylation5. Na et 
al. have combined magnetic tweezers with FRET to analyse rapid 
mechanochemical signalling in live cells, where he showed that cytoskeletal pre-
stress is required for rapid activation of Src in response to force6. 
 
Following on from these studies, Burridge et al. combined magnetic tweezers 
along with biochemical analyses to analyse the mechanical response of cells and 
the associated signalling pathways downstream of tension applied on integrins. 
Pulling on fibronectin coated in a cycling fashion led to rapid adaptive cellular 
stiffening, accompanied by cytoskeletal remodelling and strengthening of the 
focal adhesion complex. The cellular adaptation to force was mediated by 
activation RhoA via two distinct Rho GEF upstream regulators, namely LARG 
and GEF-H17. (Figure 2.6) 
 
Figure 2.6: Cell mechanical response to force. Cellular stiffening of REF52 
fibroblasts in response to pulses of force applied to fibronectin-coated (integrin-
bound) magnetic beads using magnetic tweezers. Adapted from Burridge et al. 
2011 
 
In subsequent work, magnetic tweezers was used to apply successive 
applications of force an isolated nucleus through the nuclear envelope protein 
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nesprin-18. This unexpectedly resulted in nuclear stiffening, indicating the 
mechanoresponsive nature of the nucleus. 
 
Magnetic tweezers microrheology has also been extensively used for 
characterising cellular mechanics by measuring cell deformation in response to 
magnetically generated forces both in the linear and non-linear deformation 
regime. There are different models of cellular biomechanical behaviour.  
 
The cell’s response to a step application of force is viscoelastic, with an 
immediate elastic response (phase I) followed by gradual creep (phase II and III). 
The viscoelastic behaviour of materials (including cells and many biological 
tissues) can be modelled using lumped parameter models constructed from 
arrangements of two simple elements: the linear spring and dashpot. The 
elements in these models (springs and dashpots) cannot be unambiguously 
related to specific cellular components; instead, we represent the action of all 
elastic components of the cell by a linear spring (or springs) and the action of all 
viscous components by a dashpot (or dashpots). This “lumping” of the response 
but of a complex biomechanical system is obviously an oversimplification but is 
nevertheless a good first approach to quantifying cellular mechanics (Figure 2.7). 
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Figure 2.7: Viscoelastic creep response of a cell measured by magnetic 
tweezers microrheology. The bead was coated with fibronectin bound to the 
integrin receptor providing a link to the cytoskeleton. The displacement of the 
bead under force follow a rapid elastic displacement (phase I), followed by creep 
in phases II and III. The lumped parameter model (a mechanical circuit made up 
of springs and dashpots in a series and parallel arrangement) proposed by 
Bausch et al is then used to fit the data and obtain the effective spring constant 
(cell stiffness) and viscosity. Adapted from Bausch et al. (1999) 
 
Other models have attempted to describe the viscoelastic behaviour based a 
simple power law that is timescale invariant based on the behaviour of soft glassy 
materials.  
 
The magnetic bead contact area with the cells can influence the measured cell 
compliance and is a variable that cannot be controlled accurately other than by 
keeping bead-cell incubation times consistent (~20 min) and duration of 
experiments short (30 min). A characteristic viscoelastic creep response of 
mouse embryonic fibroblasts (MEFs, n=20) using fibronectin-coated beads (4.5 
µm) closely follows a weak-power law. 
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 Figure 2.8: Power-law creep response of mouse embryonic fibroblasts 
 
In this set of experiments the creep response of mouse embryonic fibroblast was 
determined by applying a constant force (1nN) over a period of 3 seconds and 
recording the resulting bead displacement at a rate of 50 Hz or every 20ms. 
Individual beads moved over time according to a weak power law 𝑑 𝑡 = 𝑑! 𝑡𝑡! ! 
 
with the exponent β typically ranging between 0.1-0.4. In this formula time is 
normalised t0=1s to get a dimensionless exponent β. The creep compliance J(t) 
is then estimated as the applied constant force F0 from the bead displacement 
d(t) as follows. Stress σ0 is estimated as the applied force F0 divided by the bead 
cross section A=4πr2. Local strain γ(t) is defined as the bead displacement 
divided by the bead radius, the characteristic length scale during experiments 
being γ(t)= d(t)/r. Thus, the time dependent creep compliance is then given 𝐽 𝑡 = 𝛾(𝑡)𝜎! = 𝑑(𝑡)𝑟! ∙ 𝜋𝑟!𝐹! = 𝜋𝑟𝐹! ∙ 𝑑(𝑡) 
 
Thus by setting 𝐽! = !!!! ∙ 𝑑!, we have 
                                                 𝐽 𝑡 = 𝐽! !!! ! 
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Magnetic tweezers have also been used to manipulate single biomolecules. For 
example, del Rio et al. utilised a magnetic tweezers device to stretch the talin rod 
molecule that was fixed through its 6-His N-terminus on a Ni-NTA grafted glass 
slide with an avidinated magnetic bound to its biotinylated C terminus. 
Piconewton forces exerted by magnetic tweezers stretched the talin rod domain 
to expose cryptic sites for vinculin binding, revealing a novel mode of molecular 
mechanotransduction9. 
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Chapter 3 
 
 
The tumour microenvironment as a target for cancer therapy 
 
 
Tumour progression is not only dictated by the genetic and epigenetic alterations 
within tumour cells, but also by the whether the surrounding niche is permissive 
to growth at all stages of disease. Cancer cells grow and evolve in complex 
tissue microenvironments, interacting closely with the extracellular matrix (ECM) 
and stromal cells, which together form the tumour microenvironment (TME)1. 
Recognition of the essential nature of the TME in cancer progression has led to a 
shift from a tumour cell-centred view of cancer development to the concept of a 
complex tumour ecosystem that supports tumour growth and metastastic 
dissemination2.  
 
Here we address five emerging paradigms in our understanding of the TME: i) 
how biomechanical changes in the TME influences cancer progression and 
treatment response, ii) the role of cancer-associated fibroblasts in tumourigenesis 
and iii) therapeutic strategies for re-educating or normalising the TME.   
 
 
Cancer - a disease of altered mechanobiology 
 
The mechanical microenvironment has a profound influence on a variety of 
tumourigenic processes including sustained proliferation, resistance to cell death 
and invasion and metastasis. Tumours exhibit altered tissue-level and cell 
mechanics, including extracellular matrix (ECM) remodelling and stiffening, 
elevated interstitial fluid pressure and altered mass transport3. Tumours are often 
detected as a palpable “stiffening” or hardening of the tissue, and approaches 
such as magnetic resonance imaging elastography and sono-elastography have 
been developed to measure this property in order to enhance cancer detection. 
This palpable stiffening characteristic of many solid tumours is attributed to 
desmoplasia (or fibrosis) - the excessive synthesis and deposition of a dense, 
stiff collagenous stroma that can occupy up to 90% of the tumour volume 4.  
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For instance, patients with cancer who present with high levels of fibrillar collagen 
show enhanced incidence of metastasis, and women with increased 
mammographic density, an indicator of increased collagen density and ECM 
stiffening, exhibit a greater risk for developing breast cancer 5.  
 
Such findings present an enticing argument that ECM stiffening can dictate 
tumour phenotype by shifting the tensional homeostasis of resident tumour and 
stromal cells by way of engaging their mechanosensing machinery. Forces are 
detected and transduced into biochemical signals by force- bearing molecular 
elements at the cell surface, most notably via integrin-mediated adhesion 
complexes. While integrins have no intrinsic enzymatic activity, force-induced 
integrin clustering can trigger downstream signalling pathways via focal adhesion 
kinase (FAK), demonstrating their ability to influence mechano-chemical 
signaling.  
 
Tensional homeostasis requires a balance between the forces exerted by the 
cells pulling on the ECM and the reciprocal forces exerted by the ECM on the 
cells themselves. When progressive ECM stiffening disrupts this intricate force 
balance, a number of mechanosensitive signalling pathways can be adversely 
affected.  
 
In this regard, one molecular mechanism linking ECM stiffness with cancer 
progression was illustrated by recent data demonstrating a strong association 
between ECM stiffening and the expression (and activity) of the collagen 
crosslinking enzyme lysyl oxidase (LOX) during breast cancer progression5,6. 
LOX-dependent collagen crosslinking was found to elevate tissue stiffness and 
promote tumour progression by enhancing integrin clustering and 
mechanosignalling (Figure 3.1). Mechanistically, matrix stiffness was found to 
modulate ErbB receptor-dependent phosphoniositide-3 kinase (PI3K) activation, 
which led to mammary epithelial cell invasion. Conversely, inhibiting LOX-
mediated collagen crosslinking prevented tissue stiffening, delayed tumour 
progression and reduced tumour incidence.  
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Figure 3.1: Tensional homeostasis in breast cancer progression. Mammary 
epithelial cells cultured in 3D matrigel/collagen gels assemble polarised, 
spherical acini (control) evident by immunofluorescent staining of β4 integrin 
(basal orientation) and β-catenin (cell-cell junctions). Oncogene activation 
(+ERBB2) in mammary epithelium fails to produce an invasive phenotype. 
Similarly, matrix stiffening via ribose-mediated crosslinking (+ribose) also fails to 
produce an invasive phenotype. Invasion occurs only when activated oncogenes 
act together with matrix stiffening to (+Ribose, +ERBB2) to synergistically induce 
metastatic progression. Adapted from DuFort et al5. 
 
Similar functional links between increased tissue rigidity, mechanotransduction 
signalling and tumour aggressiveness have been found for pancreatic cancer. A 
specific genotype of pancreatic cancer with impaired TGF-β signalling was found 
to exhibit extensive periductal fibrosis and elevated epithelial STAT3 activity, 
along with elevated integrin mechanosignalling and epithelial actomyosin 
contractility7. Ablation of epithelial STAT3 activity - commonly associated with 
inflammation, attenuated tumour progression by reducing stromal stiffening and 
epithelial contractility induced by loss of TGF-β signalling. These data 
demonstrate that altered tumour mechanotransduction and response to anti-
stromal therapies may be functionally linked with the tumour genotype. 
 
Biophysical studies have revealed that extracellular forces evoke 
mechanoreciprocal endogenous cellular tension via Rho/ROCK activation to 
balance internal and external forces. Olson et al. used a mouse model of 
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squamous cell carcinoma - a form of skin cancer- to demonstrate that ROCK-
mediated contractile force drives tissue stiffness via elevated collagen deposition 
and promotes β-catenin mediated hyperproliferation, which increase tumour 
burden and progression8. A different study by Timpson et al. used genetically 
engineered and patient-derived mouse models of pancreatic cancer to 
demonstrate that tissue priming with ROCK inhibitor Fasudil disrupted tumour 
stroma remodeling and improved the effectiveness of subsequent treatment with 
standard-of-care chemotherapy in both primary and metastatic sites 9. These 
studies demonstrate that ROCK-mediated cellular tension aids cancer 
progression, and illustrate how a key GTPase signalling intermediate, frequently 
activated in human cancer by direct actions of regulatory proteins, oncogenes, 
growth factor receptors or increased ligand levels can promote cancer by 
modulating the interplay between cell and tissue level forces 8.  
 
Increased ECM stiffness appears to promote a malignant phenotype through 
various other mechanisms. Increases in matrix rigidity has been shown to 
promote invasion and metastasis by enhancing the activity of matrix 
metalloproteinases (MMPs), a class of proteolytic enzymes that aid in 
degradation and invasion through ECM10, via promoting invadopodia formation 
for ECM degradation11 as well as by directly inducing epithelial-mesenchymal 
transition (EMT) 12 – a phenotypic transition linked to invasion, metastasis and 
cancer stem cell properties. One mechanistic study found a molecular pathway 
directly linking mechanical forces and tissue rigidity with transcriptional regulation 
of the EMT program. Specifically, increasing matrix stiffness was found to drive 
integrin-dependent phosphorylation events to release the EMT-inducing 
transcription factor TWIST1 from its cytoplasmic anchor G3BP2 to enter the 
nucleus and drive transcriptional events of EMT and invasion 12. 
 
MicroRNAs (miRNAs) have also been found to be sensitive to mechanical cues. 
miRNAs are post-transcriptional regulators of gene expression that are altered in 
many cancers, where they modulate levels of tumour suppressors and 
oncogenes that regulate cell growth, survival, and invasion. Matrix stiffness is 
known to engage mechanotransduction signalling to regulate miRNA expression. 
In a model of breast cancer, Weaver’s group identified a mechanically regulated 
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miRNA, miRNA-18a that targets the tumour suppressor phosphatase and tensin 
homolog (PTEN), to promote PI3K-dependent malignancy 3.  
 
Altered ECM mechanics can also contribute to sustained proliferation. ECM 
stiffness can promote growth factor signalling to enhance proliferation. In a 
glioblastoma model, increased ECM stiffness enhanced activation and 
expression of EGFR and its downstream mitogenic partners such as PI3K and 
AKT 13. Matrix rigidity can also promote transition through G1/S phases of the cell 
cycle 14-17. In mouse embryonic fibroblasts, an increase in focal adhesion 
signalling such as FAK and p130Cas, led to activation of ERK and PI3K 
signalling and subsequently Rac, which induced cyclin D1 to increase cell 
proliferation14-17.  
 
Furthermore, YAP/TAZ, transcriptional co-activator of the Hippo pathway have 
been found to be sensitive to mechanical cues18 and are aberrantly activated in a 
number of human cancers, promoting cell growth, proliferation and intrinsic 
chemoresistance. In addition to mechanics, topographical features of the ECM 
are important. The periductal collagen in breast and pancreatic cancer exhibits 
architectural and structural differences in terms of linearization, alignment, and 
thickness, which can serve as independent prognostic markers but might also 
facilitate cancer invasion through topographical contact guidance 19,20.  
 
The fibrotic TME is also rich in water-absorbing polysaccharides, most notably 
hyaluronan, which swells, pressing on surrounding cells and structural elements 
of the tissue 21,22. This, along with the mechanical pressure exerted by the 
expansion of hyperproliferating stromal and cancer cells, facilitates a mechano-
pathology known as tumour-induced solid stress, resulting in compromised blood 
vessels and lymphatics, which respectively lead to increased hypoxia and 
elevated interstitial fluid pressure (IFP). Both hypoxia and IFP attenuate 
chemosensitivity via separate pathways. Low oxygen tension promotes EMT and 
genomic instability in tumour cells which directly fuels chemoresistance, while 
elevated IFP impairs intratumoural drug perfusion indirectly leading to diminished 
treatment response23. Fernández-Sánchez investigated the contribution of 
mechanical pressure exerted by tumour growth onto non-malignant epithelium of 
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murine colon tissue in vivo. Using magnetically stimulated ultra-magnetic 
liposomes to mimic tumour growth-induced solid stress, they were able to 
stimulate β-catenin to promote the cancerous behavior of both a normal and 
genetically modified colon epithelium, raising the possibility that mechanical cues, 
in addition to genomic instability, can contribute to tumour heterogeneity24,25.  
 
Increased lymphatic drainage enabled by steep IFP gradients at the tumour 
margin can also drive increased interstitial flow, which can drive tumour 
progression and invasion, both by direct mechanomodulation of the tumour 
stroma and also by altering the host immune response26. Interstitial flow in the 
stroma triggers myofibroblast differentiation and contraction, as well as alignment 
and stiffening of the ECM via TGF-β dependent mechanisms.27 In addition to 
upregulating TGF-β production by fibroblasts, flow-induced matrix contraction 
and shear stress can activate the stores of latent TGF-β in the ECM, therefore 
driving a positive feedback loop28.  
 
As for direct effects on tumour cells, flow has been shown to increase their 
invasiveness, at least in vitro.26,29,30 One proposed mechanism is autologous 
chemotaxis. For example, chemokine secretion by tumour cells leads to the 
formation of local pericellular gradients under fluid flow that drive chemotaxis and 
invasion in the flow direction. Elevated level of interstitial flow may therefore bias 
autologous chemokine gradients, promoting directional homing of tumour cells 
and myofibroblasts towards the draining lymphatic network.  
 
Intriguingly, interstitial flow and lymphatic drainage can also modulate the 
immune microenvironment. The activation and release of TGF-β in the tumour 
stroma by interstitial flow is a potentially important mechanism by which flow can 
foster an immunosuppressive microenvrionment. Although, it should be 
emphasized that TGF-β stimulates both tumour-promoting and tumour-
suppressing processes 31,32, it is among the most potent activators of tumour-
associated T(Treg) cells and myeloid-derived suppressor cells (MDSCs), which 
suppress cytotoxic T lymphocyte function to facilitate tumour immune escape 26. 
Additionally, interstitial flow can alter the chemokine and cyotkine milieu in the 
TME to promote re-education of immune cells and suppress anti-tumour 
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immunity. For instance, flow can drive the production of the chemokine CCL21, 
which can in turn alter patterns of antigen presentation and lymphatic homing of 
CCR7+ dendritic cells, which are largely maintained in an immature state 33. 
 
Lymphatic drainage can also promote the delivery of tumour antigens and 
regulatory cytokines into the immune microenvrionment of the tumour-draining 
lymph node. This altered cytokine milieu within the lymph node can promote 
immunosuppression via induction of Treg cells and inhibition of cytotoxic 
lymphocytes. Further understanding between interstitial/lymph flow, stromal 
transformation and anti-tumour immunity may lead to new immunotherapeutic 
strategies in the future to block the tolerance-promoting effects of lymphatic 
drainage in tumours.  
 
 
Role of cancer-associated fibroblasts in tumour progression 
 
Definition, molecular markers and origins of CAFs 
 
Cancer associated fibroblasts (CAFs) are a subpopulation of cells found in the 
tumour stroma with a prominent functional role in cancer progression and 
metastasis. CAFs, also referred to as tumour-associated fibroblasts (TAFs) or 
activated myofibroblasts, are found in almost all solid tumours; however their 
abundance varies between different types of cancer. For example, pancreatic, 
breast and prostate cancers contain high number of CAFs, whereas brain, renal 
and ovarian cancer demonstrate fewer34. CAFs are generally defined as all the 
fibroblastic, non-epithelial, non-immune cells found in the TME, yet a precise 
molecular definition is lacking. 
 
CAFs can be distinguished from neoplastic cells that have undergone EMT and 
show a fibroblastic-like morphology by their stable karyotype and lack of genetic 
alterations. Emerging data demonstrate that CAFs represent a complex, 
heterogeneous population of cells in the tumour stroma35. While several 
molecular markers have been suggested to define CAFs, these markers do not 
define all CAFs and most of them are not even unique to CAFs or to the 
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fibroblast lineage. One of the most robust markers is alpha smooth muscle actin 
(a-SMA), which identifies CAFs with myofibroblastic morphology and contractile 
characteristics35,36. Nonetheless, a-SMA is also expressed in other cell types 
such as pericytes and smooth muscle cells surrounding blood vessels. Fibroblast 
activation protein α (FAPα) is another common marker for distinguishing CAFs in 
many solid tumours including breat, lung, ovarian and pancreatic, but this marker 
be also expressed in quiescent mesodermal cells in multiple tissue types. 
Another well studied CAF marker is FSP-1 (also known as S-100A4), yet this 
marker is similarly not exclusively restricted to CAFs and is also expressed by 
epithelial cells undergoing EMT as well as bone marrow derived cells, including 
macrophages that respond to tissue injury35,36.  It is conceivable some of the 
aforementiontiond molecular markers are expressed or coexpressed 
heterogeneously among CAFs possibly reflecting different stages of activation 
and/or sources of CAFs. 
 
CAFs found within an individual tumour can be derived from multiple tissue types 
and numerous cell types have been reported to transdifferentiate to CAFs. 
Perhaps, the most direct source of CAFs derives from resident tissue fibroblasts 
and mesenchymal stem cells. In response to injury and disturbed tissue 
homeostasis, local fibroblasts have been shown to undergo myofibroblast 
activation in a number of different organs and in the stroma of epithelial tumours. 
EMT is another mechanism of myofibroblast generation from local epithelial and 
endothelial precursors during tumour development.  
The stellate cell is a distinct cell type that shares many of the same features and 
functions of fibroblasts. In its quiescent state, it is a vitamin A-storing and lipid 
droplet containing cell that can be found in the pancreas and liver. Similar to 
fibroblasts, stellate cells activate aSMA expression upon stimulation and acquire 
a myofibroblastic, contractile, ECM synthesizing phenotype. Stellate cells are 
responsible for the majority of the desmoplastic reaction seen in pancreatic 
cancer, pancreatitis and liver fibrosis, and are also categorised as CAFs when 
seen in the TME (Figure 3.2) 
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Figure 3.2: Activated stellate cells (or CAFs) promote disease progression.  
In pancreatic cancer, stromal fibroblasts, namely pancreatic stellate cells (PSC) 
undergo a transformation from a quiescent (vitamin A storing phenotype) to an 
activated state (myofibroblast-like phenotype). Once activated, PSCs promote 
stromal desmoplasia via aberrant ECM remodelling which leads to a 
stiffened/aligned ECM, and release growth factors and pro-inflammatory 
cytokines that aid cancer cell survival. Adapted from Sherman et al.37 
 
 
 
CAFs promote tumourigenesis and metastasis by altering the TME 
 
Substantial evidence corroborates the notion that bidirectional interplay occurs 
between cancer cells and CAFs, commensally facilitating tumour progression.  
Upon activation CAFs acquire an expansive secretome, which is starkly subdued 
in the non-activated or quiescent state. CAFs interact with adjacent cancer cells 
through soluble factors (chemokines, cytokines and inflammatory mediators), 
exosomes or direct cell-cell communication to promote cancer cell invasion.  
 
For instance, CAFs secrete soluble factors, including TGF-β, PDGF and HGF, 
which promote EMT and acquisition of an invasive phenotype in the neighbouring 
cancer cells via paracrine singalling38. Several studies have demonstrated that 
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CAF-conditioned medium increases proliferation, migration, invasion and 
chemoresistance of cancer cells and reduces their apoptosis in vitro23. The ability 
of CAFs to influence tumour growth is also partly dependent on their ability to 
induce angiogenesis by CAF-derived stromal cell-derived factor 1 (SDF1; also 
known as CXCL12) and recruitment of bone marrow-derived endothelial cells35,39. 
Activated CAFs produce ECM-degrading proteases such as MMPs, which can 
also help enhance motility and invasion of cancer cells. In vivo, co-injecting 
cancer cells together with CAFs in mice augments tumour growth and promotes 
metastatic dissemination relative to solely injecting cancer cells. Apart from 
soluble factors, exosomes released by CAFs mediate the transfer of functional 
molecules, including proteins, lipids, DNA and RNA to cancer cells, which 
stimulate the invasive and metastatic potential of cancer cells. Reciprocally, 
cancer cells recruit CAFs to the invasive front of the tumour via mitogenic and 
fibrogenic factors which promote CAF activation, proliferation, migration and 
ECM remodeling capability.  
 
CAFs can also contribute to the remodeling and stiffening of the stromal ECM, 
thereby offering a favourable microenvironment for tumour invasion and 
progression. CAFs induce desmoplasia by depositing excessive amounts of 
collagen and other ECM proteins, and also by using force and proteolytic activity 
(e.g. matrix metalloproteinases – MMPs) to remodel the ECM to generate tracks 
for migration of cancer cells as collective stands led by CAFs40. Matrix stiffening 
in the TME enhances cancer cell migration through integrin-mediated 
mechaontrasduction but also serves to maintain the activated CAF phenotype 
(Figure 3.3). Recent studies have highlighted the function of YAP and caveolin 1 
(CAV1) in CAFs to enhance actomyosin-mediated ECM stiffening which in turn 
induces cancer cell invasion41,42. CAF markers such as CAV1 have been 
associated both with tumour-promoting and tumour-suppressive functions. Loss 
of CAV1 expression in breast cancer CAFs define metabolically altered 
fibroblasts with pro-tumourigenic functions, yet high expression of CAV1 in CAFs 
could also facilitate tumour invasion via ECM remodeling35,39.  
 
ECM remodeling by CAFs may also participate in the generation and 
maintenance of the cancer stem cell niche. CAFs can be co-opted by cancer 
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stem cells to induce a milieu that could promote cancer stem cell maintenance. 
Expression of matricellular proteins, such as periostin, is probably rate limiting for 
stromal remodeling, and WNT-mediated signalling-mediated cancer stem cell 
niche maintenance.  
 
 
Figure 3.3: The CAF in tumour stroma remodelling. CAFs can arise from a 
variety of different progenitor cells, including resident fibroblasts, epithelial and 
endothelial cells via EMT as well as pericytes and mesenchymal stem cells 
(MSC). In healthy stroma, the precursor cells are stress-shielded by a healthy 
functional ECM and do not develop features associated with the myofibroblastic 
phenotype. Upon injury or loss of tissue homeostasis (cancer has been described 
as “wound that does not heal”, inflammatory soluble mediators and profibrotic 
cytokines activate stromal cells to spread and remodel the initially soft ECM. The 
graduate increase in ECM stiffness enables the formation of contractile 
microfilaments, actin stress fibres and enlarged cell-matrix adhesions. TGF-β1 
and further increases in ECM stiffness act together to stimulate proto-
myofibroblasts to CAFs. CAFs express a-smooth muscle actin (a-SMA) and an 
expansive secretome. The force generated by a-SMA containing stress fibres 
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leads to further ECM contraction, thereby establishing a mechanical feed-forward 
loop. The stiffened, aligned ECM can also facilitate invasion of the malignant 
epithelium. Adapted from Otranto et al.43 
 
CAFs can also mediate tumour growth at secondary metastatic sites. At the 
primary tumour site, CAFs may enhance metastasis by releasing growth factors, 
cytokines, chemokines and exosomes into the circulation to stimulate, indirectly 
or directly, the growth and invasive features of cancer cells at distant secondary 
sites. For example, metastasis-associated fibroblasts that express the 
matricellular protein tenascin-C and VEGFA are key mediators of breast cancer 
metastasis to the lung. Pancreatic cancer metastasis to the liver relies on 
activation of hepatic stellate cells (which are liver-resident fibroblasts) and 
fibronectin deposition in the liver microenvironment to create a favourable niche 
for metastatic outgrowth of invading pancreatic cancer cells. In the context of 
melanoma, lung microenvironment-associated fibronectin and VEGF receptor 1 
(VEGFR1)+ cells from the bone marrow also support metastasis in the target 
organ. Metastasis associated fibroblasts are usually recruited or activated at the 
metastatic site as a result of disseminating cancer cell seeding and inflammatory 
responses. They may be activated tissue resident fibroblasts or emerge from 
primary tumour sites or from the bone marrow and be recruited to metastases.  
 
Targeting CAFs may offer powerful new tools for anti-cancer treatment, however 
their functional heterogeneity may require precise targeting efforts and more 
detailed understanding to anti-CAF therapy. 
 
 
Emerging TME-targeted cancer therapies  
 
The TME can have a complex, bimodal effect on cancer progression, with both 
cancer-promoting and cancer-restraining actions. Finding ways to target the 
cancer-promoting aspects of the TME can be a challenging undertaking. Many 
studies have shown that the microenvironment is capable of normalizing tumour 
cells, suggesting that stromal reeducation, rather than targeted ablation per se, 
may be an effective therapeutic strategy. Here we outline recent efforts aimed at 
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targeting and reprogramming the cellular and acellular components of the stroma 
with a particularly emphasis on the ECM, CAFs and mechanotransduction 
pathways for cancer therapies.  
 
 
The ECM is a dynamic three-dimensional network of molecules secreted by cells 
that forms the connective tissue between cells and provides the scaffold that 
gives structural support to organs. In addition to its structural role, the ECM 
provides biochemical and biomechanical cues to regulate cellular signalling. The 
ECM is composed of proteins, proteoglycans and glycosaminoglycans, including 
collagens, fibronectin, elastin, laminin, hyaluronan and various other, tissue-
specific ECM components 5.  
 
Olive et al. first introduced the hypothesis of stromal depletion in a preclinical trial 
using mouse models of PDAC. The authors demonstrated that acute 
pharmacological disruption of the profibrotic sonic hedgehog (Shh) signalling 
pathway in the stroma by the Smoothened inhibitor (IPI-296) led to a significant 
reduction of the tumour associated stromal tissue, increased perfusion and mean 
vessel density. This was accompanied by increased intratumoural delivery of 
gemcitabine, heightened therapeutic response and increased median survival 44. 
This preclinical work prompted clinicians to postulate that the physical rigidity of 
the desmoplastic PDAC-associated ECM may contribute to therapeutic 
resistance by compressing blood vessels and impeding drug delivery. 
 
Surprisingly, more recent efforts investigating the genetic or pharmacological 
ablation of Shh signalling in PDAC mouse models, showed dramatically different 
results. Shh-ablated pancreatic tumours in genetically engineered mice exhibited 
more frequent preneoplastic lesions, including acinar to ductal metaplasia (ADM) 
and pancreatic intraepithelial neoplasia (PanIN) during early carcinonogenesis, 
while established tumours were undifferentiated, more metastastic and highly 
proliferative compared with littermate controls. In line, with previous observations, 
Shh-deficient mice displayed a reduced number of aSMA-positive myofibroblasts, 
more pronounced tumour vasculature and were more responsive to VEGF 
inhibitors. These data suggest that chronic administration of the Smoothened 
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inhibitor IPI-926 as monotherapy, leads to more aggressive tumours with reduced 
median survival which may explain the poor clinical performance of Smo 
inhibitors in patients with pancreatic cancer that resulted in early termination of 
several clinical trials and caused skepticism regarding the concept of stromal 
depletion as a relevant therapeutic approach 45.  
 
Other preclinical investigations have introduced alternative approaches to target 
different force-altering components in the TME. For instance, diverse approaches 
have been developed to target hyaluronic acid (HA) in cancer46. Hyaluronan is 
abundant in 20-30% of human tumours, most notably in pancreatic, prostate and 
breast cancer47. One method is to directly inhibit HA synthesis or HA binding to 
its receptor. 4-MU is an HA synthesis inhibitor and has anti-tumour activity in 
preclinical prostate cancer models48. Excessive accumulation of hyaluronic acid 
(HA) in the tumour stroma retains water due to its high colloid osmotic pressure 
and elevates IFP and solid stress resulting in blood vessel compression21,23. In 
addition HA enriched matrices are known to amplify integrin-mediated 
mechanotransduction49. Hyaluronidase, an enzyme that digests hyaluronan, 
reduces mechanical stress in tumours grown in mice. Preclinical studies using 
PEGPH20, a formulation of hyaluronidase coated with polyethylene glycol to 
enhance bioavailability, can ablate stromal HA in mouse models of PDAC, 
normalize IFP, re-expand the microvasculature, and when combined with 
chemotherapy (e.g. gemcitabine) results in near doubling of overall survival50. In 
a phase I clinical trial, PEGPH20 in combination with gemcitabine had a 42% 
response rate in stage IV metastatic pancreatic cancer51. PEGPH20 is currently 
undergoing phase III clinical trials. These results suggest that targeting unique 
ECM proteins could be fruitful in altering the mechanical properties of the TME, 
thus impinging on tumour progression.  
 
Angiotensin inhibitors – inexpensive drugs commonly used to treat hypertension, 
have recently shown promise as stroma-targeting agents. Losartan, an 
angiotensin II type I receptor inhibitor, was found to reduce stromal collagen and 
hyaluronan production as well as decrease the number of aSMA positive PSCs in 
orthotopic pancreatic tumours. As a result, the treatment of tumours with losartan 
reduced solid stress and increased vascular perfusion. The overall outcome was 
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reduced hypoxia and increased sensitivity to chemotherapy agents52. Another 
matrix-altering drug is the widely prescribed anti-diabetic drug metformin, which 
has been shown to decrease collagen and hyaluronan production in pancreatic 
tumours. Metformin, is currently being tested in clinical trials worldwide as a 
treatment for different types of cancer53.  
 
Other investigators have explored the possibility of re-engineering the stromal 
landscape by targeting CAFs.  Attempts to eliminate CAFs have generally met 
with limited success, possibly due to the dichotomous nature of CAFs in tumour 
progression35. Ozdemir et al genetically depleted a-SMA-positive fibroblasts in 
KrasG12D/+;Tgfbr2fl/fl mice by intercrossing them with a-SMA-tk transgenic mice54. 
Surprisingly, myofibroblast depletion led to invasive, undifferentiated tumours 
with enhanced EMT and cancer stem cells, with diminished animal survival. 
Stromal depletion was paralleled by profound alterations in infiltrating immune 
cells that was characterized by decreased numbers of CD4+ effector cells and 
cytotoxic CD8+ cells while regulatory T cells CD3+/Foxp3+ (Tregs) were increased. 
Myofibroblast-depleted tumours did not respond to gemcitabine, however anti-
CTLA4 immunotherapy reversed disease acceleration and prolonged survival, 
underscoring a regulatory function and interaction between the fibroblast and 
immune cell compartment in the TME.  
 
The immunomodulatory effect of certain CAF subpopulations is further supported 
by a recent study in which the authors conditionally depleted FAP-positive CAFs 
in autochthonous models of PDAC55. Despite the presence of anti-tumour T cells, 
immunotherapeutic antibodies are normally ineffective in these murine models of 
pancreatic cancer. However, depletion of FAP-positive CAFs permitted immune 
control of tumour growth and uncovered the efficacy of immunotherapy. The 
potentiation of immunotherapy was mediated largely by the chemokine CXCL12 
that is exclusively released by FAP-positive CAFs and signals via CXCR4 
receptor in tumour cells, as inhibitors of this chemokine produced the same effect 
as CAF depletion.  
 
These studies highlight the CAFs shape the soluble and solid environment in 
PDAC but also mediate tumour immune evasion. They also underscores the 
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functional heterogeneity in CAFs how this has a differential impact on tumour 
biology with or without chemotherapy.  
 
Attempts to revert, rather than ablate, activated CAFs towards a more quiescent 
state represent another therapeutic strategy to undermine tumour growth and 
survival. For example, all-trans retinoic acid (ATRA) – a vitamin A derivative, 
binds to ligand-responsive nuclear receptors (retinoic acid receptors; RARs) that 
regulate transcription. Our group has found that ATRA can reprogram PSCs into 
a quiescent state by inhibiting mechanosensitive signalling in PSCs and force-
mediated ECM remodeling to restrain pancreatic cancer cell invasion in 
organotypic models of the disease56. Another independent study has also found 
that stromal co-targeting with ATRA alongside chemotherapy (gemcitabine) in 
organotypic and animal models of PDAC, reduces tumour size, increases 
vascularity, and inhibits PSC activation and ECM deposition by dampening 
multiple signalling cascades in the tumour-stroma cross-talk57. Intriguingly, ATRA 
can cause the maturation of immature myeloid cells to become stimulatory 
antigen-presenting cells and may enhance cancer vaccine T-cell responses in 
patients with non-small lung cancer58,59. 
 
In a similar regard, Vitamin D analogues have also shown promise as stroma 
targeting agents. Sherman et al. have provided evidence that regulation of 
activated PSCs via vitamin D receptor (VDR) is an important determinant for the 
reactive pancreatic cancer stroma37. This study showed that VDR activation 
reduces PSC activation and fibrosis, thus reprogramming the TME to a more 
quiescent, non-inflammatory and physiological state. Vitamin D priming increased 
intratumoural delivery of gemcitabine and resulted in a 57% increased in survival 
compared to chemotherapy alone.  
 
Targeting mechanotransduction pathways by interfering with biomechanical 
proteins activated by mechanotransduction represents another promising 
strategy in stromal reprogramming. Focal adhesion kinase (FAK) is a protein 
activated downstream of integrins upon enhanced collagen deposition, 
crosslinking or other mechanical stress. The FAK inhibitors that are under 
development all present dual specificities for FAK and a kinase called Pyk2, 
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which is a homologue that can compensate for FAK46. The FAK inhibitor (PF-
562271) has shown tumour suppressive effects in pancreatic cancer cells in vitro 
through reduced cancer cell migration, invasion and proliferation and in vivo in an 
orthotopic mouse model of the disease60. In a phase I clinical trial for head, neck, 
prostate and pancreatic cancer, the drug was well tolerated and about a third of 
the patients had stable disease61,62. Subsequent FAK inhibitors have been 
developed and are now in various stages of preclinical testing. The FAK inhibitor 
(NVP-TAE226) has shown excellent anti-tumour effects in preclinical studies in 
vitro and in animal studies against glioma63,64, breast65 and ovarian cancer66. 
 
More recently, a study led by DeNardo et al repored elevated FAK activity in 
human PDAC tissues that correlates with high levels of fibrosis and 
immunosuppressive TME via reduced CD8+ cytotoxic T cell infiltration67. Notably, 
pharmacologic inhibition of FAK with the newer inhibitor VS-4718 decreased 
fibrosis and tissue stiffness, reduced tumour growth and metastasis, and 
decreased the number of tumour-infiltrating immunosuppressive cells, including 
myeloid-derived suppressor cells (MDSCs), tumour-associated macrophages 
(TAMs) and regulatory T cells (Tregs). FAK inhibition also rendered previously 
unresponsive mice with PDAC responsive to T cell immunotherapy and PD-1 
antagonists. FAK is a key mechano-chemical signalling nexus, and disrupting 
FAK signalling can perhaps unsurprisingly, induce pleiotropic beneficial effects, 
including increased immune surveillance by overcoming the fibrotic and 
immunosuppressive PDAC tumour microenvironment, while secondarily 
highlighting potential links between altered tissue tension, the fibroinflammatory 
response and immunosurveillance.  
 
Efforts to reduce ECM stiffening by targeting the lysyl oxidase (LOX) family of 
enzymes that participate in collagen crosslinking has yielded mixed results in the 
clinic so far. In preclinical studies, using β-aminopropionitrile (BAPN, a LOX 
inhibitor) and/or functional blocking antibodies against LOX inhibited lung and 
liver metastasis in tumour xenografts and transgenic mouse models46,68. A Loxl2 
targeting antibody has recently undergone phase 2 clinical trials in combination 
with gemcitabine in pancreatic cancer. Although initial studies on late-stage 
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disease did not yield promising results69, an additional study by Miller et al 
showed that this combination therapy was efficacious if administered early70. 
 
Additional efforts have been directed in targeting other common downstream 
components of mechanontrasduction including integrins, Rho, ROCK and the 
transcriptional co-activators YAP/TAZ. Integrin antagonists currently in clinical 
trails include monoclonal antibodies and RGD peptide mimetics. Preclinical 
studies showed that integrin antagonists inhibit tumour growth by affecting both 
tumour cells and stromal cells in the TME, most notably the angiogenic 
endothelium71. Strategies that target the β1 integrins, particularly α5β1, have 
shown promise in reducing tumour burden in preclinical models. An integrin β1 
inhibitory antibody significantly affected in vitro and in vivo growth of human 
breast cancer cells72. 
 
Volociximab, a function-blocking monoclonal antibody against integrin α5β1, 
inhibits angiogenesis and impedes tumour growth73,74. Phase I clinical trials in 
patients with advanced solid malignancies showed that volociximab is well 
tolerated and may have clinical efficiacy, and the drug is now in phase II clinical 
trials75. ATN-161 is a non-RGD based peptide inhibitor of integrin α5β1 that 
impedes breast cancer growth and metastasis in animal models76; in phase I 
trials, there was no toxicity and 1/3 of patients had a prolonged stable disease 
state77. Cilengitide is a cyclic RGD peptide mimetic and selective inhibitor of αvβ5 
and ανβ3 integrins with potent antiangiogenic activity. Cilengitide has shown 
promise in patients with late-stage glioblastoma by extending survival with 
minimal side effects78-80. Nevertheless, in mouse models continous infusion of 
low dose of RGD peptides paradoximally stimulates tumour growth and 
angiogenesis by promoting VEGF-induced endothelial cell migration81. However, 
the increased tumour perfusion associated with anti-angiogenic therapy could be 
exploited to increase the delivery of chemoerapeutic agents, potentially 
explaining why anti-angiogenic agents such as cilengitide are most effective 
when used in combination with chemotherapy. Given the fundamental role of 
integrins in both sensing and mechanically regulating the ECM, it is not surprising 
that recent anti-fibrotic strategies also target integrins, which may have direct 
implication in fibrotic solid tumours. 
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The transcriptional coactivators YAP and TAZ are activated in a broad range of 
solid tumours and are instrumental for tumour initiation, growth, metastsis and 
chemoresistance82. YAP/TAZ is also needed for CAF activation in the stroma and 
pathological matrix remodelling42. Activation and nuclear localisation of YAP/TAZ 
activation is sensitive to extrinsic mechanical cues and driven by RhoA-ROCK 
dependent cytoskeletal rearrangement. When inactive and located in the 
cytoplasm, YAP/TAZ have been shown to limit TGF-β signalling, further 
suggesting that inhibiting YAP/TAZ mechanotransduction at the transcriptional 
level might offer a new therapeutic approach for fibrosis. A small molecule 
verteprofin has been identified in a chemical screen for YAP inhibitors and has 
shown to limit liver tumourigenesis in vivo83.  
 
The small GTPase Rho is involved in mechanosensing and cell contraction. Rho 
effectors such as Rho-associated protein kinase 1 and 2 (ROCK1 and ROCK2) 
promote the activity of myosin II by elevating the level of phosphorylation of the 
regulatory myosin light chain (MLC). Some tumours present increased Rho 
activity, leading to elevated cytoskeletal tension8,9,84. One of the main 
approaches for targeting Rho is through the mevalonate pathway, a metabolic 
cascade that generates geranylgeranyl moieties needed for post-translational 
modification and membrane localization of Rho-GTPases. A key enzyme in this 
pathway is HMG-CoA reductase, which is targeted by statins. Statin treatment 
also inhibits YAP/TAZ activation in several cancer types and results in reduced 
tumour growth85,86 (Figure 3.4). 
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Figure 3.4: Targeting mechanotransduction pathways in cancer as a 
therapeutic strategy. 
Efforts to target mechanotransduction in cancer therapy have largely focused on 
either altering the ECM or molecules involved in mechanosensing. The first 
strategy aims to either inhibit collagen synthesis and/or collagen crosslinking or 
hyaluronan production. The second strategy is focused on inhibiting certain key 
mechanoactivators such as integrins, FAK, Src, Rho, ROCK and the 
mechanically activated transcription factors YAP/TAZ. Adapted from Majeski et 
al46. 
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Chapter 4 
 
ATRA mechanically reprograms pancreatic stellate cells to suppress matrix 
remodelling and inhibit cancer cell invasion 
 
 
Abstract 
 
Pancreatic ductal adenocarcinoma (PDAC) is a highly aggressive malignancy 
with a dismal survival rate. Persistent activation of pancreatic stellate cells 
(PSCs) can perturb the biomechanical homoeostasis of the tumour 
microenvironment to favour cancer cell invasion. Here we report that ATRA, an 
active metabolite of vitamin A, restores mechanical quiescence in PSCs via a 
mechanism involving a retinoic acid receptor beta (RAR-β)-dependent 
downregulation of actomyosin (MLC-2) contractility. We show that ATRA reduces 
the ability of PSCs to generate high traction forces and adapt to extracellular 
mechanical cues (mechanosensing), as well as suppresses force-mediated 
extracellular matrix remodelling to inhibit local cancer cell invasion in 3D 
organotypic models. Our findings implicate a RAR-β/MLC-2 pathway in 
peritumoural stromal remodelling and mechanosensory-driven activation of 
PSCs, and further suggest that mechanical reprogramming of PSCs with retinoic 
acid derivatives might be a viable alternative to stromal ablation strategies for the 
treatment of PDAC. 
 
 
Introduction 
 
Pancreatic ductal adenocarcinoma (PDAC) is an extremely aggressive cancer 
with a dismal 5-year survival rate of 4% and a median survival of 6 months 
despite advances in conventional therapies targeting cancer cells[1]. PDAC is 
characterized by a strong desmoplastic reaction or stromal fibrosis, which is 
driven by pancreatic stellate cells (PSCs) and is believed to create a unique 
microenvironment that regulates tumour growth, metastasis and 
chemoresistance2-4. Recently, this desmoplastic reaction has been the focus of 
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several studies that have emphasized the complex nature of the stromal 
components and their contribution to disease progression5-11. 
 
In pancreatic cancer, PSCs transition from a quiescent, lipid-vitamin-A storing 
phenotype to an activated, myofibroblast-like phenotype that is accompanied by 
changes in their cytoskeletal and contractile activity, migratory capacity, 
extracellular matrix (ECM) synthesis and acquisition of an expansive 
secretome12. The contractile myofibroblast-like phenotype is a general hallmark 
feature of cancer-associated fibroblasts (CAFs)13. As in other conditions featuring 
pathological tissue fibrosis, myofibroblasts need to establish a mechanical 
feedback loop to perpetuate their fully activated state by promoting and sensing a 
stiff microenvironment. Annulment of this positive-feedback loop is sufficient to 
abrogate their activation14-17. This loop entails the cell capacity to (i) remodel and 
stiffen its microenvironment by applying endogenous cell-generated forces to the 
ECM and (ii) sense and respond to external mechanical stimuli from the ECM 
(also known as mechanosensing or reinforcement). Both properties critically 
depend on the cell’s contractile actomyosin machinery18,19. 
 
CAFs alter not only the biochemical milieu but also the biomechanical 
homoeostasis of the tumour microenvironment. CAFs use contractile forces or 
proteolytic activity to remodel the ECM to create tracks for migration of cancer 
cells20,21. Force-mediated matrix remodelling is dependent on actomyosin 
contractility generated through phosphorylation of the regulatory myosin light-
chain 2 (MLC-2) and activation of myosin II. A high level of actomyosin 
contractility is crucial for the emergence, maintenance and functional activity of 
tumour-associated myofibroblasts13,22. 
 
Stromal reprogramming, as opposed to ablation, is an emerging concept gaining 
acceptance in the realm of stroma-targeting approaches for the treatment of 
PDAC23. We hypothesized that retinoids could be well poised to reprogram the 
tumour stroma due to their pleiotropic mode of action and ability to regulate a 
large number of genes involved in CAF function. We report that all-trans retinoic 
acid (ATRA), an active metabolite of vitamin A, restores mechanical quiescence 
in PSCs through a previously unidentified mechanism involving a retinoic acid 
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receptor beta (RAR-β)-dependent downregulation of actomyosin (MLC-2) 
contractility. We show that ATRA treatment reduces the ability of PSCs to 
generate high traction forces, adapt to extracellular mechanical cues and 
suppresses force-mediated ECM remodelling to inhibit local cancer cell invasion 
in three-dimensional (3D) organotypic models. 
 
Results 
 
ATRA increases focal adhesion size and cell-ECM adhesion strength 
 
The bidirectional mechanical communication between cells and the ECM is 
mediated by integrin-based focal adhesion complexes. These complexes connect 
the actin cytoskeleton with the extracellular protein ligands in the ECM, allowing 
cells to adhere to the ECM, transmit endogenous contractile forces and sense 
the ECM rigidity24. To investigate how ATRA treatment affects the ability of 
activated PSCs to promote and sense a stiff environment, and therefore to 
maintain their myofibroblasts phenotype, we first sought to characterize focal 
adhesion complexes. ATRA-treated PSCs displayed significantly larger and 
brighter focal adhesion complexes (both for talin and paxillin) relative to untreated 
control PSCs (Figure 4.1 a, c). To compare this result with the sizes of focal 
adhesions present in quiescent PSCs, we grew PSCs on matrigel for 10 days, a 
technique to induce quiescence25, and we used Oil Red staining to identify the 
lipid droplets characteristic of PSC quiescence (Figure 4.2). We observed that 
quiescent PSCs display larger focal adhesion in comparison with control PSC, 
and that ATRA-treated PSCs displayed significantly larger focal adhesions with 
respect to control activated PSCs and quiescent PSCs grown on matrigel. The 
assembly of larger focal adhesion complexes in ATRA-treated PSCs was 
positively associated with a higher matrix adhesion strength compared with 
control cells, whereby application of a pulling force of 1  nN generated by a 
magnetic tweezers device resulted in a significantly lower number (reduced by 
half) of fibronectin (FN)-coated magnetic beads detaching from the cell surface 
(Figure 4.1 d, e). We further characterized the rate of isotropic cell spreading 
with time-lapse video microscopy by measuring the spread area as a function of 
time until the cell attained its maximum spread area. ATRA-treated PSCs spread 
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significantly faster relative to untreated PSCs and attained a higher maximum 
spread area (Figure 4.1 f, g). Taken together, these results indicate that ATRA-
treated cells form larger focal adhesion complexes, spread faster, attain a larger 
spreading area and attach stronger to the ECM. 
 
 
Figure 4.1: ATRA increases foal adhesion size and cell-ECM adhesion 
strength of PSCs 
(a) Immunostaining images of talin and paxillin. Scale bar, 20  µm. Zoomed 
areas, 10  µm. (b,c) Quantification of normalized focal adhesion area and 
intensity. (d) Schematic representation of the magnetic tweezers device used in 
this study to apply forces on the cell surface. (e) Quantification of cell-bound 
beads that detached after force application. (f) Quantification of cell spreading 
area over time. (g) Time-elapsed sequential images of PSCs spreading until 
PSCs attained maximum area. Scale bars, 10  µm. In all panels, error bars 
represent SEM. *P<0.05; **P<0.01; ***P<0.001; (t-test); three experimental 
replicates. 
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Figure 4.2: Focal adhesion sizes in PSCs in the quiescent state induced by 
on matrigel culture. (a) Oil red staining of PSCs grown for ten days on matrigel 
showing lipid containing vesicles indicative of quiescent phenotype, yellow 
arrowheads. (b) Quantification of focal adhesion sizes in PSCs control (activated 
by cultured on glass), ATRA treated PSCs cultured on glass, and quiescent 
PSCs cultured on matrigel. Histogram bars show mean ± SEM, n > 10, **p < 0.01 
(one –way Anova with Tukey’s post-hoc test). (c) Immunofluorescent images of 
paxillin containing focal adhesions in PSCs grown on matrigel. Scale bars in (a) 
and (c) are 25µm and 5µm respectively. 
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ATRA reduces endogenous force generation and cell stiffness 
 
Transition of quiescent PSCs to an activated myofibroblastic phenotype is 
marked by profound cytoskeletal changes and elevated actomyosin 
contractility4,26. Indeed, acquisition of cytoskeletal contractility is required for the 
emergence, maintenance and functional activity of CAFs13. While transient 
activation of PSCs is adaptive in the context of a wound-healing scenario, the 
unabated and persistent activity of the myofibroblastic phenotype in PDAC 
represents a mal-adaptive response that can exacerbate desmoplasia and lead 
to metastasis27. ATRA is an active vitamin-A metabolite with pleiotropic action 
and potential to induce genome-wide transcriptional changes to influence PSC 
activation. To investigate whether ATRA treatment leads to the changes in the 
pattern of forces that PSCs exert on their substrate, we seeded cells on top of a 
substrate consisting of an array of elastic polydimethylsiloxane micropillars 
coated with FN. The deflection of each pillar is optically monitored and is 
proportional to the traction force (Figure 4.3a). Untreated control PSCs 
generated elevated traction stresses that were mainly concentrated around the 
cell periphery (Figure 4.3 c,d; Figure 4.4). ATRA-treated PSCs by contrast 
showed a marked decrease in the overall traction force generation during the 
early and late stages of the spreading phase (Figure 4.3b). 
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Figure 4.3: ATRA reduces traction forces and impairs mechanosensing 
capacity in PSCs. (a) Schematic representation of the elastic pillars 
microsensors (F, force; x, distance). (b) Average force applied on each pillar for 
early and late spreading. n>10 in all cases. (c) Bright-field images of 
representative PSCs on top of the micropillars—early spreading phase. Scale 
bar, 10  µm. (d) The respective force vector maps indicating the magnitude and 
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direction of applied forces calculated from the maximum pillar displacement 
through a custom-built tracking algorithm. (e) Strain energy (mean±s.e.m., n>300 
cells per condition) imparted by stationary PSCs. (f) Bright-field images of 
representative PSCs on FN-coated, polyacrylamide gels and corresponding 
traction maps. (g) Images show gel contraction by PSCs. Histogram shows 
quantification of n>10 gels per condition assessed over multiple experiments. (h) 
Left, diagram of the cell–matrix interface showing application of mechanical 
tension onto integrin receptors to mimic the transmission of mechanical force 
from the extracellular matrix to the cytoskeleton via the mechanical bridge formed 
by integrins and focal adhesions. Right, pulsatile force regimen applied with 
magnetic tweezers. (i) Left and middle, representative traces tracking the 
displacement of the beads in response to the force (mechanosensing). The 
amplitude of the bead displacement was progressively reduced in control PSCs, 
showing that cells detected force application and responded by stiffening their 
cytoskeleton. In ATRA-treated PSCs, the reduction in bead displacement was 
severely suppressed indicating impaired ability to detect external mechanical 
stimuli. Black and red arrows indicate initial and final amplitude of the bead 
oscillation, respectively. Right, cell stiffening response to force, (P<0.001, n=26 
traces for control, n=34 for ATRA). When not specified, results are expressed as 
mean±s.e.m. In all panels, error bars represent SEM. *P<0.05; **P<0.01; 
***P<0.001; (t-test); three or more experimental replicates. 
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Figure 4.4: Heat maps for PSC traction forces on micropillars. (a) Forces 
were calculated from the maximum pillar displacement through a custom-built 
tracking algorithm. Maximal forces for control PSCs were observed in regions 
located at the cell periphery, where the magnitude of the force in these regions 
saw a four-fold increase closer to the centre of the cell. ATRA treated PSCs 
displayed lower overall forces across the whole spreading area. Numbers in the 
scale represent force values in picoNewton. Scale bar 10 µm. (b) Frequency 
distribution for forces applied on each pillar for early and late spreading. 
 
 
To explore whether the difference in traction force generation was also present 
under steady-state conditions following the spreading phase, we seeded 
untreated control or ATRA-treated PSCs on FN-coated polyacrylamide gels with 
embedded fluorescent microbeads that served as fiducial markers of traction-
induced gel deformations. Before and after cell trypsinization, fluorescent images 
were taken to measure the displacement field of the gel and derive the cell 
traction stresses and the associated elastic strain energy of the deformed gel. 
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ATRA-treated PSCs displayed a reduced ability to deform the underlying matrix, 
with a twofold decrease on the strain energy of the matrix, while displaying 
significantly larger FAs compared with control cells (Figure 4.3 e,f; Figure 4.5). 
Similarly, contraction of a matrigel-collagen gel seeded on top with PSCs showed 
the same trend, whereby ATRA-treated PSCs had a severely reduced ability to 
deform the collagen matrigel matrix after 65  h, thereby confirming that ATRA 
treatment inhibits force generation in PSCs (Figure 4.3 g). 
The higher capacity of cells to apply forces on their substrates also correlates 
with increased cytoskeletal stiffness28,29. To examine the cytoskeletal stiffness, 
we used magnetic tweezers microrheology (Figure 4.6). All cells exhibited a 
viscoelastic response consistent with power-law rheology. In agreement with our 
previous observations, ATRA-treated PSCs displayed a threefold increase in 
compliance (reciprocal of stiffness) compared with untreated control cells, 
suggesting a decrease in overall cytoskeletal tension. By contrast, differences in 
cell compliance between control and ATRA-treated cells were largely offset when 
PSCs were pretreated with blebbistatin, an inhibitor of myosin II ATPase activity, 
confirming that ATRA induces cell softening mainly through a reduction of 
actomyosin contraction. These results collectively demonstrate that ATRA 
suppresses traction force generation and reduces cytoskeletal stiffness of PSCs 
in an actomyosin-dependent manner. 
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Figure 4.5: Quantification of FA areas in PSCs seeded on 12 kPa 
polyacrylamide gels. ATRA treated PSCs displayed significantly larger FAs 
(mean ± SEM 2.3212 ± 0.1180, n=76) than Control PSCs. (Mean ± SEM 1.423 ± 
0.1007, n=52) p < 0.0001 (t-test). Images show paxillin staining. Scale bar 10 µm 
	   95	  
 
Figure 4.6: Characterisation of cell mechanics in PSCs using 
microrheology. (a) Representative trace used for the quantification of PSCs cell 
compliance (inverse of stiffness). (b) Images of the bead displacement before 
(top) and after (bottom) the force application. To examine the cytoskeletal 
stiffness of pancreatic stellate cells, we recorded their viscoelastic creep 
behaviour which refers to the amount of cell deformation under constant load. 
Using magnetic tweezers we applied constant mechanical tension (3 nN for 3 
sec) onto FN-coated magnetic beads attached to the cytoskeleton of single cells 
via integrin-containing focal adhesions, and tracked the bead displacement under 
20 frames per second. (c) Quantification of PSCs compliance. ATRA induced a 
significant softening of the cells evident by a ~2.8 fold increase in the cell 
compliance compared to PSC control (1.7 kPa-1 for PSC ATRA vs. 0.6 kPa-1 for 
PSC Control). No significant differences observed when BBI was used to block 
actomyosin cell contractility (3.4 kPa-1 for PSC ATRA vs. 2.7 kPa-1 for PSC 
Control). (d) Quantification of PSCs fluidity, characterized by the dimensionless 
value β, representing values from 0 to 1, pure elastic β=0 and pure viscous β=1. 
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No differences were observed between Control and ATRA PSCs. PSCs 
displayed values close to pure elastic. **** p< 0.0001. Mann-Whitney test used in 
panels c and d. (e, f) Histograms with frequency distribution for Control and 
ATRA PSCs compliance. In all cases, more than 100 cells were analysed in 5 
experimental replicates. Bars and error bars represent geometric mean and 95% 
confidence intervals respectively. 
 
 
ATRA treatment suppresses PSC mechanosensing 
 
The ability to sense and respond to exogenous mechanical forces, also referred 
as mechanosensing, is a key determinant of tissue homoeostasis, tumour 
progression and phenotypic maintenance of tumour myofibroblasts13,21,22. To 
investigate whether ATRA affects mechanosensing in PSCs, we utilized 
magnetic tweezers to apply controlled forces on integrins through magnetic 
beads coated with FN and measured the bead displacement during successive 
pulses of constant force. Localized force application on integrins triggers an 
adaptive cellular stiffening response resulting in decreased bead displacement, 
also called ‘reinforcement’. This adaptive stiffening response involves 
remodelling of the actin cytoskeleton and requires the RhoA–ROCK–MLC-2 
signalling axis18. Cytoskeletal stiffening in response to force presumably 
represents an adaptation that allows the cell to modulate its own mechanically 
active biochemical network within a mechanical feedback loop. While untreated 
control PSCs displayed robust reinforcement and intact mechanosensing (39% 
increase in relative cellular stiffness at the end of the pulsatile force regime), 
ATRA treatment significantly suppressed reinforcement (only 17% increase in 
relative cellular stiffness) and, thus, the ability of PSCs to respond to extracellular 
mechanical cues. (Figure 4.3i) 
 
After confirming quantitatively that ATRA reduces the PSCs ability to generate 
forces on the ECM and to sense external mechanical stimuli, the tandem that 
perpetuates the activating mechanical loop in myofibroblasts, we tested the 
levels of PSC activation. Alpha smooth muscle actin and vimentin, two widely 
used markers for myofibroblasts activation, were significantly reduced in ATRA-
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treated PSCs, while desmin, a marker for PSC quiescence, was markedly 
increased (Figure 4.7). Collectively, these results show that ATRA suppresses 
the ability of PSCs to sense extracellular mechanical cues (mechanosensing) 
and induces cytoskeletal changes consistent with a quiescent-like phenotype. 
 
Fibroblasts and stellate cells are highly mechanosensitive cells that respond to 
stiff microenvironments by differentiating towards a myofibroblastic phenotype, 
even in the absence of soluble profibrotic factors, thus establishing a vicious 
cycle of increased fibroblast activation, increased matrix stiffness and fibrosis16,30. 
Inhibiting mechanosensory-driven activation of myofibroblasts has been 
proposed as a novel therapeutic strategy to target myofibroblast activation and 
fibrosis16. Targeting common mechanotransduction pathways involving Rho-
mediated actomyosin contraction, integrin-based focal adhesions or 
mechanosensitive transcription factors could all represent attractive targets for 
this purpose. 
 
Figure 4.7: ATRA induces a quiescent-like phenotype in PSCs.  
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Immunofluorescence images for the alpha smooth muscle actin, vimentin 
(markers for activate myofibroblast phenotype) and desmin (marker for quiescent 
phenotype). The intensity of the staining was calculated by measing the mean 
fluorescent intensity (MFI) of cell area by Image J. Scale bars 50 µm. Histograms 
represent mean ± SEM. **, p<0.01; ***, p<0.001 (t-test). n>30 cells per condition 
collected in 4 different experiments. 
 
ATRA inhibits matrix remodelling and cancer cell invasion 
 
Although the tumour-promoting features of activated PSCs have been 
traditionally ascribed to paracrine signalling via growth factors and cytokines3,31, 
recalcitrant activation of PSCs perturbs not only the biochemical but also the 
biomechanical homoeostasis of the tumour microenvironment13,21,22. Force-
dependent tissue remodelling and ECM stiffening can create a permissive 
microenvironment for local cancer cell invasion via modification of the 
mechanoreciprocal tumour stroma crosstalk13,21,32-34. The ability of fibroblasts to 
contract collagen gels correlates with their ECM remodelling capacity13. 
 
We employed 3D organotypic assays to investigate the effect of ATRA on the 
PSC capacity to remodel the matrix to promote cancer cell invasion. Using 
atomic force microscopy (AFM) and second harmonic generation (SHG) imaging, 
we tested the stiffness and collagen fibre organization of matrices previously 
embedded with and remodelled by untreated control or ATRA-treated PSCs. 
While untreated PSCs were able to stiffen the matrix substantially, ATRA 
treatment suppressed the remodelling ability of PSCs and decreased matrix 
stiffness by fivefold, as measured through the elastic modulus of the gels; 
furthermore, remodelled matrices by untreated PSCs were also associated with 
thicker bundles of collagen fibrils, not observed in matrices remodelled by ATRA-
treated PSCs (Figure 4.8 a,b). 
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Figure 4.8: ATRA impairs PSC capacity to remodel the ECM to promote 
cancer invasion 
(a) Elastic modulus for collagen Matrigel matrices previously remodelled by PSCs 
expressed as mean±s.e.m.; control n=113 and ATRA n=114 measurements 
obtained in three independent experiments. (b) Collagen second-harmonic 
signals (green) and cells (red). Scale bar, 20  µm. (c) Representative images of 
haematoxylin and eosin immunofluorescence staining showing AsPC1 cancer 
cell invasions. Scale bar, 50  µm. (d) AsPC1 invasion expressed as number of 
invading particles and area, respectively. Each point represents a different 
section. In all panels, ***P<0.001; ****P<0.0001; (t-test). 
 
 
To investigate whether ATRA additionally interferes with proteolytic remodelling 
of PSCs, we assayed the levels of matrix metalloproteinases (MMPs). MMPs are 
a family of calcium-dependent zinc containing proteases that hold central roles in 
a wide range of physiological and pathological processes, and have the ability to 
degrade proteins in the ECM[35]. MMP-2 and MMP-9 are the two more relevant 
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MMPs synthesized by PSCs36. While MMP-2 levels in PSCs under ATRA 
treatment were not significantly different from control PSCs, we observed a 
significant fivefold increase in MMP-9 levels in ATRA-treated PSCs in 
comparison with control PSCs (Figure 4.9). The activities of MMPs are tightly 
regulated by endogenous tissue inhibitors of metalloproteinases (TIMPs) and the 
balance between MMPs and TIMPs governs the eventual ECM and tissue 
remodelling. TIMP-1 is a specific MMP-9 inhibitor35,37. Our data show a significant 
30% reduction in TIMP-1 in ATRA-treated PSCs with respect to control PSCs 
(Figure 4.9). Previous studies on the effect of ATRA on MMPs are overlapping 
and contradictory. While some studies show that ATRA upregulates MMPs38, 
others reported an opposite effect for ATRA in different cell types39-41. A possible 
explanation for this divergence is that ATRA exerts its effect by binding to 
different isoforms of the RARs, alpha, beta and gamma. The distribution of these 
isoforms is different depending on the cell type and ATRA might activate this 
range of isoforms in a different manner in each cell type42. More MMP-9 and less 
TIMP-1 levels might have anti-fibrotic roles, and therefore be beneficial to resolve 
PSC-associated fibrosis. However, the analysis of the profibrotic and anti-fibrotic 
roles of MMPs and TIMPs is more complex and requires further experimentation 
as MMPs and TIMPs have been shown to have both stimulatory and inhibitory 
roles in fibrosis43. 
 
We further interrogated whether PSC-remodelled matrices were rendered 
permissive for the invasion of pancreatic cancer cells. Untreated control and 
ATRA-treated PSCs were left to remodel the matrices for 3 days before being 
killed and washed out from the matrices. The ability of AsPC1 pancreatic cancer 
cells to invade into these matrices was then evaluated and quantified (Figure 4.8 
c,d). We found that pancreatic cancer cells invaded deeply into matrices 
previously remodelled by activated control PSCs, but showed minimal capacity to 
invade matrices remodelled by ATRA-treated PSCs. 
 
These findings support that ATRA reprograms PSCs to suppress force-mediated 
and proteolytic matrix remodelling and peritumoural tissue stiffness to inhibit 
subsequent cancer cell invasion. The reduced invasive ability of cancer cells can 
be attributed to the change in the mechanical and/or topographical characteristics 
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of the remodelled matrices promoted by ATRA treatment on PSCs. Lines of 
tension and CAF-generated ECM tracks are known to serve as guidance cues for 
collective cancer invasion20 and generally a stiffer matrix promotes invasive 
phenotypes in malignant epithelium by forcing tumour progression through 
mechanotransduction32. 
 
Figure 4.9: ATRA treatment upregulates MMP-9 and down regulates TIMP-1 
expression in PSCs, but has no effect on MMP-2 levels. mRNA RT-qPCR 
levels of MMP-2, MMP-9, and TIMP-1 in PSCs expressed as mean ± SEM; 
values are normalised to GADPH and presented relative to control, n=3 
experimental replicates, *<0.05 and ***p<0.001 (t-test). 
 
 
ATRA downregulates MLC-2 actomyosin contractility 
 
To investigate the signalling pathway targeted by ATRA treatment in PSC, we 
focused on MLC-2, which controls actomyosin contraction and is causally 
associated with CAF emergence and maintenance through a feed-forward loop 
that entails ECM stiffening and elevated integrin mechanosignalling13. We 
observed a marked downregulation in the expression of MLC-2 at the gene and 
protein levels. Accordingly, the phosphorylated level of MLC-2 was proportionally 
reduced (Figure 4.10 a–d; Figure 4.11). The effect of ATRA treatment on the 
levels of MLC-2 was confirmed by 3D gel contraction assays, in which MLC-2 
rescue in ATRA-treated PSCs recovered their capacity to contract the gel at 
similar levels to control PSCs (Figure 4.12). 
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Figure 4.10: ATRA downregulates MLC-2 actomyosin contractility (a) 
Immunofluorescent images of total myosin light-chain 2 (MLC-2) and 
phosphorylated levels (pMLC-2). (b) Quantification of staining intensity (n>20 
cells in all cases and three experimental replicates). Scale bar, 50  µm. (c,d) 
MLC-2 level expression at the protein (western blotting) and mRNA (qPCR) 
levels. All results are expressed as mean ± SEM. and *P<0.05; **P<0.01; 
***P<0.001; (t-test), three independent experiments for western blotting and 
qPCR. 
	   103	  
 
Figure 4.11: Flow cytometry analysis of mlc-2 and p-mlc-2 expression 
levels in control and ATRA treated PSCs. (a) ATRA treated PSCs show a five-
fold decrease in both MLC-2 and p-MLC-2 levels with regard to control PSCs. 
Each value has been normalised against the respective blank (Control MLC-2 
mean ± SEM 163.50 ± 1.79, ATRA MLC-2 mean ± SEM 31.55 ± 2.63, Control p-
MLC-2 mean ± SEM 40.25 ± 5.16, ATRA p-MLC-2 mean ± SEM 8.74 ± 3.11) *** 
p < 0.0001 (t-test). (b, c, d, e, f, g) Representative histograms for control blank, 
ATRA blank, control MLC-2, ATRAMLC-2, control p-MLC-2, ATRA p-MLC-2, 
respectively. Data collected in 3 different experiments 
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Figure 4.12: Quantification of 3D collagen gel contraction expressed as % 
change of gel area. ATRA treated PSCs contracted the gel at a significantly 
smaller extent (mean ± SEM 36.01 ±1.07) than control PSCs (Mean ± SEM 67.27 
±1.20) p<0.0001 (One-way ANOVA with Tukey’s post-hoc). ATRA treated PSCs 
rescued with MLC-2 display no significant differences in their ability to contract 
the gel with regards to control PSCs (Mean ± SEM 64.37 ±1.21). Each data point 
represents a gel, 4 experimental replicates. Dotted yellow lines represent the gel 
contours. 
 
 
To test whether the observed PSC response to ATRA treatment may be affected 
by prior association with cancer cells, we collected media from AsPC1 pancreatic 
cancer cells, and grew PSCs on 40% AsPC1-conditioning media for 24  h, and 
then tested the effect of ATRA treatment on the sizes of PSC focal adhesions, 
the MLC-2 levels and the PSC ability to apply forces on their matrices (Figure 
4.13). In agreement with our previous observations, ATRA treatment significantly 
increased the size of focal adhesions, significantly reduced MLC-2 levels in PSCs 
previously exposed to cancer cell conditioning media and markedly decreased 
their ability to apply forces to contract the 3D matrigel-collagen gels. 
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Figure 4.13: ATRA treatment increases focal adhesion size and decreases 
MLC-2 levels and force induced gel contraction in PSCs previously 
exposed to AsPC1 cancer cells conditioning media (CM).  
(a) Immunofluorescent images of PSCs showing paxillin containing focal 
adhesions (green), actin (red), and nucleus (blue). Scale bar represents 20 µm. 
(b) Histogram shows quantification of focal adhesion sizes. Values are expressed 
as mean ± SEM. (c) mRNA levels for MLC-2 in PSCs previously exposed to 
conditioning media (CM) before vehicle or ATRA treatment. Values are 
expressed as mean ± SEM. n > 10 cells, 3 different experiments (d) Images 
show 3D gel contraction by PSCs. In the box-and-whisker plot, the central box 
represents values from the lower to the upper quartile. The middle line represents 
the mean. The vertical line extends from the minimum to the maximum value. 
Control and ATRA 11 and 12 gels, respectively assessed over multiple 
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experiments. Dotted yellow lines represent the gels contours. In all panels, ***p < 
0.001 (t-test). 
 
We then sought to study the mechanism that underpins the observed effect of 
ATRA on PSCs. There are two families of retinoic acid nuclear receptors, RAR or 
retinoic acid receptor and RXR or retinoid X receptor, which selectively bind the 
two main forms of retinoic acids, ATRA and 9-RA (9-cis-retinoic acid). ATRA is 
an exclusive ligand of the three subtypes of RAR (RAR-α, β and γ)44-46. PSCs 
were tested for expression of the different subtypes of RAR (RAR-α, β and γ) at 
the mRNA level. PSCs abundantly expressed RAR-α and RAR-γ but only 
minimal levels of RAR-β (Figure 4.14). ATRA treatment did not affect the 
expression of RAR-γ, but increased threefold the expression level of RAR-α, and 
induced a pronounced increase in RAR-β expression of 100-fold (Figure 4.15a), 
which is in agreement with previously reported data25. 
 
Figure 4.14: Retinoic Acid Receptors (RAR) are expressed in PSCs.  mRNA 
levels of retinoic acid receptors alpha, beta and gamma (RAR-α, RAR-β, RAR-γ, 
respectively) in PSCs. Fold changes in expression calculated and normalized to 
expression of RAR-α. Histogram bars represent mean ± SEM of three 
independent experiments. ***p<0.001 (Anova and Tukey’s post-hoc test). 
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Figure 4.15: ATRA biomechanically reprograms PSCs in a RAR-β 
dependent manner 
(a) qPCR mRNA levels of the different retinoic acid receptor (RAR) subtypes, 
RAR-α, RAR-β and RAR-γ in untreated control and ATRA-treated PSCs. Bars 
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represent mean±s.e.m. (b) qPCR mRNA levels of MLC-2 in control PSCs and in 
PSCs treated with agonists for RAR-α, RAR-β and RAR-γ. Bars represent 
mean±s.e.m. (c) 3D gel contraction assay using control and ATRA-treated PSCs 
in the presence of RAR-β antagonist. In the box-and-whisker plot, the central box 
represents values from the lower to the upper quartile. The middle line represents 
the mean. The vertical line extends from the minimum to the maximum value. 
Control and ATRA 12 and 15 gels, respectively, assessed in three independent 
experiments. NS, no significant differences. Dotted yellow lines represent the 
gels contours of representative images of gel contraction. (d) Quantification of 
focal adhesions size of the images presented in e,f. Bars represent mean±s.e.m. 
(e) Representative images of focal adhesions size in PSCs treated with agonists 
for RAR-α, RAR-β and RAR-γ. (f) Representative images of focal adhesion sizes 
in PSCs untreated control and ATRA treated in the presence of RAR-β 
antagonist. Scale bars for e,f: main image 20  µm; focal adhesion inset 5  µm; and 
blue/red channels inset 20  µm. In all panels, data were collected during three or 
more independent experiments and *P<0.05; **P<0.01; ***P<0.001; (t-test). 
 
Next, we used a battery of RAR agonists and antagonists to learn more about 
which specific RAR subtype modulates the ATRA effect on PSC focal adhesions 
and MLC-2 levels, which mediates actomyosin-dependent traction forces, and 
mechanosensing18,19. Exposing PSCs to 1  µM of the selective RAR-α 
(AM580)[44] or selective RAR-γ (BMS961)[47] agonists did not affect the MLC-2 
levels or the focal adhesion sizes in PSCs. However, treating PSCs with 1  µM of 
the selective RAR-β (cd2314)46,48 or pan-RAR agonist (TTNPB)49,50 significantly 
reduced the MLC-2 levels fivefold, and increased the size of the focal adhesions 
∼30% similarly to the observed effect of ATRA on MLC-2 levels and focal 
adhesion sizes. Furthermore, we observed that the effect of ATRA on the size of 
focal adhesion and PSC ability to deform 3D matrigel-collagen gels is reverted in 
the presence of 0.1  µM of the RAR-β antagonist (cd2665)51,52 (Figure 4.15 b–e). 
Further studies are needed to elucidate whether ATRA regulates the transcription 
of MLC-2 gene directly through a functional retinoic acid response element on its 
promoter region or indirectly via an intermediary transcription factor. Taken 
together, these data suggest that MLC-2 is transcriptionally downregulated in 
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PSCs by ATRA in a RAR-β-dependent manner, and implicates a new role for 
RAR-β signalling in controlling traction force generation, mechanosensing and 
biomechanical matrix remodelling. 
 
ATRA induces the formation of dorsal stress fibres 
 
Stress fibres are made of crosslinked F-actin filament bundles that are distinctly 
characterized by their functions, cellular localization and composition. Ventral 
stress fibres are myosin rich fibres that form at the ventral surface of spreading 
and migrating cells and generate strong traction forces53. In addition, the lamellar 
region of adherent cells contains radial or dorsal stress fibres, which 
perpendicularly elongate from the leading edge. These dorsal stress fibres 
assemble in a myosin-independent manner, are non-contractile, and have 
primarily a structural role serving as a template for the maturation of integrin-
based focal adhesions54. The fact that ATRA transcriptionally downregulates 
MLC-2 levels and concurrently increases the size of focal adhesions in PSCs 
prompted us to characterize the abundance of ventral and dorsal fibres in control 
and ATRA-treated PSCs as a potential mechanism to reconcile the discrepancy. 
Interestingly, we observed a significant threefold increase in the ratio of 
dorsal/ventral fibres in ATRA-treated PSCs in comparison with control PSCs 
(Figure 4.16 a,b). 
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Figure 4.16: Dorsal stress fibre formation and RhoA & Rac1 activation 
levels in control and ATRA treated PSCs. (a) Images of F-actin stress fibres 
on PSCs. Scale bar 25 mm. Dorsal or radial stress fibres (filled arrowhead) form 
in the lamella and elongate perpendicular from the leading edge towards the 
interior of the cell in ATRA treated PSCs, n>15 cells per condition (b) 
Quantification of the dorsal/ventreal stress fibres ratio in PSCs. (c) Quantification 
of the levels of activation of RhoA and Rac1. Percentages are relative to control 
values. In all cases histogram bars represent mean ± SEM of three independent 
experiments. **p<0.01 and n.s no significant differences (t-test). 
 
Dorsal stress fibres are known to assemble downstream of active Rac1, but not 
RhoA. After we observed that dorsal stress fibres predominate in ATRA-treated 
PSCs, we tested the levels of activation of both RhoA and Rac1 in untreated 
control and ATRA-treated PSCs. While we saw no significant differences in the 
levels of active RhoA, we observed a significant 20% increase in the activation of 
Rac1 in ATRA-treated PSCs when compared with control PSCs (Figure 4.16). 
Dorsal stress fibres are known to promote early cell spreading through Rac-1-
induced actin polymerization and membrane extension in newly spreading 
cells54. The increased levels of active Rac1 in ATRA-treated PSCs might provide 
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an explanation for the higher spreading rate of PSCs with ATRA treatment. 
Assembly of dorsal stress fibres in the lamellar cytoskeleton, while not necessary 
for force transmission or indicative of the overall force-generating potential of a 
cell, can nevertheless provide a stable scaffold for the recruitment and clustering 
of focal adhesion proteins even when actomyosin tension is suppressed by as 
much as 80%55. Taken together, the increased assembly of non-contractile 
dorsal stress fibres in ATRA-treated PSCs might explain the presence of larger 
focal adhesions despite a reduction in actomyosin contractility and force 
transmission to the ECM. 
 
ATRA impedes PSC migration 
 
CAFs are known to participate in the formation of distant metastatic sites by co-
migrating with tumour cells by first remodelling the matrix ahead of them leaving 
‘tracks’ in the matrix for the invading carcinoma cells to follow20. It is also well 
documented that stellate cells can infiltrate the stroma and migrate towards the 
tumour to communicate with the cancer cells in response to chemokine 
activation56-58. Therefore, suppressing the migration ability of stellate cells may 
have important roles in slowing down the formation of metastatic niches and 
abrogating the crosstalk between PSCs and cancer cells. Using a scratch would-
healing assay, we found that ATRA treatment severely inhibits the migratory 
activity of PSCs (Figure 4.17). This result cannot necessarily be attributed to 
reduced traction forces in PSCs, as previous studies have shown no association 
between traction forces and cell migration speed59, which is in line with other 
reports indicating that blebbistatin inhibits contraction but paradoxically 
accelerates migration in mouse embryonic stem cells60 and hepatic stellate 
cells61. 
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Figure 4.17: ATRA treatment impedes PSCs migration. (a) Brightfield images 
of PSC migration. Scale bar 200 mm. (b) quantification of wound closure given 
by the % change in the cell free area against 0h, 24h, 48h, 3 experimental 
replicates. All results are expressed as mean ± SEM. ***p<0.001 and n.s. no 
significant differences (t-test) 
 
The impaired migration in ATRA-treated PSCs could be explained by other 
mechanisms. Cell migration is a tightly regulated process dependent on 
dynamically coordinated adhesion formation and turnover at the cell front along 
with adhesion disassembly and tail retraction at the cell rear. The increased size 
of focal adhesions and cell–matrix adhesive capacity in ATRA-treated cells might 
physically impede migration by providing a stronger attachment to the underlying 
substrate, thereby interfering with normal spatiotemporal focal adhesion 
dynamics and preventing efficient cell movement. Second, wounding-induced 
PSC migration relies on chemotactic factors such as PDGF, which can be 
produced in an autocrine manner by activated PSCs26. Recent reports have 
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shown that ATRA downregulates PDGFRβ at the mRNA level in activated 
PSCs62 and this could represent another possible mechanism for disrupting 
wounding-induced migration in PSCs. 
 
 
Discussion 
 
Retinoids are vitamin A derivatives with a long history as chemotherapeutic 
agents in oncology due to their cell differentiative properties. PDAC is an 
aggressive malignancy that features disrupted retinoid signalling and particularly 
low expression and activity of RARs that correlates with poor patient survival63. 
The pleiotropic action of retinoids makes them good candidates as stromal-
reprogramming agents for tumours exhibiting pronounced desmoplasia such as 
pancreatic cancer. Here we found that human PSCs express all three RARs, 
albeit at different levels, and that treatment with ATRA, the physiologically active 
metabolite of vitamin A, mechanically reprograms PSC to promote quiescence in 
vitro and inhibit pancreatic cancer cell invasion. We uncover a previously 
unidentified mechanism through which activation of the RAR-β negatively 
regulates transcription of MLC-2 in PSCs. This activation suppresses actomyosin 
contraction, mechanosensing and force-mediated matrix remodelling and 
stiffening, which, in turn, creates a microenvironment unfavourable for invasion 
by pancreatic cancer cells. The reduced invasive behaviour of cancer cells was 
independent of paracrine signalling between PSCs and cancer cells, and was 
mostly attributed to the altered biomechanical and/or topographical 
characteristics of the remodelled microenvironment promoted by ATRA treatment 
on PSCs (Figure 4.18). 
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Figure 4.18: Model for the biomechanical reprogramming of PSCs. 
ATRA downregulates myosin II-dependent force generation and 
mechanosensing in PSCs. PSCs are reprogrammed to a more quiescent 
phenotype, cannot migrate, remodel the ECM or promote cancer invasion. 
 
This study was conducted using human culture-activated PSCs—a widely used 
in vitro model that recapitulates with good approximation the in vivo activated 
phenotype that occurs in cancer or persistent injury. However, the activated PSC 
phenotype resulting from culture-induced transdifferentiation can differ, to some 
degree, from the cancer-associated phenotype activated through exposure to the 
tumour microenvironment. Although exposure of PSCs to cancer cell supernatant 
did not change the overall PSC response to ATRA in our study, this approach 
cannot fully represent cancer-associated PSCs, because in vivo, the latter would 
be affected not only by cancer cells, which are themselves heterogeneous, but 
also by other cells in the stroma. Thus, future studies utilizing cancer-associated 
PSC is warranted for further validation. 
 
High levels of actomyosin (MLC-2)-mediated contractility is an indispensable 
feature for the emergence and functional persistence of tumour-associated 
myofibroblasts in the stroma; and MLC-2 is found to be consistently elevated in 
CAFs as opposed to normal fibroblasts13. Although paracrine factors released 
from the tumour are important for the initial activation of PSCs26, this self-
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sustaining behaviour is biomechanically regulated through a feed-forward loop 
involving actomyosin-mediated ECM stiffening and stiffness-sensing leading to 
PSC activation13,21,64. 
 
We found that ATRA lowers the magnitude of traction forces PSCs exert on their 
substrate and suppresses their ability to respond to external mechanical cues 
from the ECM, which may collectively interrupt the mechanosensory-driven 
activation of PSCs. In accordance with this, we found that ATRA induced the 
expression of cytoskeletal markers associated with PSC quiescence such as a 
reduction in Alpha smooth muscle actin and vimentin, and an increase in desmin. 
Interestingly, previous reports have shown that PSC activation could be blocked 
by ROCK inhibitors Y-27632 and HA-1077 (fausidil)65. We note that MLC-2 may 
serve as a convergence point for multiple environmental factors to regulate 
myofibroblastic differentiation of PSCs. For example, integrin-mediated 
mechanotransduction, mechanical stretch and contractile agonists, such as 
endothelin-1 and angiotensin II, are known to regulate smooth-muscle-specific 
gene expression as well as the MLC-2 axis65. 
 
It is worth noting that two independent investigations previously reported that 
retinoic acid inhibit PSC activation via suppressing the Wnt/β–catenin signalling 
pathway to either suppress pancreatic fibrosis in a mouse model of chronic 
pancreatitis or slow pancreatic tumour progression25,62. We report an additional 
mechanism by which ATRA mechanically reprograms PSC via transcriptional 
repression of MLC-2 to normalize matrix remodelling and inhibit cancer invasion 
in the absence of any secreted paracrine signalling. It is currently unknown if 
MLC-2-dependent actomyosin activity could be linked to the Wnt/β-catenin 
pathway; however, there is a literature report from Samuel et al. implicating 
actomyosin-mediated cellular contractile force with tissue stiffness and increased 
activation of β-catenin (a known mechanically activated transcription factor) to 
force tumour progression in a mouse model of skin cancer66. We suggest that 
RAR-β-selective agonists could be used to mechanically reprogram the stroma 
by targeting the actomyosin function of persistently activated PSC. 
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We also found that ATRA reprogrammed cell-to-ECM adhesion in PSCs resulting 
in stronger ECM adhesion and increased focal adhesion (talin and paxillin) size. 
Focal adhesions behave as ‘molecular clutches’ linking the ECM to intracellular 
cytoskeleton and allowing bidirectional transmission of force across the plasma 
membrane. The notion that focal adhesion maturation is regulated by actomyosin 
contractility has been called into question by recent reports that suggest that 
focal adhesion size is a poor predictor of the overall tension state of the cell66-68 
and our findings also point to this direction. Our observation that ATRA induces 
secondary cytoskeletal changes such as the formation of Rac1-dependent non-
contractile dorsal stress fibres could explain the higher rates of cell spreading in 
ATRA-treated PSCs. The increased presence of myosin II-independent dorsal 
stress fibres in ATRA-treated PSCs that serve as structural templates for 
increased focal adhesion growth55 (in a myosin-independent manner) could 
reconcile the inverse relationship between focal adhesion size and traction forces 
in ATRA-treated cells. 
 
The increasing appreciation that mechanotransduction and cell mechanical 
properties are key aspects in stromal biology and maintenance of the CAF 
phenotype in solid tumours has recently led to the discovery of YAP13 and 
caveolin-121 as key mechanoregulators of CAF function and biomechnical 
homoeostasis of the stroma with implications for metastatic progression. Our 
findings expand the aforementioned list by highlighting RAR-β as a genomic 
regulator of actomyosin tension, mechanosensing and microenvironmental 
remodelling in PSCs. 
 
Ablation of the desmoplastic stroma or genetic deletion of activated 
myofiboblasts have met with limited success in the realm of stroma-targeting 
approaches for the treatment of PDAC6,8. Due to the multi-faceted role of the 
desmoplastic stroma in both promoting and restraining PDAC progression9, 
stromal-reprogramming strategies that aim to reprogram PSCs to a quiescent-like 
state are highly sought after. Recently, the vitamin D receptor has shown promise 
in this direction. We herein suggest that ATRA or selective RAR-β agonists with 
improved toxicity profile, or potentially compounds that block actomyosin tension, 
can open new avenues in the treatment of PDAC by biomechanically 
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reprograming PSCs to a quiescent-like state, and restoring the biomechanical 
homoeostasis of the microenvironment to inhibit cancer invasion and 
progression. 
 
 
 
Materials & Methods 
 
Cell culture and antibodies 
 
Primary, culture-activated human PSCs (passages 6–8, HPaSteC #3830—Caltag 
Medsystems, UK) were exposed to ATRA dissolved in ethanol at a concentration 
of 1  µM for 10 days. Cell viability data are shown in (Figure 4.19). Medium was 
changed every 24  h and the drug treatment was performed in subdued light. 
Cells incubated with culture medium (DMEM with 2% fetal bovine serum (FBS), 
1% penicillin/streptomycin and 1% fungizone antimycotic) with an equivalent 
amount of vehicle (0.1% ethanol) served as controls. Antibodies: HSC70—Santa 
Cruz (1/10,000), Talin—Abcam ab71333 (1/100), Paxillin—BD Biosciences 
610051 (1/100), MLC-2—Millipore MABT180 (WB 1/100, IF 1/200), pMLC-2 
(Thr18/Ser19)—Cell Signalling, 3674 (WB 1/100, IF 1/200), Anti-Mouse HRP—
Invitrogen 626580 (1/2,000), Anti-Rabbit HRP—Abcam ab137914 (1/2,000) and 
Anti-Mouse 488—Invitrogen-A11029 (1/400). RAR-α agonist (AM580), Tocris 
0760; RAR-β agonist (cd2314), Tocris 3824; RAR-γ agonist (BMS 961), Tocris 
3410; pan-RAR agonist (TTNPB), Tocris 0761. In all cases, PSCs were exposed 
to 1  µM of agonist during 24  h. RAR-β antagonist (cd2665), Tocris 3800. For the 
experiments using the AsPC1-conditioning media, cells were grown under normal 
culture media with 10% FBS until 80% confluency, washed three times with PBS 
and grown in serum-free media for 24  h. The medium was collected and use in a 
proportion 40% conditioned media and 60% PSC media to grow PSCs for 24  h. 
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Western Blotting 
 
The cell lysates were prepared with radio immunoprecipitation assay buffer 
(Sigma, R0278) containing proteinase inhibitors (Sigma, P4340). The protein 
concentration was quantified by DC protein assay (Bio-Rad, 500-0113) according 
to the manufacturer’s instructions. Samples were separated by an SDS–
polyacrylamide gel electrophoresis gel under reducing conditions and transferred 
to a nitrocellulose membrane (GE Healthcare, 10401196), and then blocked with 
5% bovine serum albumin (BSA; Sigma, A8022)–0.1% Tween-20 (Sigma, 
P1379) in PBS. All primary antibodies were prepared in blocking solution and 
incubated overnight at 4  °C. The membrane was washed and incubated with 
horseradish peroxidase (HRP)-conjugated secondary antibodies in blocking 
solution for 1  h at room temperature. Finally, the membrane was washed and 
developed with HRP substrate (Millipore, WBLUR0100; Figure 4.20). 
 
RT-PCR 
Total RNA was extracted using the RNeasy Mini kit (Qiagen, 74104) and 1  µg of 
total RNA was reverse-transcribed using the High-Capacity RNA-to-cDNA kit 
(Applied Biosystems, 4387406) according to the manufacturer’s instructions. 
QPCR was performed using the SYBR Green PCR Master Mix (Applied 
Biosystems, 4309155) with 100  ng cDNA input in 20  µl reaction volume. GAPDH 
expression level was used for normalization as a housekeeping gene. The primer 
sequences for MLC-2 were as follow: forward, 5′-ATCCACCTCCATCTTCTT-3′ 
and reverse, 5′-AATACACGACCTCCTGTT-3′. The sequences were as following: 
MMP-2: forward-5′-TCTCCTGACATTGACCTTGGC-3′, reverse-5′-
CAAGGTGCTGGCTGAGTAGATC-3′; MMP-9: forward-5′-
TTGACAGCGACAAGAAGTGG-3′, reverse-5′-GCCATTCACGTCGTCCTTAT-3′; 
TIMP-1: forward-5′-TCAACCAGACCACCTTATACCA-3′, reverse-5′-
ATCCGCAGACACTCCAT-3′; MLC-2: forward, 5′-ATCCACCTCCATCTTCTT-3′ 
and reverse, 5′-AATACACGACCTCCTGTT-3′; GAPDH: forward-5′-
ACAGTTGCCATGTAGACC-3′, reverse-5′-TTTTTGGTTGAGCACAGG-3′. All 
primers were used at 300  nM final concentration. The relative gene expression 
was analysed by comparative 2−ΔΔct method. 
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Immunofluorescence staining 
 
All immunofluorescence staining was done on coverslips coated with 10  µg  ml−1 
FN (Sigma, F0895). Following pertinent treatment cells were fixed with 4% 
paraformaldehyde (Sigma, P6148) in PBS for 10  min, and then blocked and 
permeabilized with 0.2% BSA–0.1%Triton (Sigma, T8787) in PBS for 30  min. 
After blocking, cells were incubated with primary antibodies prepared in blocking 
solution for 1  h at room temperature in a humidified chamber. Then, cells were 
washed in PBS and incubated with Alexa Fluor 488-conjugated secondary 
antibodies and Phalloidin (Invitrogen, A22283, 1/1,000 dilution) prepared in PBS 
for 30  min at room temperature. Finally, coverslips were washed in PBS and 
mounted in mounting reagent with 4,6-diamidino-2-phenylindole (Invitrogen, 
P36931).  
 
Measurement of rate of cell spreading and spread area 
 
Measurements of the time-dependent spreading of cells were conducted on glass 
bottom Petri dishes (Maktek) coated with human plasma FN (10  µg  ml−1; Sigma) 
and incubated at 37  °C. Cells were trypsinised before measurements, suspended 
in culture medium (DMEM with 2% FBS) and plated on the dishes. Images of the 
cells were obtained with an inverted microscope (Eclipse Ti; Nikon) in DIC mode 
with the samples held at 37  °C. Images were obtained with a sCMOS camera 
every 5  min using a × 20 (0.4 numerical aperture (NA), air; Nikon) objective until 
noticeable cell spreading had stopped. The cell area was calculated using the 
imaging software (NIS elements; Nikon) by selecting the perimeter of the cell in 
each frame allowing the cell area to be tracked with time. 
 
Micropillar video microscopy and traction force measurements 
 
Pillar arrays were coated with human plasma FN (10  µg  ml−1; Sigma) and 
incubated at 37  °C for 1  h before measurements. Cells that had been trypsinised 
before measurements were suspended in culture media and plated onto the pillar 
substrates. Time-lapse imaging of the pillars was conducted with an inverted 
microscope (Eclipse Ti; Nikon) operating in bright-field mode with the samples 
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held at an ambient temperature of 37  °C. Image sequences were recorded with a 
sCMOS camera (Neo sCMOS Andor) at 0.5  Hz using a × 40 (0.6 NA, air; Nikon) 
objective over the early spreading phase (t<60  min) and late spreading phase 
(90  min<t<120  min). The position of each pillar in the time-lapse videos was 
tracked using a custom MATLAB program to track the centre of a point spread 
function of the intensity of the pillars across all frames. By selecting a location 
free of cells, tracking of a small set of pillars allowed a measurement of the stage 
drift to be obtained and corrected for in the data set. The time-dependent 
displacement of a given pillar was obtained by subtracting the initial position of 
the pillar (zero force) from the position in a given frame. Traction forces were 
obtained by multiplying the pillar displacements by the pillar stiffness, the maxima 
for each pillar were found to obtain the peak forces across the cell. More 
information about the pillar fabrication can be found in the section “Micropillar 
fabrication” below. 
 
Traction force microscopy 
 
Acrylamide (6.8%)–bis-acrylamide (0.36%) gels were casted on non-electrostatic 
silane-coated glass slides. The Young’s modulus of the polyacrylamide gels was 
12.8±0.8  kPa. Yellow-green fluorescent 0.5  µm carboxylated beads (Invitrogen) 
were embedded in the gels and centrifuged (300  g) towards the gel surface 
during polymerization at 4  °C. The beads served as markers for gel deformations. 
The gel surface was activated with sulfo-SANPAH (Pierce, Bonn, Germany) and 
coated with 50  µg  ml−1 FN. After cells adhered to the gels, cell tractions were 
computed from the gel surface displacements measured before and after force 
relaxation and detachment of cells (12  h after seeding) with 8  µM cytochalasin-D 
and 15  µM ML-7 in trypsin/EDTA. Gel deformations were measured using a 
Fourier-based difference-with-interpolation image analysis70. The experiments 
were performed at 37  °C, 5% CO2 and 95% humidity in DMEM containing 10% 
FCS in a microscope stage incubation chamber. 
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Cell-ECM adhesion strength 
 
To evaluate the strength of cell–matrix adhesion of PSCs (control or ATRA 
treated), 2.8  µm carboxylated magnetic beads (Dynabeads, Life Technologies) 
were coated with low concentration FN (1:100, FN:BSA) to allow for easier 
detachment. The beads were added to the cells and incubated for 5–10  min. A 
pulsatile pulling force regime of a magnitude F=1.5  nN magnitude, frequency 
1  Hz and duration 60  s was used in an attempt to detach FN beads from the cells 
(n=170 beads from ≥100 cells per condition). ECM adhesion strength was 
expression as the percentage of detached beads by the end of force application. 
 
Cell mechanosensing 
 
To assess how PSCs (control or ATRA treated) sense and respond to applied 
forces emanating from the ECM, 4.5  µm FN-coated magnetic beads coated were 
subjected to a pulsatile force regimen applied with magnetic tweezers, consisting 
of a 3  s, 1  nN pulse of force, followed by a 4  s period of rest, repeated for 12 total 
pulses over a 100  s time course. The ability of the cells to sense and respond to 
the applied tension was examined from the rapid cell stiffening response evident 
by the progressive decrease in amplitude of the bead movement (n=26 for PSC 
control and n=34 PSC ATRA). More information about the magnetic tweezers 
and cellular microrheology experiments can be found in the section cellular 
microrheology below. 
 
Two-dimensional collagen gel contraction assay 
Initially, wells in 24-well culture plates were pretreated with PBS containing 2% 
BSA for 1  h at 37  °C, washed twice with PBS and air dried. Ten parts of rat tail 
collagen I (9.06  mg  ml−1, Corning) were added to one part of 10 × DMEM, one 
part of 10 × PBS and 1.25 parts of deionized water (resulting in a final collagen 
concentration of 4.5  mg  ml−1), pH adjusted to 7.4 by adding 0.1  M NaOH and 
500  µl of this mixture added to each well. Collagen gels were allowed to solidify 
at 37  °C for 90  min. After gelation, 1.5 × 105 PSCs (control or pretreated with 
ATRA for 10 days) were layered on top of formed collagen matrices and fed with 
DMEM, 2% FBS with or without 1  µM ATRA. Collagen gel contraction was 
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evaluated after 60  h by digital image analysis software and expressed as the % 
reduction in the surface area of the gel. 
 
3D ECM remodeling assay 
 
To analyse the ECM remodelling ability of PSCs (control or ATRA treated), 
Collagen-I (BD Bioscences, 354249, stock concentration 9.37  mg  ml−1) and 
Matrigel (BD Bioscences, 354234, stock concentration 9  mg  ml−1) mixture gels 
were prepared with one part 10 × DMEM (Sigma, D2429) and one part FBS 
(Gibco, 10500), yielding to a final concentration of 4.5  mg  ml−1 Collagen-I and 
2  mg  ml−1 Matrigel. The gel mixture was neutralized with 1  M NaOH (Sigma, 
S8045), then 5 × 105 cells were embedded in gels in culture media. A measure 
of 80  µl gel volume was added per well of a 96-well plate, which was pretreated 
with 2% BSA (Sigma, A8022) for 1  h, washed with PBS and air dried for 10  min. 
Gels were set 1  h at 37  °C, and then incubated with culture media for 3 days at 
37  °C. For SHG microscopy, gels were prepared as explained above. After 3 
days of incubation at 37  °C, gels were fixed with 4% paraformaldehyde (Sigma, 
P6148) in PBS for 1  h at 37  °C, and then washed with PBS and permeabilised 
with 0.3%Triton X-100 (Sigma, T8787) in PBS for 30  min. After that, gels were 
blocked with 1% BSA–0.1% Triton X-100 in PBS for 1  h. Gels were washed with 
PBS and stained with Alexa Fluor 546-conjugated Phalloidin at 1/300 dilution in 
1% BSA in PBS for 30  min. Finally, gels were washed two times with PBS. 
 
Atomic force microscopy 
 
For AFM study, collagen/matrigels were lifted from the 96-well plates before 
measurement and immediately attached to a Petri dish with a droplet of 
cyanoacrylate adhesive, applied with a 10  µl pipette tip. After Matrigel attachment 
(1–2  min), the sample was immersed in culture medium (DMEM with 2% FBS) in 
order for the AFM measurements to be conducted within a 2  h time period. 
Measurements of the Matrigels have been conducted on a JPK Nanowizard-1 
(JPK Instruments) operating in force spectroscopy mode, mounted on an inverted 
optical microscope (IX-81; Olympus). AFM pyramidal cantilevers (MLCT; Bruker) 
with a spring constant of 0.07  N  m−1 were used with a 35  µm glass bead 
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attached to cantilever tip. Before measurements with the adapted cantilevers, 
their sensitivity was calculated by measuring the slope of force-distance curve in 
the AFM software on an empty region of the Petri dish. For indentation tests on 
the sample, the cantilever was aligned over regions in the middle of the samples 
using the optical microscope. For each sample, 30 force curves were acquired 
across six different 100  µm regions, this arrangement allowed force curves to be 
acquired in locations at least 50–100  µm apart. Force-curve acquisition was 
carried out with an approach speed of 5  µm  s−1 and a maximum set force of 
1.5  nN. Elastic moduli were calculated from the force-distance curves by fitting 
the contact region of the approach curve with the Hertz contact model, using the 
AFM software. 
 
Multiphoton confocal microscopy 
Collagen/Matrigel samples were prepared for analysis on Petri dishes via the 
same method mentioned previously for AFM analysis. All SHG images were 
obtained using a custom-built multiphoton microscope incorporating an upright 
confocal microscope (SP5, Leica) and a mode-locked Ti:Sapphire Laser (Mai Tai, 
Newport Spectra-Physics). Images of the SHG signal from collagen I were 
collected using an 820  nm excitation with SHG signal obtained with a 414/46  nm 
bandpass filter and multiphoton autofluorescence signal obtained with a 
525/40  nm bandpass filter. A ×25, 0.95 NA water-immersion objective (Leica) 
was used to deliver excitation signal and to collect the SHG emission signal from 
the sample. Images with a 200 × 200  µm field of view were obtained with 2,048 
pixel resolution and a line rate of 10  Hz giving a pixel resolution of ∼0.1  µm with 3 
× averaging on each acquisition to reduce the effect of noise. 
 
Invasion assays 
 
To assess the effect of ATRA treatment on PSC-driven ECM remodelling-related 
cancer cell invasion 3D organotypic cultures were employed. Organotypic gels 
were prepared with 52.5% Rat tail Collagen-I (BD Biosciences, 354236), 17.5% 
Matrigel (BD Bioscences, 354234), 10% FBS (Gibco, 10500) and 10% 10 × 
DMEM (Sigma, D2429). Gel mixture was neutralized by adding 1  M NaOH 
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(Sigma, S8045), and then 5 × 105 cells were embedded in gels in pertinent 
media (10% of total gel volume). A measure of 1  ml gel mixture was aliquoted per 
well of a 24-well plate. Gels were set at 1  h at 37  °C, and then maintained with 
the pertinent media for 3 days (when contraction is observed). PSCs were killed 
by incubating the gels with 400  µg  ml−1 Hygromycin (Life Technologies, 10687-
010) containing culture media for 48  h. After that gels were washed with PBS for 
45  min three times. Then, 2.5 × 105 AsPc1 cells (2:1 ratio for PSC: Cancer cell) 
were seeded on top of the gels and incubated overnight. Gels were lifted to an air 
liquid interface on top of Rat tail Collagen-I-coated nylon membranes (100  µm 
pore size, Millipore, NY1H02500) placed on stainless steel grids and fed from 
beneath for 10 days with 10% FBS containing RPMI (Sigma, R8758). Then, gels 
were collected, fixed overnight with formalin (Sigma, HT501128-4L) and 
embedded in paraffin (Fisher, 12624077). Sections (4  µm) were cut and stained 
for haematoxylin and eosin. Images were captured using the AE2000 binocular 
microscope (Motic) at × 20 magnification with Leica Application Suite 3.6 
software. The number of invading cell cohorts was counted using the ImageJ 
(NIH, 1.47v). In brief, bright-field haematoxylin and eosin images were changed 
to 8 bit type, and then converted into binary. The holes were filled and the non-
invading layer was removed. The invading cohorts were counted and the total 
area was calculated by restricting the size analysis to the size interval of cohorts 
and circularity to 0–1. Total number of invading particles per field was presented 
as one data point. 
 
MLC-2 rescue and functional assay 
 
To re-introduce MLC-2 expression in ATRA-treated PCSs; PSCs were treated 
with 1  µM ATRA for 10 days, and then transfected with 2  µg MLC-2 plasmid, 
(pEGFP-MRLC1, a gift from Tom Egelhoff, Addgene plasmid #35680) for 4  h 
using JetPRIME reagent (1:3 DNA:jetPRIME ratio (w/v)) and JetPRIME buffer 
(Polyplus, 114-15). During transfection, cells were cultured in 2  ml media without 
ATRA to exclude the possibility of it affecting the transfection efficiency. After 
transfection, culture media was changed with 2  ml media containing ATRA. Mock 
transfection was done using JetPRIME reagent and buffer only (that is, without 
DNA) and the cells were otherwise treated the same way as the transfection 
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group. Functional assays were done 48  h after transfection. To study the effect of 
MLC-2 overexpression on ECM remodelling, MLC-2 overexpressing ATRA-
treated PSCs and mock transfection group were trypsinised and 500,000 cells 
were embedded in 80  µl Collagen-I Matrigel mixture gels (4.5 and 2  mg  ml−1 final 
concentration, respectively). After 1  h incubation at 37  °C on 2% BSA-treated 
wells of 96-well plate, gels were covered with ATRA-containing media and left to 
be remodelled 3 days at 37  °C. Gel contraction was calculated as % reduction in 
the gel surface area. 
 
G-LISA assay for Rac1 and RhoA 
 
The intracellular amounts of Rac1-GTP and RhoA-GTP were determined using 
the G proteins-linked assay (G-LISA) (Cytoskeleton, Inc., Denver, CO, USA) 
according to the manufacturer’s instructions. In brief, cells were washed with cold 
PBS and homogenized gently in ice-cold lysis buffer. A measure of 20  µl was 
removed for protein quantification to adjust sample concentration to 0.5  mg  ml−1. 
After adding an equal volume of binding buffer, triplicate assays were performed 
using 1.5  µg protein per well. Samples were incubated for 30  min and then 
washed three times with washing buffer. Antigen-presenting buffer was added for 
2  min before removal; samples were then incubated with 1:250 dilution of anti-
Rac1 and anti-RhoA antibodies, respectively, at room temperature for 45  min, 
washed three times and incubated with secondary antibodies for another 45  min. 
HRP detection reagent was added and signal was read by measuring 
absorbance at 490  nm using a microplate spectrometer. 
 
Migration assay 
 
Cells were cultured on 35  mm glass-bottomed dishes pre-coated with 10  µg  ml−1 
FN and grown to a confluence of 95–100% in culture media DMEM with 2% FBS 
containing DMEM. On reaching confluence, ATRA treatment was applied to the 
treated population for 10 days before scratch assay measurements. A linear 
scratch was applied to the cell monolayer with a sterile 100  µl plastic pipette tip. 
Cellular debris was removed from the dish through a wash with DMEM before 
measurement. Scratch assays were kept at 37  °C and images taken along the 
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length of the scratch were obtained with phase contrast microscopy with a 10 × 
objective. Images were taken at time intervals of 0, 24 and 48  h. Images were 
analysed in a custom program (Matlab) to detect the cell-free area in the scratch 
and the percentage change was calculated to quantify the wound closure. 
 
Statistical analysis 
 
All statistical analyses were conducted with the Prism graphical software 
(GraphPad, Software). Data were generated from multiple repeats of different 
biological experiments to obtain the mean values and s.e.m displayed 
throughout. P values have been obtained through t-tests on paired or unpaired 
samples with parametric tests used for data with a normal distribution and non-
parametric tests conducted via the Mann–Whitney test where data had a skewed 
distribution. Significance for the t-tests was set at P<0.05 where graphs show 
significance through symbols (*P<0.05; **P<0.01; ***P<0.001). 
 
Micropillar fabrication: High-resolution photolithography was used to create 
molds containing arrays of holes on a silicon substrate. In the fabrication of the 
arrays, the photoresist was patterned using a 5x reduction autostepper and the 
desired hole depths for the pattern were achieved through a C4F8/SF4-based 
deep reactive ion etch. After removal of the photoresist the silicon molds were 
cleaned with piranha solution as well as a 1min O2 plasma clean followed by 
silanisation with (tridecafluoro-1,1,2,2,-tetrahydrooctyl)-1-trichlorosilane overnight 
under vacuum. Polydimethylsiloxane (PDMS) was mixed with its curing agent 
(Sylgard 184; Dow Corning) at 10:1, poured over the silicon molds and 
subsequently placed under vacuum for 30mins, to remove air and ensure PDMS 
penetrated the full depth of the holes. The PDMS was cured at 70°C for 12h to 
achieve a Young's modulus of 2.0 ± 0.1MPa, and the PDMS was thus peeled off 
while immersed in ethanol.  
The pillar substrates were comprised of a hexagonal array with centre-to-centre 
distances of twice the pillar diameter to achieve a constant area density. The 
pillar bending stiffness (k) was calculated through Euler-Bernoulli beam theory: 𝑘=364𝜋??4𝐿3  
where D, L and E are diameter, length and Young's modulus of the pillars, 
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respectively. The pillar dimensions used for this study were 6µm for pillar length 
and 1µm for the pillar diameter leading to a pillar stiffness of 1.36 nN/µm.  
 
Magnetic tweezers experiments: A magnetic tweezers device was used to 
apply tensional forces to fibronectin-coated beads bound to integrin receptors on 
the surface of cultured cells, and to measure stress-induced bead displacements. 
Tensional magnetic forces were induced by a high gradient magnetic field that 
was generated by an electromagnetic (solenoid-enclosed) microneedle with a 
pole tip (~15µm radius of curvature) that was microfabricated by mechanical 
milling and polishing with fine grit sandpaper (#4000 grade). The tip of the 
electromagnetic tweezers was positioned relative to a 4.5 µm diameter 
superparamagnetic bead (Dynabeads, Life Technologies) bound to cell surface 
integrins within the working distance of the 40x objective on an inverted 
microscope (Nikon Eclipse Ti-B) using an electronic micromanipulator 
(Eppendorf). Images of the bead position were recorded with an sCMOS camera 
at 20 frames/sec in brightfield mode. A computer control amplifier (TS200, Accel 
Instruments, CA) was used to provide electric current to the electromagnetic 
tweezers, and LabVIEW software was used to program the desired voltage 
waveform that was digitised and sent to the input terminals of the amplifier. A 
custom-built MATLAB algorithm was then used to analyse the image sequences 
and track bead displacement by following the intensity-weighted centroid of the 
bead across all captured frames. To calibrate the applied magnetic force, 4.5 µm 
beads were magnetically pulled through a silicone oil solution of known viscosity 
and their velocity was tracked across successive frames to obtain the force-
distance relationship at various currents using the Stokes formula F=6πηrv, 
where η=viscosity of silicone oil, r = radius of bead, v = bead velocity.  
 
Cellular microrheology: To characterize the mechanical properties of PSCs, we 
used magnetic tweezer microrheology to measure cell deformation in response to 
magnetically generated forces. Superparamagnetic 4.5 µm epoxylated beads 
(Dynabeads, Life Technologies) were coated with fibronectin (40 µg per 8 x 107 
beads) and incubated with adherent cells for 30 minutes, prior to measurements, 
to allow integrin binding and provide a mechanical link between the bead and the 
cytoskeleton. The unbound beads were removed by multiple washing with PBS. 
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The experiments were performed at 37°C, 5% CO2 and 95% humidity in DMEM 
containing 2% FΒS in a microscope stage incubation chamber. A viscoelastic 
creep experiment was conducted by applying mechanical tension onto single 
beads bound on the apical surface of the cells with a constant pulling force (F0 = 
3nN) for 3 seconds generated by the magnetic tweezers. The viscoelastic creep 
response of the cells was recorded by tracking the resulting bead displacement in 
brightfield (40x objective at 20 frames per second) that is indicative of the local 
cell deformation. The viscoelastic creep response J(t) of cells during force 
application followed a power-law in time J(t) = J0(t/t0)β with the prefactor J0 
representing cell compliance (J0 = inverse of cell stiffness in units of kPa-1) and 
the dimensionless exponent β representing cell fluidity with values ranging 
between 0<β<1 pure elastic (β = 0) or viscous behaviour (β = 1) and with the 
reference time t0 was set to 1 sec. The creep compliance J(t) of the cell is 
essentially the ratio ( γ(t)/σ0 ) of the localized cellular strain γ(t) induced by the 
applied stress from the magnetic tweezers σ0, with γ(t) taken as the radial bead 
displacement normalised over the bead radius γ(t)=d(t)/r and the applied stress 
as σ0 =F0/4πr2 taken as the applied force normalised over the bead cross-
sectional area. 
 
 
 
Figure 4.19: ATRA treatment does not change cell viability significantly. 
Trypan Blue was used to quantify number of dead cells from days 0 to 12 since 
the beginning of the ATRA treatment. No significant differences were observed 
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between the untreated control and ATRA treated PSCs, and both groups showed 
viability around 90%. p = 0.8580 (t-test). Three independent experiments 
 
 
 
Figure 4.20: Uncropped images of the Western Blot membranes 
corresponding to experiments presented in figure 4c. 
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Chapter 5 
 
Syndecan-4 is a cellular mechanotransducer that tunes cell mechanics by 
activating the integrin-RhoA pathway and YAP 
 
 
Summary 
 
Mechanotransduction describes the cellular processes that translate mechanical 
stimuli into biochemical signals, thus enabling cells to adapt to their physical 
environment. Extensive research has focused on the coordination of 
mechanochemical signalling cascades downstream of integrins. Here we show 
that syndecan-4 is a cellular mechanotransducer that tunes cell mechanics by 
eliciting a global mechanosignalling response. Localised mechanical stimulation 
of syndecan-4 triggers a synergistic cell-wide activation of β1 integrins, in a PI3K-
dependent manner, to subsequently activate the RhoA pathway and induce 
adaptive cell stiffening. Furthermore, syndecan-4 mediated tension at the cell-
ECM interface is required for YAP nuclear translocation. The variable region of 
the cytosolic domain of syndecan-4 is indispensable for the mechanical 
adaptation to force by stabilising the assembly of syndecan-4/α-actinin/F-actin 
molecular scaffold at the focal adhesion to potentiate the mechanoresponse. . 
This newly identified mechanotransductive ability of syndecan-4 should have 
immediate implications in biology and medicine. 
 
Introduction 
 
Physical forces regulate cellular behaviour and function during all stages of life. 
Mechanotransduction, the process by which cells convert mechanical stimuli into 
biochemical signaling events, is central to a number of physiological and 
pathological processes. Diseases including atherosclerosis, cancer and chronic 
fibrotic conditions can all arise from disturbances in normal cellular 
mechanotransduction and altered cellular sensitivity to mechanical stress1. The 
best characterised mechanosensitive proteins to date are integrins: 
transmembrane receptors that couple the internal actin cytoskeleton to the 
	   137	  
extracellular matrix (ECM) via force-bearing adaptor proteins within focal 
adhesion complexes (e.g. talin, vinculin, α-actinin). Several studies have 
revealed that cells respond to exogenous tension on mechanosensitive proteins, 
such as integrins, by employing a rapid adaptive cellular stiffening response in an 
effort to resist the increased tensile strain2-4. This cellular adaptation to force 
requires the coordination of mechanically activated signalling cascades, including 
the small GTPase RhoA and its effectors, which mediate local changes in focal 
adhesion growth and actomyosin contractility5.   
 
Syndecans belong to a small family of four transmembrane proteoglycan 
adhesion receptors that can interact with the ECM. They are thought to act 
synergistically with integrins to regulate adhesion, focal adhesion assembly and 
cytoskeletal organization6-8. Among them, synedcan-4 (Syn-4) is the only 
syndecan member that is ubiquitously expressed across all nucleated cells and 
enriched in focal adhesions. Much like integrins, Syn-4 provides 5 a direct 
mechanical linkage from the ECM to the actin cytoskeleton, and is thus well 
positioned to support force transmission and act as a mechanotransducer. The 
extracellular domain of Syn-4 bears heparan sulphate (HS) chains that bind to 
ECM proteins with heparin binding domains (e.g. fibronectin) as well as growth 
factors. The transmembrane domain drives dimerization, and the cytosolic 
domain promotes binding to focal adhesion components and intracellular 
kinases, and thus connects Syn-4 to the actin cytoskeleton. The cytoplasmic 
domain is comprised of two conserved (C1 and C2) regions, proximal and distal 
to the membrane, respectively. Between them is a variable (V) region, which 
interacts with the phospholipid PIP2 to stabilize the cytoplasmic domain in dimers 
or higher-order oligomers. The (V) region further associates with the actin-
crosslinking protein α-actinin to provide a mechanical and signaling link to the 
cytoskeleton9. Intriguingly, syn-4 null cells display impaired contractility and 
cytoskeletal organization as well as immature focal adhesions, all suggestive of 
mechanosensitive deficits7, 10-12. 
 
Here, we sought to explore if Syn-4 acts as a cellular mechanotransducer. We 
use biophysical tools combined with biological assays and steered molecular 
dynamics (SMD) simulations to investigate cellular responses to mechanical 
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tension on Syn-4. We reveal that localised tension on Syn-4 triggers a PI3K 
dependent, cell-wide activation of β1 integrins to consequently activate the small 
GTPase RhoA to induce adaptive cell stiffening. Furthermore, Syn-4 mediated 
tension at the cell-ECM interface is needed for YAP activation. Molecular 
simulations reveal that tension applied on the extracellular domain of Syn-4 
induces conformational changes of its cytoplasmic tail to potentially alter the 
interactions with various scaffolding and signaling proteins. Further to this, we 
show that the (V) region of its cytoplasmic tail is indispensable for the mechanical 
adaptation to force by stabilizing a Syn-4/α-actinin/F-actin molecular scaffold to 
potentiate force transmission and syndecan-4 mechanosignalling. 
 
Results 
 
Tension on syndecan-4 induces adaptive cell stiffening and 
mechanosignalling 
 
Tensional force application on mechanosensitive receptors, such as integrins, 
triggers rapid cytoskeletal remodelling and adaptive cellular stiffening evident as 
a gradual reduction in the amplitude of oscillation of the bead attached on the 
receptor3. This stiffening response has recently been extended to cadherins 
present in cell-cell junctions and nesprin-1 on the nuclear envelope13, 14.  
 
To investigate if Syn-4 acts as a cellular mechanotransducer, we utilized an 
electromagnetic tweezers device to apply localised mechanical tension on 
magnetic beads bound to endogenous Syn-4 in pancreatic stellate cells (PSCs) –
a type of myofibroblast- coupled with live cell imaging to track the bead 
displacement due to a known force induced by the magnetic field (Figure 5.1 
A,B). Application of 12 successive force pulses (3 s on, 4 s off) of constant force 
(~ 1 nN) on Syn-4 triggered an adaptive increase in cellular stiffness resulting in 
decreased bead displacement (Figure 5.1 C; Figure 5.2). The relative bead 
displacement was calculated by normalizing all displacements to that observed 
during the first pulse. The decrease in bead displacement was significant after 
the 4th pulse and reached a maximum of 40% by the 12th pulse. When the same 
force protocol was applied on magnetic beads coated with poly-L-lysine, and 
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bound to the cell surface non-specifically via electrostatic interactions, no change 
in bead displacement could be observed (Figure 5.1 D). These results show that 
applying localised tension on Syn-4 triggers a mechanotransduction pathway that 
adjusts cell mechanics.  
 
Figure 5.1: Adaptive cell stiffening downstream of tension on Syn-4 
requires filamentous actin and active biochemical signaling via Rho and 
PI3K  
(A) Schematic representation of electromagnetic tweezers pulling on a magnetic 
bead bound to the extracellular domain of Syn-4 receptor on the dorsal surface of 
a cell. (B) Typical cell stiffening response indicated by the progressively 
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diminished displacement of magnetic bead bound to Syn-4 over the course of 12 
successive force pulses (3 s on, 4 s off) of constant magnitude (~1 nN). (C) 
Quantification of relative displacement of magnetic beads bound to Syn-4 (n=33) 
on pancreatic stellate cells plated on a thin layer of fibronectin. Displacement for 
all pulses was normalized to the average displacement of first pulse. (D) 
Quantification of relative displacement of magnetic beads coated with poly-L-
lysine and bound non-specifically on the cell surface (n=20). (E) Relative change 
in bead displacement between the 1st and 12th pulse of force applied to beads 
bound to Syn-4 in control pancreatic stellate cells (n=33), or pretreated with 
latrunculin A (0.5 uM for 1h; n=20), C3 transferase Rho inhibitor (2 ug/mL for 4h; 
n=20), ROCK inhibitor Y- 27632 (10 uM for 1 h; n=20), PI3K inhibitor LY-294002 
(30 uM for 1 h; n=20), and AKT inhibitor SH-5 (10 uM for 1 h; n=24). In all cases, 
bars represent mean ± SEM, * P<0.05 
 
We next used a battery of pharmacological inhibitors to further delineate this 
newly identified Syn-4 mechanotransduction pathway. Pretreatment of cells with 
the F-actin polymerisation inhibitor latrunculin A prevented the stiffening 
response. Likewise, pharmacological inhibition of Rho or Rho-associated kinase 
(ROCK), respectively with C3 transferase or Y-27632 also abolished the 
mechanoresponse. Less intuitively, the stiffening response also showed a 
dependency on phosphoinositide 3-kinase (PI3K), as treatment with the PI3K 
inhibitor LY-29932 similarly abrogated the mechanical adaptation to force. 
However, inhibition of the main downstream effector of PI3K, namely AKT, with 
the SH-5 inhibitor failed to inhibit the stiffening response (Figure 5.1 E). 
Collectively these results suggest syndecan-4 is a cellular mechanotransducer 
that tunes cell mechanics in response to tension and the adaptive cell stiffening 
response requires active cytoskeletal remodelling and biochemical signalling via 
Rho and PI3K. 
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Figure 5.2: Tension on Syn-4 increases cellular stiffness. To examine the cell 
stiffness in response to an applied force, the time-dependent compliance of the 
cell was calculated from the time-dependent (bead) displacement using 
J(t)=6πax(t)/F(t), where a is the bead radius a, The viscoelastic response of the 
cell was characterized by fitting the creep compliance during force application to 
a modified Kelvin-Voigt model, a mechanical equivalent model comprising a 
spring and dashpot in parallel with a dashpot in series, used to describe 
viscoelastic materials. b, Example bead displacement curve. c, Example bead 
displacement curve transformed into compliance and fitted to the modified Kelvin-
Voigt model. d, Comparison of cell stiffness denoted by the spring constant k 
during the first and last pulse. 
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Tension on syndecan-4 drives global β1 integrin activation in a PI3K 
dependent manner 
 
Cell-ECM adhesion is mediated by both integrins and syndecans. Intriguingly, 
nearly all ECM molecules contain binding sites for both types of receptor and 
there is substantial evidence of a clear synergy between the two receptor 
families6. Cooperative signalling from both integrins and syndecans is required 
for generating a physical link to the cytoskeleton, for force transduction, for 
spatial control of the assembly of focal adhesion complexes, for directional 
migration and the regulation of cytoskeletal dynamics6-8, 15. We thus asked if 
localised tension on Syn-4 results in activation of integrins. Using a permanent 
neodymium magnet system, we exposed Syn-4 antibody bound beads on 
pancreatic stellate cells (plated on fibronectin) to 5 min of mechanical tension 
(~200 pN) after which the cells were fixed (Figure 5.3 B). Immunostaining 
against the active conformation of β1 integrins revealed that tension applied 
locally on Syn-4 induced a global, cell-wide activation of β1 integrins even at 
remote sites away from force application (Figure 5.3 A, C). Activated clustered 
integrins can also serve as sites of mechanotransduction. PI3K has been 
implicated in (inside-out) integrin activation in various contexts and cell types, 
although the exact mechanism remains obscure. Activation of PI3K results in the 
production of freely diffusible PIP3 phosphoinositides (PI3K phosphorylates PIP2 
to form PIP3) that act as lipid second messengers to propagate signaling 
cascades throughout the cell16. Upon pharmacological inhibition of PI3K, we 
found that tension on Syn-4 failed to induce the previously seen cell-wide 
activation response of β1 integrins (Figure 5.3 A). Using a PIP3 fluorescent 
reporter (GFP-PH-AKT) and electromagnetic tweezers we further show that 
localised tension (~1 nN) on Syn-4 directly activated PIP3 evident by the 
accumulation of GFP intensity around the magnetic bead (Figure 5.3 D, E). 
Collectively, these results suggest that localised tension on Syn-4 triggers a rapid 
PI3K- dependent, cell-wide activation of β1 integrins. 
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Figure 5.3: Tension on Syn-4 triggers cell-wide integrin activation through 
the PI3K-dependent production of freely diffusible lipid PIP3 
phosphoinositides.  
(A) Pancreatic stellate cells plated on fibronectin were incubated with anti-
syndecan-4 coated magnetic beads and exposed to tensional force (~200 pN) 
with a permanent neodymium magnet for 5 minutes. The cells were fixed and 
stained with HUTS-4, an antibody against the active conformation of β1 integrin, 
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and phalloidin to mark the F-actin cytoskeleton. White spots and arrows 
represent the location of magnetic beads and are the sites of force application 
(n>10 cells/conditions from three independent experiments, scale bar 20 µm (B) 
Respective schematic of neodymium magnet for controlled mechanical 
stimulation of specific ligands with permanent magnet. (C) Quantification of 
integrin activation (for images in panel A). (D) Pancreatic stellate cells were 
transfected with PIP3 biosensor (GFP-PH-AKT) and exposed to tensional force 
with magnetic tweezers. Representative images of the area around the magnetic 
bead before and after force application, scale bar is 5 mm (E) Mean fluorescent 
intensity around the bead was recorded before and after force application (60 s). 
Quantification of mean GFP-PH-AKT intensity. In all cases, bars represent mean 
± SEM, * P<0.05, data were collected from 3 independent experiments and 
analysed by a two-tailed unpaired t-test. 
 
New integrin-FN connections are required for adaptive cell stiffening and 
RhoA activation downstream of mechanical tension of Syn-4 
 
Rho GTPases are master regulators of the cellular cytoskeleton, and their 
activities are critical in mechanotransduction. Active RhoA interacts with effector 
proteins, which leads to actomyosin contractility and actin stabilisation5,17. 
Furthermore, Syn-4 clustering has been previously found to activate RhoA-
dependent signalling to aid in the formation of focal adhesions and stress 
fibres18. However, it remains unclear if mechanical force applied on Syn-4 affects 
RhoA. For this reason, we measured activation levels of RhoA in response to 
tensile force on Syn-4. We found that pulling on Syn-4 for 5 minutes elevated 
RhoA activity almost by 50% relative to basal levels and the magnitude of 
activation was dependent on the duration of force application reaching ~ 100% 
increase relative to basal levels after 15 minutes (Figure 5.4 A). RhoA-mediated 
cytoskeletal stiffening in response to force on Syn-4 presumably represents an 
adaptation that allows cells to modulate their own mechanical active biochemical 
network within a mechanical feedback loop. Syn-4 is known to work in concert 
with integrins to regulate focal adhesion growth and cytoskeletal organisation. 
Thus, we next sought to investigate if force-induced RhoA activation and 
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adaptive cell stiffening downstream of tension on Syn-4 requires engagement of 
integrins. Fibronectin (FN) contains domains that can engage both integrins and 
syndecans. The integrin-binding domain of FN lies within the 10th type III module 
containing the ArgGly-Asp (RGD) motif, while the heparin-binding domain of FN 
lies within FN type III repeats 12-14. We thus plated PSCs on fibronectin together 
with an antibody (3E3) that blocks the β1 integrin-binding domain on the 
fibronectin molecule (Figure 5.4 B). Then we 10 applied a pulsatile force regimen 
on Syn-4 with the electromagnetic tweezers. Blocking the integrin-binding domain 
inhibited the stiffening response, suggesting that Syn-4 mediated force 
transduction requires engagement and activation of β1 integrins (Figure 5.4 C). 
Consistent with this, incubating cells with the FN-blocking antibody and 
measuring RhoA activity following mechanical stimulation of Syn-4 with the 
permanent magnet assay, showed greatly suppressed RhoA activation. Still, at 
the 15 min mark we detected a small not significant increase in RhoA activity 
(Figure 5.4 D). Taken together, these results suggest that tension on Syn-4 
activates RhoA-mediated adaptive stiffening and this response requires new 
integrin-FN ligation and activation. 
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Figure 5.4: Tension on Syn-4 activates RhoA-mediated adaptive stiffening 
in a β1-integrin dependent manner (A) ELISA and GLISA analysis of cell 
lysates for total and active RhoA levels in PSCs plated on FN before and after 
tensional force application (~200 pN) on syn-4 (B) Schematic representation of 
the FN blocking antibody binding to the integrin binding domain preventing new 
integrin FN connections. (C) Quantification of relative bead displacement (1st 
pulse and 12th pulse) of Syn-4-coated magnetic bound on PSCs plated on FN 
along with FN-blocking antibody (3E3). (D) ELISA and GLISA of cell lysates for 
total and active RhoA levels in PSCs plated on FN along with a FN-blocking 
antibody (3E3, 30 min incubation) that occupies the integrin-binding domain 
preventing new-integrin FN connections. In all cases, bars represent mean ± 
SEM, ** P<0.01, *** P<0.001, data were collected from 3 independent 
experiments and analysed by ANOVA and Tukey posthoc test. 
 
 
Syn-4 mediated tension at the cell-ECM interface is required for YAP 
activation  
 
The Yorkie homologue YAP (Yes-associated protein) is an effector of the Hippo 
pathway that has recently been identified as a key mechanotransducer relaying 
exogenous and endogenous mechanical cues, including matrix stiffness, stretch 
and cytoskeletal tension into the nucleus to influence gene expression and cell 
fate. YAP shuttles between the cytoplasm (where it is inactive) and the nucleus 
(active conformation) where it associates with several promoter-specific 
transcription factors to regulate gene expression and cell fate decisions19. 
However, how syndecan-4, mechanical cues and the F-actin cytoskeleton can 
regulate these transcriptional effectors remains elusive. 
 
We plated wild-type mouse embryonic fibroblasts (MEFs) and Syn-4 null (-/-) 
MEFs on fibronectin-coated 25 kPa polyacrylamide substrates and 
immunostained against F-actin and YAP. WT MEFs adopted a well-spread cell 
shape with prominent F-actin stress fibres and displayed predominantly nuclear 
YAP localisation. In stark contrast, Syn-4 null (-/-) MEFs failed to form F-actin 
stress fibres, an indication of disrupted cytoskeletal architecture and low 
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intracellular tension and displayed predominantly cytoplasmic YAP localisation 
(Figure 5.5 A, B). Consistent with this finding, the mRNA expression of the well-
characterised YAP target gene, connective tissue growth factor (CTGF) was also 
found to be lower on syn-4 null MEFs plated on glass FN-coated substrates 
(Figure 5.5 C). Previous studies have highlighted YAP as sensors for mechanical 
stimuli including matrix stiffness, and internal cytoskeletal forces as F-actin 
destabilisation or Rho inhibition contrubutes to nuclear exclusion of YAP. 
Integrins and Syn-4 are central transducers of mechanical cues from the ECM. 
As such, Syn-4 mechanosignalling clearly occurs upstream of YAP activity and 
appears to be critical for the maintenance of normal stress fibre assembly, 
cytoskeletal tension and nuclear YAP localisation. 
 
These results suggest that Syn-4-mediated tension at the cell-ECM interface is 
essential for the nuclear shuttling and activation of YAP and the assembly of 
cytoskeletal F-actin stress fibres. 
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Figure 5.5: Syndecan-4 mechanosignalling is required for YAP activation. 
(A) F-actin, DAPI and YAP immunofluorescent staining of Syn-4 WT MEFs and 
Syn-4 -/- MEFs plated on 25kPa FN-coated polyacrylamide gels. Images are 
representative (n=18 for Syn-4 WT MEF, n=16 for Syn-4 -/- MEF) Scale bar is 20 
µm (upper panel) and 10 µm (lower panel) (B) Quantification of 
nuclear:cytoplasmic YAP intensity. (C) qPCR quantification of CTGF mRNA 
levels. Bars represent mean ± s.e.m, ***P<0.001, **P<0.01 data were collected 
from 3 independent experiments and analysed by a two-tailed unpaired t-test. 
 
 
The variable (V) region of the cytoplasmic domain of Syn-4 is indispensable 
for the mechanical adaptation to force 
 
The cytoplasmic domain of Syn-4 interacts with various scaffolding and signalling 
proteins; as such, the cytosoplasmic domain might be crucial in mediating the 
mechanosignalling function of Syn-4. Induction of protein phosphorylation is one 
of the first events that occurs when mechanical force is applied to cells20, 21. We 
investigated the tyrosine residue Y180 in the C1 region of Syn-4 that was 
recently identified as a major phosphorylation site controlling integrin trafficking, 
focal adhesion dynamics and migratory behaviour15. For this, we transfected 
Syn-4 null (-/-) MEFs (mouse embryonic fibroblasts) with a plasmid encoding for 
phosphonull Syn-4 mutant that could not be phosphorylated on Y180 (Syn-4-
Y180L), as well as a phosphomimetic mutant (Syn-4-Y180E) and applied tension 
on the syn-4 receptor with the electromagnetic tweezers. We found that both the 
phosphonull Syn-4-Y180L and phosphomimetic Syn-4-Y180E MEFs were able to 
stiffen under force indicating the phosphorylation status of Y180 is dispensable 
for Syn-4 mechanosensing (Figure 5.6 A,B; Figure 5.7). We then expressed a 
truncated Syn-4 core protein lacking the C-terminal C2 (EFYA) domain (Syn-4-
Δ199Ε) in Syn-4 null (-/-) MEFs. The C2 domain (EFYA), which is universally 
conserved across all four syndecans, contains a PDZ-binding site that interacts 
with PDZ-domain containing proteins, namely syntenin, synectin, synbidin and 
calcium/calmodulin depdendent serine protein kinase (CASK) 22. These proteins 
bind to the C-terminus of the Syn-4 cytoplasmic domain and coordinate receptor 
clustering, exosome biogenesis and formation of connections to the actin 
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cytoskeleton mainly via CASK 23,24. Deletion of the C2 domain (Syn-4-Δ199Ε), 
however, had no effect on the mechanosensing ability of Syn-4 (Figure 5.6 A,B 
and Figure 5.7). We then interrogated the effect of truncating the cytoplasmic 
domain of Syn-4 within the V region at the isoleucine191 (Syn-4-Δ191I). The V-
region of Syn-4 binds to both protein kinase C alpha (PKCα) and the 
phospholipid PIP2 to transduce downstream signals for cytoskeletal 
organisation18-24. The Syn-4 V-region further interacts with α-actinin to provide a 
direct mechanical link to the actin cytoskeleton. We expressed the Syn-4-Δ191I 
cDNA construct in syn-4 null MEFs and examined the ability of these cells to 
adapt to force applied on Syn-4. We found that Syn-4-Δ191-expressing MEFs 
were unable to reinforce upon mechanical stimulation of Syn-4 (Figure 5.6 A,B). 
The Syn-4-Δ191 truncation deletes the binding site for PKCα and α-actinin9, 25. 
Previously, V-region truncation in MEFs (Syn-4-Δ191) has been associated with 
defects in cytoskeletal organisation, stress fibre assembly and focal adhesion 
formation as well as myofibroblastic differentiation11, 26. In stark contrast, syn-4 
null (-/-) MEFs that re-expressed full length Syn-4 (Syn-4 WT) were able to 
exhibit the reinforcement response as expected. These results suggest that 
interactions of the Syn-4 V region with its binding partners, for example α-actinin 
or PKCα can modulate cellular mechanosensing. In summary, the V-region of 
Syn-4 cytoplasmic domain is necessary for the mechanical adaptation to force. 
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Figure 5.6: The central variable (V) region of syn-4 cytoplasmic domain is 
required for mechanical adaptation to force (A) Representation of Syn-4 
structure with a focus on the cytoplasmic domain. Syn-4 cytoplasmic mutations 
on the phosphorylatable tyrosine residue (Y180) along with two cytoplasmic 
truncation mutants (Δ191I & Δ199Ε) are depicted. (B) Relative displacement 
between 1st and 12th force pulse of Syn-4-coated magnetic beads bound on 
MEFs with modifications in the Syn-4 cytoplasmic domain: phosphomimetic Syn-
4Y180E (n=43), phosphonull Syn-4-Y180L (n=35), Syn-4-Δ191I (n=23, 
cytoplasmic truncation within the V region), Syn-4-Δ199Ε (n=23, cytoplasmic 
truncation of C2 domain), Syn-4-WT (n=27). Bars represent mean ± s.e.m, 
*P<0.05, data were collected from 3 independent experiments and analysed by a 
two-tailed unpaired t-test. 
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Figure 5.7: Immunofluorescent staining of MEFs transfected with Syn-4 
plasmids. HA tag immunofluorescent staining with various syndecan 4 (Syn4) 
plasmids into syndecan 4 null (Syn4-/-) mouse embryonic fibroblasts (MEFs). WT 
and mutant Syn4 pIRES-GFP expression in cells fixed at 24 hours. Syn4-/- MEFs 
transfected with 500 ng DNA and 1.5 µL Lipofectamine LTX on glass coverslips in 
24 well plate format. Phalloidin CF488 (Santa Cruz Biotechnology sc-363791, 
1:1000) and mouse anti-HA.11 (BioLegend 901513, 1:250) with goat anti-mouse 
AF555 (Thermo Fisher Scientific A21424, 1:1000). Scale bar: 100 µm. 
 
Steered molecular dynamics simulations reveal that tension applied on the 
extracellular domain of Syn-4 is able to induce a conformational change in 
the cytosolic domain 
 
We next used molecular dynamics (MD) simulations to further investigate the 
effect of tensional force on Syn-4 down to the molecular level. The system 
consisted of homodimeric transmembrane and cytoplasmic domains of Syn-4 
embedded into membrane bilayer containing a mixture of lipids, including PIP2. 
In equlibrium MD simulations (with no force applied) Syn-4 structure was stable 
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during the 50 ns 14 simulations with no significant conformational changes in the 
cytoplasmic domain. Constant force pulling at 50 pN applied to the extracellular 
side of Syn-4 caused directed movement of the cytoplasmic domain, towards the 
membrane (Figure 5.8 A). RMSF (root mean square fluctuations) of Cα show 
that the transmembrane helices in the hydrophobic core of the membrane are 
most stable during the simulation while the C-terminal residues (C2 region) are 
most flexible (Figure 5.8 B). We chose residue Lys190 as one of the most stable 
positions in V region to monitor the conformational changes of the cytoplasmic 
domain on the membrane plane (Figure 5.8 C). The directed movement of the 
cytoplasmic domain was found to lead to interactions of Syn-4 with the 
membrane, where strong electrostatic intereactions between lysine residues and 
heads of PIP2 lipids take place. Using constant force pulling at 50 pN (Figure 
5.9; FIgure 5.10) and 100 pN we have observed quite similar behaviour resulting 
in tilting of the cytoplasmic domain towards the plasma membrane in 50 ns of 
simulation. The use of constant force of 25 pN caused similar but significantly 
slower conformational change within the cytoplasmic domain and 100 ns 
simulation was performed to observe an effect similar to that seen under 50 
pN/50 ns. Using higher force magnitude of 200 pN causes more significant 
sliding of the protein through the membrane, resulting in no directed movement of 
the cytoplasmic domain (Figure 5.10). It is possible that the force-dependent 
orientation of the cytoplasmic domain leading to membrane interactions is 
important in the modulation of the intracellular interactions of Syn-4 with its 
binding partners, including the scaffolding protein α-actinin, which is known to 
interact with the region forming tight interactions with the membrane under force. 
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Figure 5.8: Conformational changes of Syn-4 in molecular dynamics (MD) 
and steered molecular dynamics (SMD) simulations. (A) Structure snapshots 
of syndecan-4 at every 5 ns during 50 ns of simulations (from blue to red) with no 
force applied (MD) (left) and with constant force pulling (SMD) at 50 pN (right). 
Cytoplasmic domain has directed movement towards membrane in SMD. (B) 
RMSF of syndecan-4 Cα atoms show that the most stable are transmembrane 
helices in hydrophobic core of the membrane and the most flexible are the C-
terminal residues (C2 domain). (C) Average position of Lys190 Cα atoms on the 
membrane plane representing directed movement of cytoplasmic domain from 
virtual axis (located between transmembrane helices) towards membrane in 
SMD. Average position was calculated for both Lys190 Cα atoms (chain A and B) 
in every 5 ns time window. (D) Syndecan-4 sequence, where aa 1-18 – signal 
peptide, 19-145 – extracellular domain (green), 146-170 – transmembrane 
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domain (brown), 171-198 – cytoplasmic domain (purple). (E) Schematic 
representation of syndecan-4 conformations in MD (left) and SMD (right).  
 
Figure 5.9: Steered molecular dynamic simulations. Conformational changes 
of cytoplasmic domain of syndecan-4 (upper panel) and sliding of syndecan-4 
through the membrane (lower panel) in MD (4 repetitions) and SMD simulations 
using constant force pulling at 50 pN (4 repetitions), 25 pN (2 repetitions), 100 pN 
(2 repetitions) and 200 pN (2 repetitions).  
  
	   155	  
 
Figure 5.10: Steered molecular dynamic simulations. Conformational 
changes of cytoplasmic domain of syndecan-4 (upper panel) and sliding of 
syndecan-4 through the membrane (lower panel) in MD (4 repetitions) and SMD 
simulations using constant force pulling at 50 pN (4 repetitions), 25 pN (2 
repetitions), 100 pN (2 repetitions) and 200 pN (2 repetitions).  
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Force stabilises a Syn-4/α-actinin/F-actin molecular scaffold to provide 
mechanical linkage to the cytoskeleton and potentiate Syn-4 
mechanotransduction 
 
We next sought to investigate how the force-induced conformational change in 
the cytoplasmic V region is linked to Syn-4 mechanosignalling. We examined α-
actinin, an actin-binding molecule and focal adhesion component, which 
constitutes an important binding partner of the Syn-4 cytoplasmic V region. Syn-4 
interacts with α-actinin in an integrin β1-independent manner to provide a direct 
mechanical linkage to the actin cytoskeleton. This interaction occurs via the V 
region of the Syn-4 cytoplasmic domain which binds to the α-actinin spectrin 
repeat 4 (SR4) present in the rod domain of α- actinin (Figure 5.11 A) 9-12. We 
used siRNA to knockdown the endogenous expression of a-actinin in MEFs 
(Figure 5.12) and subsequently expressed fluorescently tagged GFP-α-actinin. 
When tension (~1 nN) was applied on Syn-4 with the electromagnetic tweezers, 
a significant increase in the GFP intensity at the periphery of the magnetic bead 
could be observed (Figure 5.11 B,C). Further to this finding, MEFs with siRNA-
mediated knockdown of α-actinin displayed impaired Syn-4 mechanosensing 
evident by their inability to exhibit the adaptive stiffening response with pulsatile 
tension applied on Syn-4. Following siRNA mediated depletion of their 
endogenous pool of α-actinin, MEFs expressing the α-actinin mutant that lacks 
the actin-binding domain (ABDel) similarly failed to exhibit an adaptive stiffening 
response when tension was applied on Syn-4. Less surprisingly, MEFs 
transfected with non-targeting/scramble siRNA maintained the adaptive stiffening 
response (Figure 5.11 D). α-actinin also associates with integrins, vinculin and 
zyxin within focal adhesions. There may also be potential signalling roles as 
reports indicate α- actinin interacts with PIP2 and FAK. Force-induced 
stabilisation of α-actinin at Syn-4 enriched focal adhesions may result in 
recruitment of other essential focal adhesion components (zyxin, vinculin and β1 
integrins) to facilitate cell contractility and downstream Syn-4 mechanosignalling. 
These results collectively suggest that force on Syn-4 stabilises the assembly of 
a Syn-4 (V)/α-actinin/F-actin molecular scaffold at the focal adhesion to facilitate 
force transmission and downstream Syn-4 mechanosignalling (Figure 5.11 E). 
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Figure 5.11: Tension on Syn-4 stabilises a Syn-4/α-actinin/F-actin molecular 
scaffold to enable Syn-4 mediated adaptive stiffening and 
mechanosignalling (A) Representation of the interaction between α-actinin and 
Syn-4. The α-actinin spectrin repeat 4 (SR4) binds to the Syn-4 cytoplasmic V 
region; and the calponin homology domain (CH) of α-actinin binds to F-actin to 
provide a mechanical link to the cytoskeleton (B) MEFs were first depleted of 
their endogenous α-actinin via siRNA mediated knockdown and subsequently 
transfected with the fluorescently tagged reporter GFP-α-actinin. Tension was 
then applied on Syn-4 bound beads with electromagnetic tweezers and GFP 
intensity around the bead was recorded. Images are representative. Arrows 
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indicate the position of the bead. Scale bar = 50µm (C) Quantification of 
normalised mean GFP α-actinin intensity around beads (n=9 beads, from at least 
3 independent experiments) (D) Relative displacement of Syn-4 bound beads on 
MEFs with siRNA mediated knockdown of endogenous α-actinin (blue, n=18), 
MEFs with siRNA mediated knockdown of α-actinin + re-expression of the α-
actinin mutant (ABDel) that lacks the F-actin binding domain (green, n=21), and 
MEFs with siRNA mediated knockdown of endogenous α-actinin transfected with 
a non-targeting scramble siRNA (grey, n=18). Error bars represent s.e.m, 
*P<0.05, data were collected from 3 independent experiments and analysed by a 
two-tailed unpaired t-test. (E) Outline of syndecan-4-mediated cellular 
mechanotransduction 
 
 
 
Figure 5.12: Transfection efficiency of the siRNA alpha-actinin in wild type 
MEFs. Ctrl=control, NT=non targeting 
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DISCUSSION 
 
Syndecan-4 is a transmembrane heparan sulphate proteoglycan that acts as a 
receptor for multiple ECM proteins and regulates diverse cellular processes 
including adhesion, migration and cytoskeletal organization. Syn-4 is unique 
among syndecans in that it is ubiquitously expressed in most cell types and 
becomes incorporated into focal adhesions together with integrins. So far, the 
existing body of research on transmembrane mechanotransduction has largely 
focused on integrins.  
 
In the present study we combined biophysical and biological approaches to 
reveal that Syn-4 functions as a cellular mechanotransducer. Using an 
electromagnetic tweezers system along with live cell imaging we uncovered a 
previously unidentified mechanotransduction pathway whereby tension applied 
on Syn-4 elicits an adaptive cellular stiffening response.  
 
Through pharmacological inhibition, we showed that the Syn-4-mediated 
stiffening response requires actin cytoskeletal remodelling and active biochemical 
signaling via Rho and PI3K. Intriguingly, we report that tension on Syn-4 triggers 
a cell-wide, PI3K-dependent engagement and activation of β1 integrins even at 
regions remote from the site of force application. Using a fluorescent PIP3 
biosensor, we proposed that the “inside-out” activation of β1 integrins in 
response to tension on Syn-4 is induced by the production of freely diffusible 
PIP3 phosphoinositides. The diffusion rate of PIP3 is ~0.1-1 um2 /sec making the 
propagation of the biochemical signal fast enough for global activation of 
integrins within the timescale involved (~60 sec). The exact mechanism of PI3K-
induced integrin activation is unknown but might be related to further downstream 
activation of the integrin-associated adaptor proteins talin and/or kindlin. The cell-
wide activation of β1 integrins suggests that the stiffening response may be a 
cell-wide phenomenon rather than a localized event that occurs at the site of 
bead attachment/focal adhesion. 
 
 We proceeded to show that that tension on syn-4 activated the small GTPase 
RhoA to induce adaptive cell stiffening and this activation response is to a large 
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extent contingent upon the formation of new integrin-ECM connection and 
activation of β1 integrins. Syn-4 has previously been shown to work in concert 
with integrins to regulate focal adhesion growth and cytoskeletal stress fibre 
assembly via RhoA signalling 6-8,11,18.  
 
Our results expands on these previous reports by highlighting that Syn-4 
mechanosignalling requires the synergistic mechanosensory input of β1 integrins 
to promote RhoA-mediated adaptive cytoskeletal remodelling. To investigate 
longer-term responses to Syn-4-mediated force transduction, we examined 
activation of YAP in response to matrix tension; YAP is a known mechanosensor 
that relays mechanical and cytoskeletal signals to the nucleus. We observed that 
Syn-4-mediated tension at the cell-ECM interface is required for nuclear shuttling 
and activation of YAP and subsequent transcription of the downstream YAP 
target gene CTGF. The absence of Syn-4 engagement and mechanosignalling 
caused cytoplasmic YAP retention and deactivation. We could speculate, based 
on previous reports, that this is likely secondary to the disrupted F-actin 
cytoskeletal architecture and stress fibre assembly induced by Syn-4 knockout. It 
is likely that F-actin reorganisation downstream of mechanical stimulation of Syn-
4 may promote activation of positive cofactor that mediates YAP activation. 
Alternatively a specific F-actin structure might physically sequester a YAP 
inhibitory factor (e.g. LATS1 or LATS2), or serve as a platform to promote its 
post-translational modification, in any case preventing it from interacting with 
YAP. 
  
Using cytoplasmic truncation mutants as well as phosphomutants, we further 
demonstrated that the central variable (V) region of the cytoplasmic domain 
appears to be necessary for Syn-4-mediated mechanosensing. Molecular 
dynamics simulations revealed that appled force on the extracellular domain of 
Syn-4 elicits a rapid conformational change in the cytoplasmic domain causing 
the tail to bend towards the plasma membrane. This force-induced 
conformational change of Syn-4 cytoplasmic tail could in principle provide a 
binding platform for scaffolding and/or signalling partners, such as α-actinin. 
Consistent with this, we found that MEFs with truncation of the central variable 
(V) domain of the cytoplasmic tail, but not the C2 domain, displayed impaired 
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Syn-4 mechanosensing. Indeed, α-actinin binds directly to the V region of the 
Syn-4 cytoplasmic domain and Syn-4 knockout fibroblasts have been previously 
shown to display decreased actin cytoskeletal organization with fewer 
microfilament bundles, perhaps indicative of decreased tension exerted on the 
matrix. Congruent with the above, we found that force applied on Syn-4 led to 
recruitment of α- actinin. Force-induced stabilisation of a Syn-4(V)/a-actinin/F-
actin molecular scaffold 19 at the focal adhesion appeared to serve as a 
structural link to the cytoskeleton necessary for force transmission and 
downstream mechanosignalling. Our data collectively suggest that Syn-4 is a key 
cellular mechanotransducer that responds to mechanical stimulation by 
regulating global cell mechanics and activating YAP with important implications 
for wound healing, inflammation and tumour progression. 
 
 
Methods 
 
Cell culture, reagents, and antibodies 
 
Immortalised wild type and syndecan-4 -/- mouse embryonic fibroblasts (MEFs) 
were grown in Dulbecco’s Eagles medium (DMEM) (Sigma Aldrich) 
supplemented with 10% fetal bovine serum (FBS). Primary, culture-activated 
human pancreatic stellate cells (passages 6-8, HPaSteC #3830 - Caltag 
Medsystems, UK) were incubated with culture medium (DMEM with 2% FBS, 1% 
penicillin/streptomycin and 1% fungizone antimycotic). Antibodies: syndecan-4 
(sc-12766, Santa Cruz Biotechnology Inc); Phalloidin (Invitrogen, A22283); anti 
beta1 integrin antibody, activated, clone HUTS-4 (MAB2079Z, Merck Millipore); 
YAP (Santa Cruz Biotechnology sc-101199); Alphaactinin-4 antibody (Santa Cruz 
Biotechnology sc-390205); Alpha-actinin-4 siRNA (sc-43102); Anti-Mouse HRP 
(Invitrogen 626580); Anti-Rabbit HRP (Abcam ab137914); Anti-Mouse 488 
(Invitrogen-A11029). Latrunculin A (Calbiochem, CA, USA 428026), C3 Rho 
inhibitor (Cytoskeleton, Inc., Denver, CO, USA); Y-27632 (Calbiochem, CA, USA 
688001); LY294002 PI3K inhibitor (L9908, Sigma Aldrich); SH-5 AKT inhibitor 
(ab141442, Abcam). The GFP-PH-AKT was a gift from Tamas Balla (addgene 
plasmid 51465) 
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Preparation of magnetic beads 
 
Carboxylated paramagnetic beads (2.8 or 4.5 µm, Dynabeads) were washed 
twice with 0.1 M NaOH and dH2O, reacted with the carbodiimide crosslinker EDC 
(0.3M) for 30 min and coated with the anti-syndecan-4 antibody according to 
manufacturer’s instructions. Beads were quenched in 50 mM Tris buffer to 
remove any unreacted surface carboxylic groups, subsequently washed 4 times 
with 50 µM Tris with added 0.1% BSA and resuspended in PBS. Before 
experiments, the antibody-coated magnetic beads were resuspended in cell 
medium and incubated with the cells (PSCs or MEFs) for 30 min at 37°C. Cells 
were briefly washed with fresh media to remove unbound beads prior to force 
application. 
 
Force application on the beads attached to the cell surface 
 
A custom-built electromagnetic tweezers apparatus was used to apply controlled 
pulsatile forces to individual anti-syndecan-4-coated magnetic beads. Application 
of the pulsatile regimen consisting of 12 brief pulses of force (1 nN) with 
intervening periods of relaxation (3 s on, 4 s off) was achieved through a 
LabVIEW interface. On force application, bead displacements were recorded with 
a high-speed CMOS camera (Neo sCMOS Andor) at 50 Hz using a x40 (0.6 NA, 
air; Nikon) objective and tracked using a custom-written particle tracking 
algorithm in MATLAB that detects the intensity weighted centroid of the bead with 
subpixel accuracy. The electromagnetic tweezers device was calibrated before 
the experiments using a fluid of known viscosity. Beads that showed 
displacements of less than 50 nm (detection resolution) and loosely bound beads 
were not selected for analysis. For pharmacological interventions in the cellular 
mechanosensing experiments, cells were allowed to spread for 30 minutes to 1 h 
and then treated with 500 nM LatrunculinA; or 10 µM Y-27632; or 2 ug/mL of C3 
Rho inhibitor; or 30 µM of LY294002 PI3K inhibitor; or 10 µM of SH-5 AKT 
inhibitor. To apply a constant force on a larger number of beads, we used a 
permanent neodymium magnet system that allowed us to apply a vertical tensile 
force on the beads with magnitudes of around 200 pN. 
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Immunofluorescence staining 
 
Immunofluorescent staining was done on coverslips. Following pertinent 
treatment cells were fixed with 4% PFA (Sigma, P6148) in PBS for 10 minutes 
then blocked and permeabilised with 2% BSA-0.1%Triton (Sigma, T8787) in PBS 
for 30 minutes. After blocking, cells were incubated with primary antibodies 
prepared in blocking solution for 1 hour at room temperature in a humidified 
chamber. Then cells were washed in PBS and incubated with Alexa Fluor 488 
conjugated secondary antibodies and Phalloidin prepared in PBS for 30 minutes 
at room temperature. Finally, coverslips were washed in PBS and mounted in 
mounting reagent with DAPI (Invitrogen, P36931). 
 
YAP IF measurements 
 
YAP immunofluorescence studies were conducted on 5 different samples 
incorporating 5 separate regions of interest to obtain images of single cells. IF 
images were obtained using a fluorescence microscope (AE31 trinocular, Motic) 
with a 480/30 nm excitation filter and a 535/40 nm emission filter. Images were 
obtained with a CMOS camera (Moticam 5, Motic) for 35 regions across the 
different coverslips with each population. Images for DAPI were also obtained 
with an excitation filter of 350/50 nm and emission of 460/50 nm in order to 
visualise the nucleus for the quantification of YAP staining regions. Images for 
the YAP and DAPI channels were combined to allow accurate location of the 
nucleus for the analysis of images in ImageJ. Measurements of the intensity of 
the fluorescence in the nucleus was obtained in ImageJ and compared against 
the total cell fluorescence intensity with the nuclear staining removed. Ratios of 
the 
nuclear to cytoplasm fluorescence intensities were calculated in order to analyse 
the localisation of YAP in the different cell populations and significances analysed 
via a nonparametric t-test in Prism (GraphPad). 
 
MD and SMD simulations 
 
In simulations, we used syndecan-4 structure including transmembrane and 
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cytoplasmic domains. NMR structure of cytoplasmic domain (ID 1EJP in protein 
data bank) was used, while transmembrane domain modeled with SWISS-
MODEL tool using NMR structure of dimeric transmembrane domain of human 
glycophorin A (ID 1AFO in protein data bank) as template. Lipid membrane with 
40 % of POPC (144 residues), 15 % POPC (54 residues), 5 % PIP2 (18 
residues) and 40 % cholesterol (144 residues) was generated using Charmm-gui. 
Embedding of protein into membrane was performed by applying high lateral 
pressure on system as described before [Javanainen et al 2014]. All simulations 
were performed using Gromacs 2016.1 [van der Spoel et al 2005] at the Sisu 
supercomputer, CSC, Finland. All-atom OPLS-AA force field [Kaminski et al 
2001] and explicit TIP3P water model [Jorgensen et al 1983] in 0.15 M KCL 
neutral solution were used. Energy minimization of the system was performed in 
10 000 steps using steepest descent algorithm. The system was equilibrated in 
three phases using harmonic position restraints on lipid/cholesterol heads in Z 
dimension and on all heavy atoms of protein. First phase of equilibration was 
performed with NVT ensemble for 100 ps using the 
Berendsen weak coupling algorithm [Berendsen et al 1984] to control the 
temperature of the system at 100 K. Integration time step of 2 fs was used in all 
the simulations. 
Following NVT, system is linearly heated from 100 to 310 K over 1 ns using an 
NPT ensemble at 1 atm of pressure. During this process, the Berendsen 
algorithm was used to control both temperature and pressure. Semiisotropic 
pressure coupling was used for all 
the simulations to control pressure in XY plane (membrane plane) and in Z 
dimension separately. Temperature coupling was applied separately for 
protein/membrane and solution parts. For the final phase of equilibration and for 
all subsequent simulations, an NPT ensemble was maintained at 310 K and 1 
atm using as implemented in Gromacs 
2016.1. Equilibrium MD simulations (with no force applied) for 50 ns were 
conducted, considering first 20 ns as relaxation step. Hence, conformation of the 
system at 20 ns of the first run of equilibrium MD simulation was used as starting 
structure for SMD simulations. Pulling vector vas set between membrane (center 
of mass) and Cα of N27 terminal residues of the protein. SMD simulations were 
performed with constant force pulling using different force regimes: 25 pN, 50 pN, 
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100 pN and 200 pN. Two simulations were conducted for 25 pN, 100 pN and for 
200 pN, and four simulations for equilibrium MD and SMD with 50 pN of constant 
force pulling. All the simulations were run for 50 ns, except SMD simulations with 
25 pN were run for 100 ns. 
 
 
Western blotting 
 
The cell lysates were prepared with radio immunoprecipitation assay (RIPA) 
buffer (Sigma, R0278) containing proteinase inhibitors (Sigma, P4340). The 
protein concentration was quantified by DC protein assay (Biorad, 500-0113) 
according to manufacturer’s instructions. Samples were separated by an SDS-
PAGE gel under reducing conditions and transferred to a nitrocellulose 
membrane (GE Healthcare, 10401196) then blocked with 5% bovine serum 
albumin (BSA, Sigma, A8022) - 0.1% Tween20 (Sigma, P1379) in PBS. All 
primary antibodies were prepared in blocking solution and incubated overnight at 
4˚C. The membrane was washed and incubated with horseradish peroxidase 
(HRP) conjugated secondary antibodies in blocking solution for 1 hour at room 
temperature. Finally the membrane was washed and developed with HRP 
substrate (Millipore, WBLUR0100). 
 
 
RT-PCR 
 
Total RNA was extracted with RNeasy Mini Kit (Qiagen, 74104) and 1µg of total 
RNA was reverse transcribed by High-Capacity RNA-to-cDNA Kit (Applied 
Biosystems, 4387406) according to manufacturer’s instructions. Q-PCR was 
performed with SYBR Green PCR Master Mix (Applied Biosystems, 4309155) 
with 100 ng cDNA input in 20 µl reaction volume. GAPDH expression level was 
used for normalisation as a housekeeping gene. The sequences were as 
following GAPDH: forward28 5’ACAGTTGCCATGTAGACC3’, reverse-
5’TTTTTGGTTGAGCACAGG3’, CTGF (connective tissue growth factor) forward-
5’ CATACTCCACAGAATTTAGCTC 3’, reverse-5’ 
TTAAGAAGGGCAAAAAGTGC 3’. All primers were used at 300 nM final 
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concentration. The relative gene expression was analysed by comparative 
2−ΔΔCt method. 
 
 
ELISA and GLISA assay for RhoA 
 
The intracellular amounts of total RhoA and RhoA-GTP were determined by 
using the total RhoA ELISA and G proteins-linked (G-LISA) assays 
(Cytoskeleton, Inc., Denver,CO, USA) according to the manufacturer’s 
instructions. Briefly, cells were washed with 
cold PBS and homogenized gently in ice-cold lysis buffer. 20 µl was removed for 
protein quantification in order to adjust sample concentration to 0.5 mg/ml. After 
adding an equal volume of binding buffer, triplicate assays were performed using 
1.5 µg protein per well. Samples were incubated for 30 minutes and then washed 
three times with washing buffer. Antigen-presenting buffer was added for two 
minutes before removal; samples were then 
incubated with 1:250 dilution of anti-RhoA antibody at room temperature for 45 
minutes, washed three times, and incubated with secondary antibodies for 
another 45 minutes. HRP detection reagent was added and signal was read by 
measuring absorbance at 490 nm using a microplate spectrometer. 
 
Statistical analysis 
 
All statistical analyses were conducted with the Prism graphical software 
(GraphPad, Software). Data was generated from multiple repeats of different 
biological experiments in order to obtain the mean values and standard errors 
(s.e.m) displayed throughout. P values have been obtained through t–tests on 
paired or unpaired samples with parametric tests used for data with a normal 
distribution and non-parametric tests conducted via the Mann-Whitney test where 
data had a skewed distribution. Significance for the t-tests was set at P<0.05 
where graphs show significance through symbols (*, P<0.05; **, P<0.01; ***, 
P<0.001). For experiments with more than two groups Anova and the indicated 
post hoc test were used. 
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Chapter 6 
 
Concluding remarks 
 
 
6.1 Stromal biology and therapeutic approaches in PDAC – Implications 
and future directions 
 
 
The research reported in this thesis has investigated the role of all-trans retinoic 
acid (ATRA) – an active metabolite of vitamin A in the context of PDAC therapy. 
Our results provide in vitro evidence that ATRA might be repurposed as a stromal 
targeting agent to inhibit activated fibroblasts, fibrotic ECM changes and the 
invasive potential of pancreatic cancer cells. The combined biophysical and 
biochemical techniques employed herein further implicate the retinoic acid 
receptor beta (RARβ) to the mechanical reprogramming of activated fibroblasts 
through its effects on the transcriptional regulation of the actomyosin machinery, 
specifically the myosin regulatory light chain-2 (MLC-2).  
 
An indirect implication from this study is also that the associated biophysical ECM 
remodelling (rigidity and architecture) observed with PDAC progression and 
mediated primarily by activated fibroblasts, has a facilitating effect in the invasive 
potential of transformed epithelium. From a clinical standpoint, it needs to be 
stressed that the in vitro results from this research may or may not translate to 
the clinic owing to the immense complexity encountered in humans and living 
organisms – including, but not limited to, altered drug metabolism, bioavailability, 
off-target effects along with toxicity concerns.  
 
Two recent independent research studies from Kocher and colleagues 
corroborate with a beneficial effect of retinoids on stromal targeting of PDAC1,2. 
The most recent study suggested that ATRA co-administered alongside standard 
chemotherapy (gemcitabine) in genetically engineered mice results in normalized 
the desmoplastic stroma at the cellular and tissue level, resulting in decreased 
PSC activation, ECM deposition, along with decreased cancer cell proliferation 
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and enhanced cancel cell apoptosis compared to either agent alone. At the tissue 
level, this was accompanied by enhanced tumour necrosis, increased vascularity 
and diminished hypoxia. These effects were mediated by the dampening of 
multiple signalling cascades in the tumour-stroma crosstalk (Wnt, hedgehog, 
retinoid, and FGF), rather than ablating stroma or targeting a single pathway. 
Similarly the effect of ATRA on the stroma was found to be through the RARβ 
receptor. Importantly, these results however need to be critically appraised in the 
broader context of stromal depletion/modification therapies in PDAC, which have 
yielded, so far, contradictory results in the clinic.  
 
Stromal depletion or modification therapies should be investigated carefully in 
light of recent research suggesting both tumour-suppressive and promoting 
functions of the stroma3. For instance, pharmacological and genetic depletion of 
activated fibroblasts result in accelerated pancreatic tumour growth and immune 
evasion4, whereas reprogramming of activated fibroblasts promotes improved 
response to cytotoxic drugs5. These recent data reinforce the need to revisit the 
complexity and complicity of the tumour stroma with translational implications for 
future therapy and clinical trial design.  
 
 
Figure 6.1: Stromal depletion strategies. Depending on the targeted stromal 
component, pharmacological compound and length of treatment, the balance can 
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be tipped either towards pro-tumourgenic or anti-tumourigenic effects. Adapted 
from Neesse et al.6 
 
Some of the pharmacological stroma reprogramming compounds and/or 
approaches that have shown an overall tumour-suppressing effect in PDAC - not 
all with the same degree of evidence- are vitamin D analogues (calcitriol)5, 
vitamin A analogues (ATRA)2,7, angiotensin inhibitors (losartan)8, hyaluronan-
degrading enzymes (PEGPH20)9, depletion of FAP+ fibroblasts10, JAK11 and 
ROCK inhibitors12, CTGF inhibitors13. On the other hand, some of the stromal-
targeting approaches that appear to lead to tumour-promoting effects include 
pharmacological and genetic depletion of αSMA+ myofibroblasts4 and inhibitors of 
the pro-stromal sonic hedgehog pathway (IPI-926)3,14.  
 
In contrast to the previously held notion that the tumour stroma is strictly tumour 
promoting, certain components such as myofibroblasts may operate as tumour 
suppressors in certain contexts6. In fact, evidence regarding the prognostic role 
of the activated stroma in human PDAC assessed by aSMA expression also 
appears to be conflicting. New evidence suggests that aSMA expression does 
not always correlate with the level of fibrosis or inflammatory cell infiltration. The 
reason for this discrepancy, as agreed by leading scientists in the field, is that 
aSMA expression is a marker for transdifferentiation rather than PSC activity per 
se.  
 
aSMA+ fibroblasts or stellate cells can be dominantly fibrotic or fibrolytic. New 
more reliable stromal indices have been proposed for more accurate prognosis. 
Among them is the activated stroma index (ASI), which is the ratio between 
aSMA stained area and the aniline stained (collagen deposition) area. This index 
shows whether the stroma is dominantly fibrolytic (high aSMA-low collagen), 
fibrogenic (high aSMA-high collagen), inert (low aSMA-low collagen) or dormant 
(low aSMA-high collagen)15. One might also argue that the fibrotic stroma leads 
to the evolution of cancer cells. Consequently, somatic evolution of invasive 
cancer could be viewed as a sequence of phenotypical adaptation to the stromal 
barrier, highlighting the protective effect of the fibrotic microenvironment in the 
behavior of PDAC. 
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In any case, this pro-tumourigenic function is likely to depend on the tumour 
stage, the specific tissue context and tumour genotype and may also be variable 
for certain components of the microenvironment. For instance, while depletion of 
certain subpopulations of fibroblasts (e.g. aSMA+) may promote tumour 
progression and invasiveness, blockade of stroma-derived soluble factors, 
mechanotransductive abilities and/or ECM remodelling may result in opposite 
effects. Therefore, a detailed understanding of fibroblast heterogeneity and 
different TME components is critical for the development of future therapies. 
Bearing potential risks in mind, stromal reprogramming therapies may still be 
very promising therapeutic strategies in the management of PDAC as they may 
open therapeutic windows to sensitise for targeted therapies such as 
chemotherapy, immunological checkpoint blockade or anti-angiogenic therapy.  
 
 
6.2 Implications and future directions for syndecan-4 in 
mechanotransduction 
 
 
Mechanical forces regulate nearly all aspects of cell behaviour in health and 
disease, from guiding stem cell differentiation to promoting cancer progression. 
Extensive research over the past decades has identified integrins to be the 
primary transmembrane molecules that connect the extracellular matrix (ECM) to 
the internal actin cytoskeleton via force-bearing focal adhesion complexes (e.g. 
talin, α-actinin) enabling cells to sense and transduce mechanical forces into 
downstream signalling. However, the existence of other transmembrane proteins 
involved in mechanotransduction has been largely overlooked. 
 
In this work, we have revealed that syndecan-4 - a ubiquitous transmembrane 
proteoglycan receptor- is a cellular mechanotransducer able to transmit forces 
from the ECM to the cytoskeleton via the α-actinin-actin axis. We show that 
applied tension on syndecan-4 tunes global cell mechanics via a coordinated 
mechanochemical signaling response that involves synergistic integrin and Rho 
GTPase signaling. We have identified that synecan-4-mediated mechanosensing 
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is required for YAP activation and downstream changes in gene expression, 
propelling syndecan-4 as a master transmembrane mechanoregulator with 
implications for a number of biological processes (such as organ growth and 
wound healing) and pathological conditions known to be influenced by 
mechanical cues (fibrosis, cardiovascular diseases and cancer). 
 
There is still more work to be done on uncovering the fundamental of syndecan-4 
mechanosensing and syn-4 adhesion machinery. This includes uncovering focal 
adhesion proteins that interact specifically with syndecan-4. The role between 
YAP and syndecan-4 mechanotransduction is also ripe for further investigation. 
Elucidating the precise molecular mechanism that syndecan-4 mechanosensing 
invokes inside-out integrin activation warrants further investigation. Last but not 
least, syndecan-4 mechanosensing needs to be examined in a broader biological 
context in various physiological and pathological scenarios. Interesting questions 
include how disrupted syndecan-4 mechanosignallng affects various biological 
processes such as fibronectin fibrillogenesis, angiogenesis and/or fibrosis.  
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